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1. The nails
Nails	cover	the	dorsal	aspects	of	the	digits,	and	are	an	integral	part	of	the	digital	tip.	
The shape and opacity of the nail varies considerably among individuals, and 
throughout	 life	 the	 appearance	 of	 the	 nail	 changes	 with	 alteration	 in	 thickness,	
contour,	surface	and	color.	In	daily	practice,	disorders	of	the	nail	are	common	and	are	
often	 a	 diagnostic	 and	 therapeutic	 challenge	 for	 the	 doctors.	 Nail	 disorders	 can	
present	 as	 a	 change	 of	 color,	 shape	 or	 structure	 of	 the	 nail,	 and	 are	 sometimes	
accompanied	by	changes	of	the	surrounding	tissue.	Abnormalities	of	the	growth	and	
development	of	the	nail	can	impede	with	several	functions	of	the	nail	which	can	give	
varying complaints. Although nails are a skin appendage, they have their own signs 
and	symptoms	which	may	relate	to	varies	medical	conditions.
1.1  Function of the nail
The	 nail	 apparatus	 serves	 various	 important	 functions.	 The	 lateral,	 proximal,	 and	
distal borders of the nail protect against intrusion of the nail apparatus by bacteria 
and	external	substances,	and	the	nail	plate	protects	the	distal	phalanx,	the	fingertip,	
and	the	surrounding	tissue	against	trauma.	The	nail	plate	also	enhances	the	sensory	
discriminatory	 ability	 of	 the	 fingertips	 through	 counter-pressure	 that	 opposes	 the	
volar side of the terminal phalanx.1, 3	Besides	above	mentioned	functions,	nails	can	
also	be	used	as	a	defense	mechanism,	a	tool	for	scratching,	a	tool	for	the	manipulation	
of	 small	 objects,	 and	 as	 a	 cosmetic	 accessory.	 The	 latter	 function	 emphasizes	 the	
major	role	nails	play	in	social	interactions.	Nails	can	give	a	reflection	of	an	individual’s	
well	being,	as	several	internal	and	dermatological	conditions	can	express	nail	features.	
In fact, nail changes may occasionally provide clues to the diagnosis of underlying 
disease,	 sometimes	 before	 the	 clinical	 presentation	 of	 the	 disease.4 One of the 
dermatological diseases which can be preceded or accompanied by nail features is 
psoriasis. 
1.2 Development of the nail
In	embryos	the	digits	can	be	distinguished	upward	of	8	weeks	of	gestation.	From	nine	
weeks	of	gestations	 the	first	elements	of	 the	nail	apparatus	 start	 to	develop,	as	a	
transverse ridge on the distal dorsal surface of the digit develops, described as the 
primary	 nail	 field.	 In	 the	 next	 four	 weeks	 this	 ridge	 moves	 more	 proximal	 and	
eventually invaginates beneath the emerging proximal nail fold.5 At 13 weeks of 
gestation	a	wedge	of	matrix	moves	proximally,	and	by	14	weeks	the	nail	plate	is	seen	
emerging from beneath the proximal nail fold.3 At 17 weeks the nail plate covers most 
of	the	nail	bed,	and	from	week	20	and	further	the	nail	plate	and	finger	grow	in	parallel.
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2. Psoriasis
2.1 Epidemiology
Psoriasis is a common, and chronic skin disease characterized by epidermal hyper-
proliferation.	The	prevalence	of	psoriasis	in	Europe	varies	between	0.7%	and	2.9%,	
with	a	preference	for	the	Caucasian	population.8, 9 Although psoriasis may begin at 
any age, two peak incidences have been reported; an early onset type (16-22 years of 
age)	and	a	late	onset	type	(57-60	years	of	age).	A	previous	study	has	shown	that	37.1%	
of	psoriasis	patients	had	the	first	signs	of	skin	disease	before	the	age	of	20	years.10 
There	is	no	gender	predilection.11	Psoriasis	often	presents	with	skin	signs	but	may	also	
exhibit	abnormalities	in	the	joints	and	on	the	nails,	even	in	patients	without	psoriasis	
of the skin. 
2.2 Clinical features
The	most	 characteristic	psoriatic	 lesion	 consists	of	 sharply	demarcated	erythema-
tosquamous	plaques,	 typically	 in	 a	 symmetrical	 distribution,	 and	 characteristically	
localized	 on	 the	 extensor	 prominences	 of	 the	 upper	 and	 lower	 extremities,	 scalp,	
lumbosacral region and umbilicus.12 The clinical course is characterized by remissions 
and	exacerbations,	 influenced	by	various	exacerbating	factors.2 Psoriasis is hetero- 
geneous	in	the	clinical	presentation	with	several	clinical	phenotypes.	The	most	common	
clinical	variant,	psoriasis	vulgaris,	affects	approximately	85%	to	90%	of	all	patients	
with psoriasis.2, 13	Other	localizations	of	psoriasis	include	flexural	(inverse)	psoriasis,	
scalp psoriasis, seborrhoeic psoriasis and palmoplantar psoriasis, and other types 
of	 psoriasis	 are	 guttate	 psoriasis,	 eyrthroderma	 and	 pustular	 psoriasis.	While	 skin	
1.3 Anatomy of the nail
The	nail	unit	can	be	subdivided	into	the	proximal	nail	fold,	the	cuticle,	the	nail	matrix,	
the nail plate, the hyponychium, and the nail bed (see Figure 1).6 The proximal nail fold 
is	 a	 continuation	 of	 the	 skin,	 that	 folds	 underneath	 itself,	 and	 continues	 into	 the	
cuticle	(eponychium)	which	adheres	to	the	dorsal	aspect	of	the	nail	plate.	It	protects	
the	nail	matrix	from	external	influences.1 The nail plate is produced in the nail matrix, 
which is located beneath the proximal nail fold. It is the growth center of the nail 
(see Figure 2). As shown in Figure 2, the nail plate can be divided into three layers; 
the	dorsal	 layer,	the	 intermediate	(germinative	matrix)	 layer,	and	the	ventral	 layer.	 
As	the	nail	grows,	cells	of	nail	matrix	divide,	differentiate,	keratinize,	and	form	the	nail	
plate.1, 3 The nail plate grows from proximal to distal by sliding over the nail bed, 
whereupon the distal end detaches from the nail bed.7 The hyponychium is located 
underneath	this	free	edge	of	the	nail	plate	at	the	distal	end.	It	is	the	transition	of	nail	
bed	to	normal	epidermis	of	the	fingertip.1 The nail bed is located underneath the nail 
plate and is the vascularized area of the nail apparatus.1, 3	A	 longitudinal	pattern	of	
ridges	in	the	nail	bed	provides	attachment	to	the	ventral	aspect	of	the	nail	plate	which	
has corresponding ridges. This enhances adhesion between these two structures 
and	enables	the	free	edge	of	the	nail	plate	to	be	used	as	a	tool	without	lifting	the	nail	 
from the nail bed.5 
Figure 1.  Anatomy of the nail apparatus.
(from Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F.1).
Figure 2.		Close-up	of	the	nail	matrix	and	the	different	layers	of	the	nail	plate.
(from Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F.1).
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activate	keratinocytes	leading	to	keratinocyte	hyperproliferation	and	the	secretion	
of	different	chemokines.	The	hyperproliferation	of	the	keratinocytes	 is	responsible	
for	the	clinical	feature	of	scaling,	while	the	chemokines	are	responsible	for	attraction	
of	more	inflammatory	cells	to	the	skin.	In	recent	years	more	and	more	pieces	of	the	
immunological puzzle have been added or adapted in this model. This has resulted in 
the	 production	 of	 molecules	 interfering	 in	 the	 pathogenic	 steps,	 the	 so-called	
biologics.	This	is	a	class	of	pharmaceuticals	that	are	proteins	produced	by	recombinant	
DNA	technology	which	inhibit	different	actions	of	several	above	mentioned	cytokines,	
thereby	preventing	the	full	pathogenetic	cascade,	and	reducing	the	clinical	features	
of	psoriatic	disease.	However,	the	pathogenetic	picture	is	still	expanding	and	there	
are	still	many	pieces	which	have	to	be	discovered	as	shown	in	recent	publications.18
manifestations	are	the	most	characteristic	finding	in	psoriasis,	lesions	as	a	consequence	 
of	psoriasis	can	also	manifest	in	the	nails	of	these	patients,	predominantly	in	patients	
with	psoriatic	arthritis	(PsA).	
2.3 Pathogeneses
Psoriasis	appears	to	be	a	multi-factorial	disease	with	an	interplay	of	many	genetic	and	
environmental factors.2	 The	exact	underlying	mechanisms	are	still	unclear,	but	genetic	
susceptibility,	abnormal	function	of	keratinocytes,	and	immunological	disturbances	
of the innate and acquired immune system are postulated.2 
2.3.1 Environment
Various	environmental	factors	have	been	identified	in	the	pathogenesis	of	psoriasis.	
Streptococcal	 throat	 infections,	medications,	 stressful	 life	events	 and	 smoking	are	
known factors which can trigger psoriasis. These factors, and many others, can also 
exacerbate	or	modify	the	disease	in	patients.2
2.3.2 Genetic factors
Population	 studies	 have	 shown	 that	 the	 incidence	 of	 psoriasis	 is	 greater	 among	
first-degree	and	second-degree	relatives	of	patients	with	psoriasis	than	among	the	
general	 population.2	 Genome-wide	 association	 studies	 have	 identified	 nine	
chromosomal loci (PSORS1 through PSORS9) which can be linked to psoriasis.2 The 
major	genetic	determinant	seems	to	be	PSORS1,	which	probably	accounts	for	35	to	
50%	of	the	hereditary	of	psoriasis.	Human	Leukocyte	Antigen	(HLA)-Cw6,	involved	in	
the	 antigen-presentation,	 seems	 to	 be	 the	 susceptible	 allele	 located	 on	 PSORS1.	
However,	 patients	 with	 nail	 psoriasis	 and/or	 PsA	 are	 more	 frequently	 HLA-Cw6	
negative.14	In	recent	years	several	other	genome-wide	association	studies	identified	
genes	related	to	the	adaptive	immunity,	innate	immunity	and	skin	barrier	function.15-17 
2.3.3 Immunological factors
During the years various cells and mediators playing a role in the immunopathogenesis of 
psoriasis	have	been	identified	or	postulated,	including	keratinocytes,	dendritic	cells,	
T lymphocytes, complement proteins, and varies cytokines and chemokines. A widely 
accepted model for the interplay of cells and their mediators is demonstrated in 
Figure	3.	This	Figure	shows	that	an	initial	trigger	(e.g.,	trauma,	infection,	stress)	can	
induce	a	cascade	of	events	 leading	 to	 the	activation	of	dendritic	cells	 through	 the	
production	of	cytokines	(tumor	necrosis	factor	α	(TNF-α),	interferon-α,	interferon-Ү, 
interleukin	 (IL)-1β,	and	 IL-6)	by	 innate	 immune	cells.	When	activated,	 the	dendritic	
cells	start	to	present	antigens	and	secrete	mediators	(e.g.,	IL-12,	IL-23)	to	T	cells.	This	
leads	 to	 the	 differentiation	 of	 type	 1	 and	 type	 17	 helper	 T	 cells	 (Th1,	 Th17).	 These	
activated	 T	 cells	 subsequently	 secrete	 mediators	 (IL-17A,	 IL-17F,	 IL-22)	 which	 then	
Figure 3.		Schematic	suggested	overview	of	the	pathogenesis	of	psoriasis.
(from Nestlé FO, Kaplan DH, Barker J.2).
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documented in several other (dermatological) disorders (e.g., lichen planus, alopecia 
areata,	cardiac	failure,	hepatic	cirrhosis).	
Crumbling. In nail plate crumbling, the plate is thickened, largely deformed, and with 
an irregular and scaly surface.39 The structure of the nail plate is lost, and is seen in 
severe involvement of the matrix in nail psoriasis.  
Leukonychia. Leukonychia	is	the	whitish	discoloration	of	the	nail	plate.	Since	the	nail	
plate	 is	 smooth,	 it	 represents	psoriatic	alterations	 in	 the	 intermediate	and	ventral	
layers	of	 the	nail	 plate,	 and	 is	 attributable	 to	 the	matrix	dysfunction.	The	nail	 has	
milky	white	 spots	due	 to	 the	presence	of	parakeratotic	 cells	within	 the	nail	 plate.	
Leukonychia does not fade with pressure and moves distally as the nail grows.39 This 
phenomenon is also rather frequently seen in healthy nails.
Beau’s lines.	 Beau’s	 lines	 are	 transverse	 ridges	 and	 indentations	 in	 the	 nail	 plate	
caused	by	a	temporary	cessation	of	cell	division	in	the	nail	matrix.	These	indicate	a	
mild	 insult	 to	 the	 proximal	 nail	 matrix	 that	 interferes	 with	 matrix	 keratinization,	
resulting	 in	 a	 temporary	 reduced	 nail	 plate	 formation.	 After	 recovery	 of	 the	 nail	
matrix	 the	nail	 plate	 formation	also	 recovers	and	 the	nail	 plate	 regains	 its	normal	
3. Nail Psoriasis
3.1 Epidemiology
The	prevalence	of	nail	psoriasis	documented	in	the	literature	varies	between	10%	and	
82%,	with	an	estimated	lifetime	incidence	of	80%	to	90%.1, 19-32 A study by de Jong et 
al.,	among	1728	psoriasis	patients,	found	nail	involvement	in	79.2%,	which	indicates	
that	the	prevalence	of	nail	psoriasis	might	often	be	underestimated.20 Nail psoriasis in 
the	absence	of	cutaneous	disease	is	present	in	5%	to	10%	of	psoriatic	patients.26, 33 The 
prevalence of nail psoriasis in children seems to be much less frequent, varying from 
7%	to	13%.3, 25, 34
3.2 Pathogenesis
Identical	to	psoriasis	of	the	skin,	expression	of	the	same	psoriatic	inflammation	process	 
in the nail matrix or nail bed causes the clinical features seen in the nail. However, 
because	of	 the	particular	physiology	and	anatomy	of	 the	nail	 apparatus,	 characteristic	
psoriatic	features	seen	on	the	skin,	like	erythema	and	hyperkeratosis,	have	a	different	
clinical expression in the nail. 
3.3 Clinical aspects of nail psoriasis
The	clinical	nail	manifestations	 seen	 in	psoriasis	depend	on	 the	 localization	of	 the	
inflammation	in	the	nail	unit.	When	psoriasis	is	present	in	the	nail	matrix	it	can	give	
the	 following	manifestations:	 pitting,	 leukonychia,	 red	 spots	 of	 the	 lunula,	 Beau’s	
lines and crumbling of the nail plate, whereas psoriasis of the nail bed presents as 
oil-drop	 discoloration,	 splinter	 haemorrahages,	 subungual	 hyperkeratosis	 and/or	
onycholysis.	The	different	nail	features	seen	in	nail	psoriasis	are	discussed	below,	and	
clinical examples are displayed in Figure 4.
3.3.1 Nail matrix
Pitting. A	pit	indicates	a	defect	in	the	uppermost	layers	of	the	nail	plate.	In	psoriatic	
inflammation	clusters	of	parakeratotic	cells	disrupt	the	process	of	normal	keratinization	 
as they accumulate on the surface of the nail plate. When the nail plate grows past 
the	 nail	 fold,	 the	 clusters	 of	 cells	 shed	 from	 the	 nail	 plate,	 leaving	 a	 superficial	
depression within the nail plate. Sparse pits can be seen in healthy individuals, and 
can also appear in other diseases (e.g., alopecia areata, lichen planus, chronic 
eczema),	but	are	typically	numerous	and	deeper	in	patients	with	psoriasis.1 In psoriasis 
they	often	can	be	found	in	a	linear	pattern	rather	than	involving	the	whole	nail	plate.
Red spots lunula. Red spots in the lunula is an infrequently found phenomenon in nail 
psoriasis.	 The	 prevalence	 varies	 between	 0.4%	 and	 10.1%	 in	 patients	 with	 nail	
psoriasis.29, 35-38	The	red	spots	may	be	a	consequence	of	inflammatory	processes	in	the	
nail	matrix	that	 likely	reflect	distal	matrix	 involvement.	Red	spots	 in	the	lunula	are	
Figure 4.		Nail	manifestations	seen	in	nail	psoriasis.
Nail bed features; A.	Oil-drop	discoloration	(arrow); B. Onycholysis; C. Subungual hyperkeratosis; D. Splinter 
hemorrhages. Nail matrix features; E.	Pitting	of	 the	nail	plate;	F. Crumbling in proximal quadrants nail plate; 
G. Leukonychia; H. Red spots in the lunula (arrow).
A
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from	1996	emphasizes	that	effective	treatment	options	for	nail	psoriasis	are	highly	
desirable.20 However, a Cochrane review from 2013 concluded that there is only high 
quality evidence for treatment of nail psoriasis with two biologics and radiotherapy.47 
Only 18 studies could be included as the quality of studies was generally poor.47 
The	use	of	 the	biologics	 infliximab	 (TNF-α	antagonist)	 and	golimumab	 (also	TNF-α	
antagonist, not registered for patch psoriasis in the Netherlands), resulted in 
significant	improvement	of	nail	psoriasis.	Although	frequently	used,	there	is	limited	
evidence	for	the	efficacy	of	topical	therapies	in	nail	psoriasis.	Positive	effects	of	solely	
or	combined	therapy	with	topical	corticosteroids	and	vitamin	D3 analogues are most 
frequently described.48-51	 It	 is	 recommended	 that	 before	 application	 of	 topical	
therapy, the nail plate must be trimmed back as close as possible to the nail bed.19 
Intralesional	corticosteroid	 injections,	 injected	 in	the	proximal	nail	 fold,	have	been	
shown	 effective	 in	 the	 treatment	 of	 predominantly	 nail	 matrix	 lesions.40 In few, 
mostly	uncontrolled	trials,	triamcinolone	has	been	injected	in	varies	concentrations	
(10	-	40	mg/ml)	and	dosages	schemes	(weekly	or	monthly)	showing	positive	effects.52-54 
However,	it	should	be	taken	into	account	that	injection	into	the	nail	matrix	region	is	
very	painful	due	to	the	lack	of	space,	and	local	anesthetics	are	sometimes	necessary.	
Repetition	of	treatment	is	frequently	needed,	however	repetition	frequency	is	limited	
because of the risk of atrophy.55 When local therapies fail, systemic therapies may be 
used.	However,	clinicians	are	restrained	in	the	prescription	of	systemic	therapies	for	
nail	 psoriasis	 solely,	 because	 of	 the	 potential	 toxicity,41 so the advantages and 
disadvantages	 should	 be	 taken	 into	 account.	 Indications	 for	 prescribing	 systemic	
treatments are because of severe cutaneous psoriasis, coexistence of PsA, or when 
nail	 psoriasis	 is	 interfering	with	 patients’	 quality	 of	 life	 and	 is	 refractory	 to	 other	
therapies.47	Methotrexate	 seems	 to	 be	 a	 good	 first	 option,40, 56, 57 followed by fumaric 
acid,	 ciclosporin,	 and	 acitretin.56 In the Netherlands, biologic treatment can be 
prescribed	for	treatment	of	patients	with	moderate	to	severe	plaque	psoriasis	who	
had	not	 responded	 to	phototherapy	and	methotrexate	and/or	 ciclosporin,	or	who	
had	 contraindications	 to,	 or	 did	 not	 tolerate	 these	 therapies.58 According to the 
guideline	of	the	Dutch	dermatological	association	there	is	no	indication	for	biologic	
therapy	for	patients	with	solely	nail	psoriasis,	most	likely	because	of	the	high	costs	of	
therapy and the absence of an appropriate label. However, in literature there are 
studies	 describing	 the	 effects	 of	 biologics	 on	 psoriasis	 nail	 features.	 Although	 all	
biological	 therapies	 have	 demonstrated	 varying	 levels	 of	 efficacy	 in	 treating	 nail	
psoriasis,	 the	most	robust	data	are	available	for	 infliximab.38, 47, 56, 59	But	positive	effects	 
from	adalimumab,	etanercept	 (both	TNF-α	 inhibitors),	and	golimumab	on	nail	 features	
have also been described.60, 61, 62, 63
3.5 Evaluating the severity of nail psoriasis
Scoring systems are indispensable in this era of evidence-based medicine. They are 
thickness.	They	are	usually	deep	 in	 the	central	portion	of	 the	nail	plate	and	move	
distally	with	nail	growth.	Multiple	lines	indicate	a	repetitive	insult.39
3.3.2 Nail bed
Onycholysis. Onycholysis	describes	the	whitish	discoloration	seen	at	the	distal	end	of	
the nail, caused by detachment of the nail plate from the nail bed. Because a 
parakeratotic	psoriatic	area	of	the	nail	bed	detaches	from	the	nail	plate	and	a	space	
between the nail plate and nail is created, air can enter this space between the two 
structures,	causing	the	whitish	discoloration.	It	generally	starts	distally	due	to	disruption	 
of the onychocorneal band and moves proximally.
Oil-drop discoloration. Psoriatic	 lesions	 in	 the	 nail	 bed	 can	 give	 oil-drop	 colored	
patches which can be seen through the nail plate.1	Both	oil-drop	discoloration	and	
onycholysis	 are	 the	 results	 of	 the	 same	pathogenic	 process,	 namely	 parakeratotic	
changes	in	the	nail	bed.	Desquamation	of	these	parakeratotic	cells	at	the	hyponychium	
leads to onycholysis.40, 41
Subungual hyperkeratosis.	Nail	 bed	hyperproliferation	with	 accumulation	of	 keratino	-	
cytes under the nail plate which do not desquamate, results in subungual hyper-
keratosis.41 The extent to which the nail plate is elevated depends on the degree of 
psoriatic	activity	and	resulting	accumulation	of	nail	bed-derived	cells.
Splinter hemorrhages. These linear, “splinter” shaped hemorrhages are the result of 
dehiscence	of	fragile	capillaries	found	in	the	nail	bed	of	psoriatic	patients.1, 42 Because 
of	the	nail	plate	changes	and	capillary	fragility,	psoriatic	nail	units	are	predisposed	to	
develop splinter hemorrhages, most commonly precipitated by traumas.41 Most of 
them can be seen at the distal third of the nail plate. Proximal splinter hemorrhages 
can be seen in various cardiovascular, renal and pulmonary diseases.43
3.4 Treatment of nail psoriasis
Treatment	of	nail	psoriasis	is	challenging	and	hindered	by	the	construction	of	the	nail	
apparatus.	The	delivery	of	effective	drugs	to	the	nail	unit	 is	 limited	because	of	the	
impermeability of the nail plate and inaccessibility of the nail matrix by topical 
treatments.	 The	 toxicity	 associated	 with	 many	 conventional	 systemic	 therapies	
makes treatment even more challenging.44	Moreover,	as	nails	grow	slowly	(fingernails	
3.47	mm/month,	toenails	1.62	mm/month),45 treatment has to be persevered for a 
long	time	which	is	a	challenge	for	the	compliance	of	patients.46	The	treatment	options	
available for the treatment of the cutaneous component are not registered for the 
treatment	of	nail	features	specifically,	and	evidence-based	studies	infrequently	focus	
specifically	on	the	effects	on	the	nails.	However,	a	study	of	de	Jong	et	al.20 showed 
that	only	35.4%	of	nail	psoriasis	patients	was	treated	for	their	nail	features,	while	a	
major	part	of	these	patients	reported	that	they	were	restricted	in	their	daily	activities,	
housekeeping	and/or	profession	in	58.9%,	56.1%	and	47.9%	respectively.	This	article	
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psoriasis.	Studies	using	the	DLQI	 in	these	patients	showed	significant	more	impairment	 
in	nail	psoriasis	patients.28, 30	However,	the	specific	impact	of	nail	features	on	QoL	cannot	
be	abstracted	 from	this	 scorings	systems.	Therefore,	nail	psoriasis	 specific	 instruments	
need to be developed, validated and used.
3.7 Differential diagnosis of nail psoriasis
Differential	diagnostic	considerations	in	patients	suspicious	for	having	nail	psoriasis	
are	 onychomycosis,	 lichen	 planus,	 contact	 dermatitis,	 alopecia	 areata,	 bacterial	
infection,	idiopathic	onycholysis,	yellow-nail	syndrome,	and	congenital	pachyonychia.	
Top	of	the	differential	diagnostic	considerations	in	these	patients	is	onychomycosis.	
Onychomycosis can clinically mimic nail psoriasis, and is the most frequent nail 
disease	as	it	accounts	for	more	than	half	of	all	nail	abnormalities,	and	one-third	of	all	
mycotic	skin	 infections.69	Discrimination	between	onychomycosis	and	nail	psoriasis	
can be complicated as clinical nail features as subungual hyperkeratosis and 
onycholysis are also frequently seen in onychomycosis. 
4. Onychomycosis
4.1 Epidemiology and pathogens
Onychomycosis	 is	 an	 infection	 of	 the	 nail	 apparatus	 by	 fungi	 that	 include	
dermatophytes, nondermatophyte moulds and yeast.70	A	 recent	systematic	review	
showed	that	the	mean	prevalence	of	onychomycosis	is	11%	in	the	general	population,	
however these numbers depend on geographical and ethnical factors.71 The main 
causative	pathogens	of	onychomycosis	are	dermatophytes	(Trichophyton rubrum and 
Trichophyton mentagrophytes)	 and	 are	 responsible	 for	 80-90%	of	 cases.72, 73 Yeast 
(Candida species (spp.)) and nondermatophyte moulds (e.g., Acremonium spp., 
Alternaria spp., Aspergillus spp.) are much less frequently cultured as primarily 
pathogens. Of these, Candida species are the most common and account for 
approximately	 1.5%	 to	6%	of	nail	 infections,	more	 frequently	 in	fingernails	 than	 in	
toenails.7, 74, 75	Dermatophytes	are	normally	transmitted	through	infected	moist	floors	
areas,	and	are	less	frequently	transmitted	by	personal	contact.	Tinea	pedis	(mycoses	
of the foot) can lead to onychomycosis and has been associated with onychomycosis 
in	30-59%	of	cases.76
4.2 Clinical presentation
Several types of onychomycosis have been recognized which are categorized according to 
clinical	presentations	and	route	of	invasion.	The	most	prevalent	type	of	onychomycosis	 
is distal and lateral subungual onychomycosis. In this type the organism invades the 
nail bed and underside of the nail plate at the hyponychium and migrates towards 
needed	to	objectify	and	to	evaluate	a	treatment	response.	Using	one	and	the	same	
scoring	system	for	a	certain	disease	is	also	prerequisite	to	compare	results	of	different	
studies. The most common methods to determine disease severity in psoriasis, such 
as	the	psoriasis	area	and	severity	index	(PASI),	do	not	include	specific	features	of	nail	
psoriasis.	In	the	past	years	attention	towards	nail	psoriasis	and	the	treatment	of	nail	
psoriasis	 in	 literature	 is	 increasing	 and	 specific	 nail	 psoriasis	 severity	 scores	 are	
needed. In 2003 the nail psoriasis severity index (NAPSI) was developed by Rich et al., 
one	 of	 the	 first	 nail	 specific	 scores	 created	 for	 the	measurement	 of	 nail	 psoriasis	
severity.44 During the course of years several other nail psoriasis scoring systems 
have been developed, however the NAPSI is most widely used in clinical trials.40 In 
this NAPSI score the nail is divided into 4 equal quadrants. Each quadrant is then 
evaluated	for	the	presence	or	absence	of	nail	matrix	(pitting,	red	spots	in	the	lunula,	
crumbling, leukonychia) and nail bed (onycholysis, splinter hemorrhages, oil-drop 
discoloration,	subungual	hyperkeratosis)	features	separately.	Each	nail	is	assigned	a	
nail bed and a nail matrix score of 0-4, and combined the score for one nail can range 
from 0-8. The nail bed and nail matrix scores of all nails are summed and the maximum 
score	 for	 the	fingernails	 can	 range	 from	0-80,	with	 higher	 scores	 indicating	more	
severe nail psoriasis.  
3.6 Evaluating the impact on quality of life
It	is	already	known	that	dermatological	conditions	can	have	a	substantial	impact	on	
patients’	 quality	 of	 life	 (QoL).64 As psoriasis can be present on visible parts of an 
individuals’	 body,	 the	 impact	 can	 be	 significant.64 Scoring systems have been 
developed and validated to measure the impact of diseases on QoL. Health-related 
quality	of	 life	 (HRQoL)	scores	can	be	generic,	dermatology-specific,	or	disease-specific.	 
An	 often	 used	 generic	 HRQoL	 questionnaire	 is	 the	 Short-Form	 36	 (SF-36)	 which	
measures	 different	 aspects	 of	 health	 applicable	 on	 every	 patient,	 and	 makes	
comparison	between	the	impact	of	different	diseases	possible.65, 66 A frequently used 
dermatology-specific	 questionnaire	 is	 the	 Dermatology	 Life	 Quality	 Index	 (DLQI)	
which	have	been	developed	to	measure	the	impact	of	dermatological	conditions	on	
QoL.67	 It	 is	 an	 easy	 applicable	 and	 short	 questionnaire	 consisting	of	 ten	questions	
concerning	the	most	common	limitations	of	QoL	caused	by	skin	conditions.	Question	
categories	are	symptoms,	daily	activities,	work	and	school,	leisure,	feelings,	treatment	
and	 personal	 relationships.	 The	 higher	 the	 score,	 the	 more	 the	 QoL	 is	 impaired.	 
A	limitation	of	the	DLQI,	when	applied	to	nail	psoriasis	patients,	 is	that	 it	does	not	
specifically	displays	the	impact	of	nail	features	on	QoL.	Therefore,	recently	Ortonne	
et al.68,	developed	 the	nail	psoriasis	questionnaire,	NPQ10,	a	nail	psoriasis	 specific	
QoL	 questionnaire.	 The	 questionnaire	 consists	 of	 ten	 questions	 constructed	 to	
address the physical aspects which are associated with nail psoriasis.68	Until	2010,	the	
DLQI	was	the	most	disease-specific	QoL	instrument	applicable	for	patients	with	nail	
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nail	plate	is	insufficient.	Oral	treatment	with	systemic	antimycotics	form	the	mainstay	
of	therapy	of	onychomycosis.	However,	for	efficacy	of	therapy,	compliance	is	needed	
for	a	long	period	considering	the	slow	growth	rate	of	the	nail.	In	addition,	systemic	
antimycotics	have	a	 realistic	 risk	of	 side	effects.72	 Terbinafine	 (ergosterol	 synthesis	
blocking	)	is	one	of	the	most	effective	systemic	therapy	for	onychomycosis.72, 82 It is 
effective	against	predominantly	dermatophytes	and	 some	moulds.	However	 it	has	
less	 activity	 against	C. albicans.	 Itraconazole	 is	 a	more	broad-spectrum	antifungal	
triazole,	and	is	also	effective	against	C. albicans.7 Most frequently seen adverse events 
are	gastrointestinal	adverse	effects	(e.g.,	nausea,	diarrhea).	Hepatic	site	effects	can	
occur	with	both	treatment	modalities,	so	the	monitoring	of	liver	enzymes	is	advised.7, 72 
Because	of	the	disadvantages	and	long-term	administration,	differentiation	between	
nail psoriasis and onychomycosis is important in order to prevent overtreatment.
5. Psoriatic arthritis
5.1 History and epidemiology
The	association	between	psoriasis	and	joint	disease	was	first	recognized	by	Alibert,83 
and	 has	 been	 defined	 as	 an	 inflammatory	 arthritis,	 usually	 seronegative	 for	
rheumatoid factor, associated with psoriasis. Though PsA is known for more than two 
centuries,	 it	was	 initially	 thought	 to	be	a	 variant	of	 rheumatoid	arthritis	 (RA).	 The	
discovery	that	rheumatoid	factor	is	present	in	majority	of	patients	with	rheumatoid	
arthritis	but	only	in	minority	of	patients	with	PsA	resulted	in	the	differentiation	of	two	
separate	 disease	 entities.84	 PsA	 is	 uncommon	 in	 the	 general	 population	 (0.25%	
prevalence	 in	 the	 United	 States),	 but	 its	 prevalence	 in	 psoriasis	 patients	 varies	
between	6%	and	42%	according	to	different	study	population.85-89 The prevalence of 
nail	 psoriasis	 in	 patients	 with	 PsA	 is	 very	 high	 reaching	 nearly	 50-87	 percent.86,88 
Typically, the cutaneous psoriasis lesions precede the development of joint 
involvement by 12 years.88, 90	Psoriasis	patients	with	nail	involvement,	scalp	lesions,	
and intergluteal lesions are associated with an increased risk of developing PsA in the 
course of their disease.86
5.2 Clinical manifestations 
The	main	symptom	of	PsA	is	arthritis	which	can	affect	any	joint,	but	most	common	
the peripheral joints of the hands and feet.90	 Various	 clinical	 patterns	 of	 joint	
distribution	 can	 be	 seen;	 distal	 predominant	 pattern,	 asymmetrical	 oligoarticular,	
symmetrical	 polyarticular	 resembling	 seronegative	 RA,	 spondylitis,	 and	 arthritis	
mutilans.	 However	 the	 majority	 of	 patients	 has	 polyarthritis,	 followed	 by	
oligoarthritis.88 Besides swollen en tender joints, PsA is frequently accompanied by 
dactilytis	 (32-48%),	 enthesitis	 (25-53%),	 nail	 psoriasis	 (50-87%),	 and/or	 uveitis	
proximal.7	 Clinically,	 infection	 of	 the	 nail	 results	 in	 subungual	 hyperkeratosis	 and	
onycholysis, which are both frequently seen in nail psoriasis. Therefore, it may be 
impossible	to	distinguish	clinically	nail	psoriasis	from	onychomycosis.	
4.3 Risk factors
Various predisposing factors for the development of onychomycosis are known like 
environmental factors (community bathing areas, moist areas), and subject charac-
teristics	(e.g.,	age,	gender).	But	also	several	disease	modalities	have	been	associated	
with a higher risk of onychomycosis like diabetes mellitus and peripheral vascular 
disorders.77	In	addition,	patients	with	immunosuppressive	disorders	or	patients	using	
immunosuppressive therapy are at a higher risk of developing onychomycosis.78 Also 
psoriasis	is	named	as	a	risk	factor	of	onychomycosis,	however,	if	patients	with	(nail)	
psoriasis really have a higher risk of developing onychomycosis remains unclear. In 
recent	 years	 more	 and	 more	 psoriasis	 patients	 are	 using	 immunosuppressive	
therapies which might increase the risk of developing onychomycosis in this groups of 
patients.79
4.4 Diagnosis
Clinical	discrimination	between	nail	psoriasis	and	onychomycosis	is	often	difficult,	
therefore	appropriate	diagnostic	techniques	are	important	to	ensure	correct	diagnosis	
and	 treatment.	 Diagnostic	 techniques	 including	 direct	 microscopy	 (10%	 potassium	
hydroxide	preparations),	fungal	culture	(cultures	with	and	without	cycloheximide),	and	
polymerase	chain	reactions	may	identify	onychomycosis	and	help	to	distinguish	it	from	
nail psoriasis. Direct microscopy can be used to test for the presence or absence of 
fungi,	 and	based	on	 the	microscopic	 elements	 seen	one	 can	make	 a	 differentiation	
between	 dermatophytes	 and	 yeast,	 however	 a	 reliable	 identification	 of	 the	 exact	
pathogen	can	only	be	made	by	culture.	When	using	direct	microscopy	false-negative	
rates	in	5%	to	15%	of	patients	are	described.7	With	culture	the	specific	microorganism	
can	be	identified.7 Since most dermatophytes tend to grow slowly in culture, cultures 
must	 be	 continued	 for	 3	 weeks	 before	 they	 are	 pronounced	 negative.80 Correct 
localization	of	sample	collection	is	important	and	depends	on	the	type	of	onychomycosis.	
In distal and lateral subungual onychomycosis the nail should be clipped short and 
should	be	taken	from	the	transition	zone	into	healthy	nail	and	from	the	underside	of	the	
nail plate.7 Coexistence of onychomycosis and nail psoriasis also occurs, as both are 
frequent	disorders	in	the	general	population.81
4.5 Treatment 
Treatment	of	onychomycosis	is	mainly	by	antimycotics,	and	topical	as	well	as	systemic	
antimycotics	are	registered.	The	advantage	of	topical	therapy	is	the	limited	number	
of	side-effects,	however	curative	response	is	extremely	poor	as	penetrations	into	the	
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	 Psoriasis	can	be	found	at	several	different	localizations	which	may	be	of	various	
impact	on	patients‘	QoL.	In	particular	psoriasis	on	highly	visible	areas	of	the	skin,	such	
as	 the	 face	and	hands,	can	have	a	significant	 impact.	The	aim	of	chapter 3 was to 
achieve	more	insight	into	the	quality	of	life	of	psoriatic	patients	with	nail	psoriasis,	
and	to	characterize	the	patients	with	nail	involvement	which	are	more	prone	to	the	
impact	of	the	nail	alterations	caused	by	psoriasis.
	 Fortunately,	attention	towards	nail	psoriasis	 is	 increasing,	and	more	and	more	
studies	 are	 attempting	 to	 evaluate	 therapeutic	 options	 for	 nail	 psoriasis.	 Scoring	
systems	are	indispensable	for	the	evaluation	of	the	severity	of	disease	and	to	monitor	
treatment	 response,	 but	 also	 to	 compare	 results	 from	 different	 studies.	 Several	
scoring systems have been proposed to assess nail psoriasis severity. Despite the 
importance, there is lack of consensus on the most appropriate of these measures. In 
chapter 4	we	compared	these	different	nail	psoriasis	scoring	systems	in	patients	with	
nail	 psoriasis,	 and	 evaluated	 the	 competence	 of	 these	 different	 assessment	 tools.	
Furthermore,	it	was	attempted	to	formulate	a	better	scoring	system.
	 Clinical	manifestations	associated	with	nail	psoriasis	are	heterogeneous	in	their	
representation	 and	 many	 psoriatic	 nail	 features	 may	 morphologically	 resemble	
onychomycosis.	It	is	hypothesized	that	morphological	abnormalities	in	psoriatic	nails	
are predisposing factors for onychomycosis and vice versa. Consequently, the goal of 
chapter 5	 was	 to	 systematically	 review	 all	 available	 literature	 concerning	 the	
prevalence	of	onychomycosis	in	psoriasis	patients	to	give	insight	into	the	coincidence.
Based	upon	the	high	prevalence	of	nail	psoriasis	in	PsA	patients,	and	the	increased	
percentage	of	PsA	patients	with	nail	psoriasis,	it	was	already	concluded	that	there	is	
an	association	between	nail	psoriasis	and	PsA.	It	was	thought	that	the	link	between	
arthritis	and	psoriasis	could	be	explained	by	an	autoimmune	reaction	to	a	common	
autoantigen	 in	both	 skin	 and	 synovium.	However,	 this	hypothesis	 is	 challenged	by	
recent	studies	which	emphasize	on	the	association	between	PsA	and	nail	psoriasis	
with	the	entheses	as	the	epicenter	of	both	manifestations.	It	is	suggested	that	they	
play a key role, as the entheses of the DIP joint are suggested as the anatomical link 
between	 the	 nails	 and	 the	 joints	 and	 therefore	 as	 starting	 point	 of	 a	 generalized	
disease. Therefore, the aim of chapter 6	was	 to	 contribute	 to	 the	elucidation	and	
exploration	of	the	hypothesis	concerning	the	anatomical	link	between	nail	psoriasis	
and PsA with the extensor entheses as the epicenter.
The	results	of	the	subsequent	chapters,	together	with	the	possible	implications	for	
future clinical research and care are summarized and discussed in chapter 7. 
(4-18%).84	Dactilytis	is	a	diffuse	swelling	of	an	entire	digit	caused	by	a	combination	of	
enthesitis,	 tenosynovitis	 and	 arthritis.	 Entheses	 are	 sites	 at	 which	 tendons	 or	
ligaments are integrated into bone.91	Longstanding	inflammation	of	a	joint	can	give	
deformation	of	the	joint	leading	to	disabilities.	Joint	damage	is	seen	in	27%	of	patients	
within	 ten	months	of	 start	 symptoms,	 and	 in	47%	of	patients	within	 two	years	of	
symptom onset despite treatment.92
5.3 Pathogenesis
The	pathogenesis	of	PsA	is	complex	with	an	interplay	of	environmental,	genetic	and	
immunological factors comparable to that seen in psoriasis. PsA has an important 
hereditary	factor	as	it	is	documented	that	the	risk	in	first-degree	relatives	of	patients	
with	 PsA	 was	 30-55	 times	 higher	 than	 in	 the	 general	 population.	 In	 contrast	 to	
psoriasis,	 PsA	 patients	 are	 frequently	 HLA-Cw6	 negative.	 Associations	 have	 been	
found between PsA and several other class I HLA genes, like HLA-B27, HLA-B38 and 
HLA-B39.90, 93	Originally,	it	was	thought	that	the	link	between	arthritis	and	psoriasis	
could	be	explained	by	an	autoimmune	reaction	to	a	common	autoantigen	in	both	skin	
and synovium.94	However,	recent	studies	showed	that	the	inflammation	starts	in	the	
entheses	 instead	 of	 the	 synovium,	 from	 which	 T	 cells,	 dendritic	 cells,	 mast	 cells,	
neutrophills	and	macrophages	infiltrate	the	synovium	of	joints	in	a	similar	manner	as	
described in psoriasis.90 Recently several studies have been published which speculate 
on	the	association	between	nail	psoriasis	and	PsA	with	the	entheses	as	epicenter	of	
the	disease,	as	there	might	be	a	direct	anatomical	link	between	inflammation	of	the	
distal interphalangeal (DIP) joint and nail changes via the entheses of the extensor 
tendon.95-98 
Aims and outline of the thesis
This	thesis	describes	studies	on	the	different	aspects	of	nail	psoriasis	in	order	to	provide	
insight	into	the	prevalence,	clinical	manifestations,	and	the	impact	on	patients’	QoL	
of	patients	with	nail	psoriasis.	In	addition,	studies	contributing	to	the	elucidation	of	
the	 link	between	nail	psoriasis	and	psoriatic	arthritis,	and	the	coexistence	of	 (nail)	
psoriasis and onychomycosis are described. 
	 To	improve	care	for	patients	with	nail	psoriasis,	it	is	essential	to	acquire	knowledge	
concerning this disease. The documented data on the prevalence and clinical 
	characteristics	are	incomplete	and	divergent,	and	prevalence	numbers	vary	considerably	
in literature. Therefore, the aim of chapter 2 was to give insight into the prevalence 
of	nail	psoriasis,	and	to	obtain	quantitative	information	on	the	clinical	characteristics	
of	patients	with	nail	psoriasis.	A	secondary	aim	of	this	chapter	was	to	give	insight	into	
self-reported	treatment	experiences	of	patients	with	nail	psoriasis.	
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CHAPTER 2
Introduction
The	prevalence	of	nail	psoriasis	varies	between	10%	and	79%.1-6 It is reported that 
80%	 to	 90%	 of	 psoriatic	 patients	 develop	 nail	 psoriasis	 some	 time	 during	 their	
disease.1-4,6	 However,	 psoriatic	 nail	 lesions	 rarely	 appear	 as	 the	 only	 clinical	
manifestation	of	psoriasis,	as	psoriasis	limited	to	the	nails	occurs	in	only	1%	to	10%	of	
patients	with	psoriasis.1,3,4	 It	is	mentioned	that	psoriatic	arthritis	(PsA)	is	associated	
with higher rates of nail psoriasis, and the severity of nail disease correlates with 
indicators of severity of joint disease.7 Previous research states that nail psoriasis is 
associated	with	both	longer	duration	and	greater	extent	of	skin	disease.2
 The clinical spectrum of nail psoriasis is heterogeneous, depending on the 
involvement	of	nail	bed,	nail	matrix,	or	both.	Widely	accepted	manifestations	attributed	 
to	psoriatic	inflammation	of	the	nail	matrix	are	pitting,	red	spots	in	the	lunula,	leukonychia,	
and	nail	plate	crumbling.	Nail	bed	manifestations	are	oil-drop	discoloration,	onycholysis,	
splinter hemorrhages, and subungual hyperkeratosis.5,6	Additional	symptoms	found	
in	 literature	 include	 Beau’s	 lines,	 onychomadesis,	 nail	 fold	 involvement,	 and	
longitudinal ridging.6 These are not included in the widely used Nail Psoriasis Severity 
Index	 (NAPSI)	 scoring	 system,	 which	 is	 limited	 to	 the	 first	 eight	 mentioned	 nail	
changes.	 Using	 this	 instrument	 each	 quadrant	 of	 each	 fingernail	 is	 evaluated	 for	
presence or absence of nail bed or nail matrix disease. The sum of the scores for all 
the	fingernails	 is	 the	NAPSI	 score	 for	 the	patient	 at	 that	time	 (see	 Figure	 1	 for	 an	
example	of	 calculation).8 In most recent studies concerning nail psoriasis only the 
total	NAPSI	 score	 is	 used.	 Literature	 concerning	 the	 frequency	of	 each	 specific	 clinical	 
sign of nail psoriasis is limited.2,7,9-17 
	 The	aim	of	 this	 study	was	 to	describe	 the	epidemiological	 characteristics	 and	 the	
frequency	 of	 clinical	 signs	 of	 fingernail	 psoriasis	 and	 compare	 them	with	 healthy	
controls.
Methods
Study population
A	total	of	49	patients	with	fingernail	psoriasis	were	 recruited	consecutively	 in	 this	
case-control	study	from	the	outpatient	clinic	at	the	Department	of	Dermatology	of	
the Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. 
Patients	were	 included	 from	December	2009	 through	 July	2012.	 Included	patients	
were	older	than	18	years	with	clinically	diagnosed	fingernail	psoriasis	(NAPSI	score	≥	
1).	Patients	who	used	artificial	nails	in	the	past	six	months	or	had	presence	of	a	skin	
disease	 (other	 than	 psoriasis),	 which	 is	 associated	 with	 nail	 manifestations,	 were	
excluded,	 as	 were	 patients	 with	 toenail	 involvement	 exclusively,	 because	 of	 the	
increased	risk	of	coexistence	of	onychomycosis.	To	exclude	patients	with	concomitant	
Abstract
Background: Literature concerning clinical signs and frequency of nail psoriasis is 
incomplete. Recent studies focus only on signs included in the Nail Psoriasis Severity 
Index (NAPSI).
Objective:	 We	 sought	 to	 describe	 clinical	 characteristics	 of	 fingernail	 psoriasis	 in	
comparison with healthy controls.
Methods:	We	collected	data	on	49	patients	with	fingernail	psoriasis	who	visited	our	
outpatient	department	and	49	control	subjects,	through	questionnaires	and	clinical	
examination.	The	disease	severity	was	measured	by	the	NAPSI.
Results:	 Mean	 NAPSI	 score	 in	 patients	 and	 control	 subjects	 was	 26.6	 and	 3.6,	
respectively.	 Most	 items	 included	 in	 the	 NAPSI	 were	 specific	 for	 nail	 psoriasis.	
Onycholysis and splinter hemorrhages were most frequently observed. Leukonychia 
was	more	frequent	in	control	subjects.	Longitudinal	ridges	and	Beau’s	lines	are	not	
included	in	the	NAPSI	but	are	significantly	more	frequently	seen	in	patients	than	in	
control subjects. 
Limitations:	Limited	sample	size	was	a	limitation.
Conclusion:	 The	 NAPSI	 was	 able	 to	 discriminate	 patients	 with	 fingernail	 psoriasis	
from healthy control subjects. Onycholysis and splinter hemorrhages were the most 
prevalent	fingernail	changes	in	psoriatic	patients.	Leukonychia	was	more	frequently	
observed	 in	 control	 subjects,	 which	 raises	 the	 question	 of	 whether	 leukonychia	
should	remain	in	the	NAPSI.	On	the	other	hand,	longitudinal	ridges	and	Beau’s	lines	
occurred	more	frequently	in	psoriasis	patients	but	are	not	included	in	the	NAPSI.
CHAPTER 2 PREVALENCE AND CLINICAL CHARACTERISTICS OF NAIL PSORIASIS
38 39
2
Results
A	total	of	49	psoriatic	patients	and	49	healthy	control	subjects	were	included	in	the	
study.	The	descriptive	demographical	patient	characteristics	have	been	summarized	
in	 Table	 1.	 No	 statistical	 difference	 was	 observed	 between	 psoriatic	 patients	 and	
control	subjects	for	gender	and	age.	The	mean	age	of	the	included	psoriatic	patients	
was	48	years	(±SD	13.4).	The	mean	age	at	onset	of	psoriatic	skin	manifestations	was	
29	years	 (±SD	14.1)	and	the	mean	duration	of	skin	disease	was	19	years	 (±SD	13.6).	
Median	PASI	score	was	3.7	(range	0.0-29.5)	with	a	mean	body	surface	area	of	6.6%	
(±SD	11.2).	At	study	enrollment	19	patients	 (38.8%)	were	actively	treated	with	systemic	
therapy.
	 Nail	psoriasis	 features	started	predominantly	after	the	onset	of	the	cutaneous	
lesions, with a mean delay of 9 years and appeared most frequently simultaneously 
on	fingernails	and	toenails	(79.6%).	Mean	age	of	onset	of	fingernail	psoriasis	was	38	
onychomycosis,	clippings	and	subungual	scrapings	of	affected	fingernails	were	collected	
for	direct	microscopic	examination	(10%	potassium	hydroxide	preparations)	and	fungal	
culture.	 Cultures	 were	 carried	 out	 on	 two	 different	 types	 of	 Sabouraud	 dextrose	 
agar: one with chloramphenicol and cycloheximide and one without cycloheximide. 
None	of	the	patients	tested	positive.
	 In	addition,	a	total	of	49	age-	and	gender-matched	control	subjects	were	included.	
They	were	healthy	individuals	older	than	18	years	without	(skin)	diseases	or	medication	
associated	with	nail	manifestations	and	were	recruited	from	patients,	visitors,	and	
employees	of	the	above	mentioned	outpatient	clinic.
Survey details 
The	survey	of	the	psoriatic	patients	consisted	of	a	questionnaire	taken	by	interview	
and	clinical	examination	conducted	by	the	same	investigator.	The	interview	included	
items	 concerning	 demographic	 patient	 characteristics,	 general	 health,	 psoriasis-	
related	 data,	 and	 specific	 nail	 psoriasis	 questions.	 Diagnosis	 of	 concomitant	 PsA	 
was	made	through	physical	examination	by	a	rheumatologist.	Nail	manifestations	in	
both	 groups,	 i.e.,	 fingernail	 psoriasis	 and	 healthy	 control,	 were	 documented	 and	
photographed.
Severity of disease measurement
The severity of psoriasis was assessed by the Psoriasis Area and Severity Index (PASI) 
(range 0-72).18 Higher scores indicate more severe psoriasis of the skin. The body 
surface	area	represents	the	percentage	of	body	surface	affected	and	classifies	the	
severity	 of	 the	 condition.	 The	 severity	 of	 fingernail	 psoriasis	was	 assessed	 by	 the	
NAPSI score (Figure 1).8	 Additional	nail	 changes	 (e.g.,	 Beau’s	 lines,	 onychomadesis,	
longitudinal	ridging,	and	nail	fold	involvement)	were	also	assessed	for	each	fingernail.	
The	fingernails	of	the	healthy	control	subjects	were	scored	for	the	presence	of	the	
same	manifestations	of	nail	psoriasis	and	a	NAPSI	score	was	measured.	
Statistical analysis
Data	were	entered	 in	a	Statistical	Package	for	Social	Sciences	 (SPSS	18.0,	SPSS	 Inc,	
Chicago,	 IL)	 database	 and	 subsequently	 statistical	 analyses	 were	 performed.	
Descriptive	statistics	were	provided	using	mean	(SD)	and	median	(range)	for	normally	
and	 nonparametric	 distributed	 numeric	 values,	 respectively.	 Frequencies	 and	
percentages were used for categorical variables. Missing values were not included to 
calculate percentages. Comparison of numeric variables were analyzed with the 
unpaired t	tests	or	the	Mann-Whitney	U	test	and	the	χ2 or Fisher exact test was used 
for	 differences	 between	 categorical	 variables.	 Spearman	 rank	 test	 was	 used	 to	
explore	the	relationship	between	continuous	variables.	P values less than 0.05 were 
considered	to	be	statistically	significant.	All	tests	were	2-sided.
Figure 1.  Fingernail psoriasis; grading with Nail Psoriasis Severity Index (NAPSI).8
The nail is divided into 4 quadrants. Each quadrant is evaluated for presence or absence of nail bed 
psoriasis (0-4) and nail matrix psoriasis (0-4). Score is 0 if no sign of nail bed involvement is present in any 
quadrant. Score is 4 if signs of nail bed involvement are present in all 4 quadrants. Score for matrix is 
calculated	in	a	similar	way.	In	this	example,	pitting	and	nail	plate	crumbling	are	present	in	quadrants	A,	B,	
and C, and therefore score for nail matrix psoriasis is 3. We see onycholysis, splinter hemorrhages, and nail 
bed hyperkeratosis in quadrants C and D, and therefore score for nail bed psoriasis is 2. Sum of these 
scores	is	total	score	of	that	nail	(in	this	example	5),	with	minimum	of	0	(representing	no	nail	psoriasis)	and	
maximum	of	8,	with	higher	scores	indicating	more	severe	nail	psoriasis.	Sum	of	all	fingernails	(not	in	this	
Figure)	would	be	total	NAPSI	score,	ranging	from	0	to	80.	Beau’s	lines	are	also	present,	but	they	are	not	
included in NAPSI score.
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	 Nail	 changes	 not	 included	 in	 the	 NAPSI,	 but	 seen	 in	 psoriatic	 patients,	 were	
longitudinal	ridges	(40.8%,	mean	4.3	fingers	affected),	nail	fold	involvement	(16.3%,	
mean	 4.3	 fingers	 affected),	 Beau’s	 lines	 (10.2%,	 mean	 1.8	 fingers	 affected),	 and	
onychomadesis	 (2.0%,	mean	1.0	finger	affected).	Of	 these,	only	 longitudinal	 ridges	
were	seen	in	the	control	group	(16.3%).
	 The	mean	NAPSI	score	in	patients	and	control	subjects	was	26.6	(±SD	14.5)	and	
3.6 (+SD	 3.3),	 respectively	 (p<0.001). When separated, in both study groups nail 
matrix	NAPSI	 scores	were	higher	 than	nail	bed	NAPSI	 scores,	 in	psoriatic	patients,	
respectively,	14.6	(+SD 11.6) and 12.8 (+SD	8.0),	and	in	control	subjects,	respectively,	
2.5 (+SD 2.8) and 1.1 (+SD	1.8).	Overall,	44	psoriatic	patients	(89.8%)	showed	both	nail	
matrix	and	nail	bed	changes;	the	remaining	patients	had	matrix	changes	only.	In	the	
control	group	40	 individuals	 (81.6%)	showed	any	fingernail	 changes,	most	of	 them	
were minor.
	 Of	the	49	patients	with	psoriatic	fingernail	disease,	nine	patients	(18.4%)	displayed	
nail	changes	as	the	exclusive	manifestation	of	psoriasis.	Also	nine	psoriatic	patients	
(18.4%)	were	given	the	diagnoses	of	PsA	by	a	rheumatologist,	of	which	five	patients	
years	(±SD	12.6)	and	mean	duration	of	nail	disease	was	10	years	(±SD	8.1).	The	mean	
number	of	fingernails	presenting	with	psoriasis-specific	nail	changes	in	patients	with	
nail	psoriasis	was	8.3	(±SD	2.2).	The	mean	number	of	involved	fingernails	for	the	left	
hand was 4.1 (±SD 1.1) and for the right hand was 4.2 (±SD 1.3).
	 The	 observed	 frequency	 of	 fingernail	 changes	 in	 the	 studied	 population	 is	
displayed	in	Table	2.	All	eight	nail	manifestations	included	in	the	NAPSI	were	seen:	
onycholysis	(93.9%),	splinter	hemorrhages	(93.9%),	pitting	(73.5%),	oil-drop	discoloration	
(67.3%),	subungual	hyperkeratosis	(46.9%),	nail	plate	crumbling	(42.9%),	leukonychia	
(40.8%),	and	red	spots	in	the	lunula	(2.0%)	(Figure	2).	Onycholysis	was	predominantly	
seen	 in	 the	distal	 quadrants	of	 the	fingernail	 (60.0%).	Median	number	of	 pits	 per	
fingernail	was	5.5	(range	1-26);	74.2%	of	patients	had	less	than	10	pits.	As	expected,	
the	frequency	of	most	nail	changes	was	statistically	significantly	lower	in	the	control	
group	 (Table	 2).	 However,	 leukonychia	 was	 significantly	more	 frequent	 in	 healthy	
control	subjects	(65.3%	vs.	40.8%,	p=0.015).
Table 1		Sociodemographic	and	clinical	characteristics.
Nail psoriasis 
group
(n = 49)
Control 
group
(n = 49)
p-value
Gender,	n	(%)
    Female
    Male
23 (46.9)
26 (53.1)
23 (46.9)
26 (53.1)
1.000 (NS)
Age (years), mean ±SD 48 ± 13.4 48 ± 13.4 0.958 (NS)
Age start psoriasis (years), mean ±SD 29 ± 14.1
Duration	of	psoriasis	(years),	mean	±SD 19 ± 13.6
Age start nail psoriasis (years), mean ±SD 38 ± 12.6
Duration	of	nail	psoriasis	(years),	mean	±SD 10 ± 8.1
Localization	nail	psoriasis,	n	(%)
    Fingernails
    Toenails
    Both
10 (20.4)
 0 (0)
39 (79.6)
NAPSI score, mean ±SD 26.6 ± 14.5 3.6 ± 3.3 <0.001*
Modified	target	NAPSI	score,	mean	±SD 10.4 ± 7.3
PASI score, median ( range) 3.7 (0.0 –29.5)
BSA score, mean ±SD 6.6 ± 11.2
* p<0.05	(significant).
BSA,	Body	Surface	Area;	NAPSI,	Nail	Psoriasis	Severity	Index;		NS,	not	significant;	PASI,	Psoriasis	Area	
and	Severity	Index;	SD,	standard	deviation.
Table 2		Frequency	of	fingernail	changes.
Nail psoriasis 
group
(n = 49)
Control 
group
(n = 49)
p-value
Nail signs included in the NAPSI, n (%)
Subungual hyperkeratosis 23 (46.9) 1 (2.0) <0.001*
Oil-drop	discoloration 33 (67.3) 0 (0) <0.001*
Splinter hemorrhages 46 (93.9) 18 (36.7) <0.001*
Onycholysis 46 (93.9) 9 (18.4) <0.001*
Nail plate crumbling 21 (42.9) 0 (0) <0.001*
Red	spotted	lunula 1 (2.0) 0 (0) 1.000 (NS)
Leukonychia 20 (40.8) 32 (65.3) 0.015*
Pitting 36 (73.5) 5 (10.2) <0.001*
Nail signs not included in the NAPSI, n (%)
Longitudinal ridges 20 (40.8) 8 (16.3) 0.007*
Nail fold involvement 8 (16.3) 0 (0) 0.003*
Beau’s	lines 5 (10.2) 0 (0) 0.027*
Onychomadesis 1 (2.0) 0 (0) 1.000 (NS)
NS,	not	significant
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Discussion
We	 collected	 data	 on	 49	 adult	 psoriatic	 patients	 with	 fingernail	 involvement	 to	
describe	the	features	of	fingernail	psoriasis	and	their	prevalence.	We	compared	these	
results with data collected on 49 age- and gender-matched control subjects without 
fingernail	disease	to	determine	which	of	the	observed	features	are	disease-specific	
for	 fingernail	 psoriasis.	 Patients	 with	 concomitant	 onychomycosis	 were	 excluded	
from this study, because Gupta et al.19 found a higher prevalence of onychomycosis in 
psoriatic	 patients	 and	 discussed	 that	 fungal	 infection	 might	 have	 a	 role	 in	 the	
maintenance	 or	 aggravation	 (Koebnerization)	 of	 nail	 psoriasis.	 Diagnosis	 of	 nail	
psoriasis	 was	 made	 clinically	 and	 not	 confirmed	 histologically,	 which	 may	 have	
influenced	our	study	results.	Furthermore,	we	enrolled	19	patients	who	were	actively	
treated	with	systemic	therapy,	which	could	affect	the	nail	signs	we	have	observed.	
 Reports of prevalence of clinical features of nail psoriasis vary considerably in the 
literature,	which	may	partly	be	a	result	of	differences	in	descriptions	and	definitions	
used in previous studies. Grover et al.9 reported onycholysis as the most prevalent 
nail	change	in	76.0%	of	patients.	Gisondi	et	al.15	studied	nail	involvement	in	psoriatic	
patients	using	ultrasonography	and	found	onycholysis	to	be	the	most	common	clinical	
sign.	 Other	 studies	 reported	 pitting2,10-12,14,17,	 oil-drop	 discoloration,7 or subungual 
hyperkeratosis13,16	to	be	the	most	prevalent	nail	change	in	psoriatic	patients.	The	most	
prevalent	fingernail	changes	found	in	our	fingernail	psoriasis	group	were	onycholysis	
(93.9%)	 and	 splinter	 hemorrhages	 (93.9%).	 Three	 previous	 studies	 found	 splinter	
hemorrhages	 to	 be	 the	 second	 (20.4%10)	 or	 third	 (39.3%,14 42%17) most common 
manifestation	in	fingernail	psoriasis.	However,	others	reported	it	to	be	less	common,	
ranging	 from	 1%	 to	 28.9%.7,11,12,15,16 Onycholysis and splinter hemorrhages are 
manifestations	of	nail	bed	psoriasis.	However,	overall	nail	matrix	NAPSI	scores	were	
higher	than	nail	bed	NAPSI	scores	in	our	patients.	This	result	is	in	line	with	previous	
investigations.12,20	The	red	spotted	lunula	is	an	infrequent	nail	change	in	psoriasis.	In	our	
study	population	only	one	psoriatic	patient	(2.0%)	showed	red	spots	in	the	lunula.	In	
previous	studies	this	nail	symptom	was	observed	in	0.4%	by	Aktan	et	al.16,	in	1.3%	by	
Kyriakou et al.,7	and	in	10.2%	by	Rich	et	al.12 In most previously published literature 
concerning	nail	psoriasis	additional	nail	symptoms	such	as	Beau’s	 lines	and	longitudinal	
ridging were not taken into account and scored, probably because these features are 
not included in the NAPSI score8	and	may	be	even	less	specific	for	psoriasis	than	the	
eight	 above-mentioned	 features.	 Nevertheless,	we	 found	 Beau’s	 lines	 in	 10.2%	 of	
patients	and	in	none	of	the	control	subjects	(Figure	1).	Longitudinal	ridging	was	even	
present	 in	 40.8%	of	 patients	with	 fingernail	 psoriasis	 but	 also	 in	 16.3%	of	 healthy	
control	subjects,	making	this	 feature	rather	sensitive	but	not	specific	for	fingernail	
psoriasis.	 Both	 longitudinal	 ridging	 and	 Beau’s	 lines	 can	 be	 explained	 by	 the	
inflammatory	 process	 in	 the	 proximal	 nail	matrix.	 Baran21 also has recognized the 
mentioned	 arthritis	 of	 the	 distal	 interphalangeal	 joints.	 NAPSI	 and	 PASI	 scores	 of	
patients	with	and	without	PsA	were	not	significantly	different	(p=0.079).
Correlations
No	 significant	 correlation	was	 found	between	NAPSI	 and	PASI	 scores	 (Spearman	 r	
=0.042, p=0.784).	The	age	of	onset	of	fingernail	psoriasis	was	positively	correlated	to	
age	of	onset	of	cutaneous	manifestations	of	psoriasis	(Spearman	r	=0.718,	p<0.001). 
Figure 2.		Fingernail	psoriasis.	Nail	changes	in	fingernail	psoriasis	observed	in	this	study.
A, Nail fold involvement, nail plate crumbling, and splinter hemorrhage (arrow).B, Leukonychia (asterisk), 
pitting,	and	onycholysis.	C,	Oil-drop	discoloration,	onycholysis,	and	splinter	hemorrhages	(arrow).D,	Beau’s	
lines, onycholysis, and splinter hemorrhages (arrows). E, Longitudinal ridges and splinter hemorrhages 
(arrow). F, Subungual hyperkeratosis.
A
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increasingly	over	time	with	the	percentage	improvement	of	NAPSI	score	in	a	group	of	
patients	with	psoriasis	 treated	with	 infliximab.	Of	course,	 this	only	shows	that	this	
anti-tumor	necrosis	factor-α	treatment	is	effective	against	psoriasis	of	the	skin	and	
psoriasis	of	the	nails	but	does	not	prove	direct	correlation	between	both.	The	same	
was found by Sánchez-Regaña et al.20; as the skin lesions improve, the nail symptoms 
improve	as	well.	On	the	other	hand	Augustin	et	al.27	found	significantly	higher	PASI	
scores	 in	psoriatic	patients	with	nail	 involvement	 compared	with	patients	without	
nail involvement. Further research with a larger sample size is needed to see whether 
there	is	a	direct	relation	between	nail	psoriasis	and	the	cutaneous	manifestations	of	
psoriasis. 
	 Based	on	the	questionnaire	fingernail	psoriasis	started	predominantly	after	the	
onset	of	the	skin	lesions,	with	a	mean	delay	of	nine	years.	Interestingly,	De	Marco	et	
al.28 and Palmou et al.14 found a similar delay in the onset of PsA. Those delays may be 
explained	by	shared	pathogenetic	principles,	which	differ	from	the	pathogenesis	of	
psoriatic	skin	disease.	Psoriatic	disease,	encompassing	skin,	joint	and	nail	involvement,	
has	 been	 considered	 as	 an	 autoimmune	 disorder	 with	 a	 major	 role	 for	 adaptive	
immunity.	However,	recently	the	view	on	the	pathogenesis	of	psoriatic	joint	and	nail	
disease has been challenged.29-31	 Genetic	 studies	 fail	 to	 demonstrate	 a	 human	
leukocyte	antigen-Cw6	(HLA-Cw6)	association	in	nail	psoriasis	and	PsA.32-34 The nails 
and	joints	share	a	common	microanatomical	basis	and	psoriatic	nail	and	joint	disease	
may	 be	 linked	 to	 tissue-specific	 factors	 that	 lead	 to	 activation	 of	 innate	 immune	
responses	 (autoinflammatory	 basis),	 rather	 than	 adaptive	 immunity	 (autoimmune	
basis).29-31 
	 In	conclusion,	the	most	common	clinical	signs	of	nail	involvement	in	our	fingernail	
psoriasis study group were onycholysis and splinter hemorrhages. Red spots in the 
lunula appear to be an infrequent sign. Various nail psoriasis symptoms, such as 
splinter hemorrhages, also appeared in individuals without nail disease, however 
they	 were	 significantly	 less	 frequent.	 Remarkably,	 we	 showed	 that	 leukonychia	
appears frequently in individuals without nail disease and is a nail change found in 
both	healthy	individuals	and	patients	with	fingernail	psoriasis.	Therefore,	it	should	be	
reconsidered	whether	leukonychia	is	the	consequence	of	the	inflammatory	process	
of psoriasis or a more common phenomenon and whether it should play a role in any 
scoring system for nail psoriasis, such as the NAPSI score. On the other hand, 
longitudinal	ridges	and	Beau’s	lines	occurred	more	frequently	in	fingernail	psoriasis	
but	are	not	included	in	the	NAPSI.	A	significant	correlation	between	NAPSI	and	PASI	
scores	 could	 not	 be	 found,	 which	 raises	 the	 question	 whether	 nail	 psoriasis	 is	 a	
comorbidity of psoriasis or an isolated disease expression.
relevance	of	Beau’s	lines	for	estimating	disease	activity	in	nail	psoriasis	and	included	
the	number	of	Beau’s	lines	in	his	nail	psoriasis	severity	scoring	system.
 Various nail symptoms known to occur in nail psoriasis (splinter hemorrhages, 
onycholysis,	pitting	and	subungual	hyperkeratosis)	were	also	observed	in	the	control	
group	 without	 nail	 disease.	 However,	 those	 nail	 changes	 were	 significantly	 less	
frequent	 in	 the	 control	 group	 compared	 with	 the	 fingernail	 psoriasis	 group.	 In	
contrast, leukonychia was even more frequently seen in the control group. This 
finding	suggests	that	leukonychia	is	not	a	nail	psoriasis-specific	symptom	and	raises	
the	question	of	whether	leukonychia	is	the	consequence	of	the	inflammatory	process	
characterizing psoriasis or just occurring in nail psoriasis because it has a very high 
prevalence	 in	the	general	population.	Leukonychia	was	present	 in	over	65%	of	our	
healthy	control	subjects.	Consequently,	the	NAPSI	score	and	especially	the	positioning	
of leukonychia in this score should perhaps be reconsidered. The same applies to the 
red	spotted	lunula,	because	this	sign	was	rarely	observed.	However,	the	red	spotted	
lunula,	oil-drop	discoloration,	and	nail	plate	crumbling	were	only	observed	in	patients	
with	fingernail	psoriasis	and	therefore	seem	more	specific	for	the	diagnosis	of	nail	
psoriasis. 
	 The	NAPSI	score	is	an	objective	tool	for	the	evaluation	of	nail	psoriasis8 and the 
interobserver reliability is established.16,22	A	modification	of	this	scoring	system,	the	
modified	 (target)	NAPSI	 score,	using	gradation	systems	 for	 the	different	nail	 signs,	
was proposed by two separate study groups.23,24 Chandran et al.25 found excellent 
agreement	on	the	modified	NAPSI24 among rheumatologists and dermatologists. Our 
study	 results	 made	 us	 reconsider	 these	 (modified)	 NAPSI	 scoring	 systems.	 We	
question	whether	leukonychia	should	remain	in	nail	psoriasis	disease	severity	scores	
and	whether	 additional	 symptoms,	 such	 as	 Beau’s	 lines,	 should	 be	 added.	 Baran21 
proposed	 a	 different	 scoring	 system,	which	meets	 these	 criteria.	However,	 to	 our	
knowledge reliability assessment of this scoring system has not yet been done and 
assessing nail psoriasis severity based on only four clinical features seems 
questionable.	Furthermore	evaluating	subungual	hyperkeratosis	with	a	calliper	is	not	
convenient.	Different	fingernail	findings	have	been	taken	into	account	in	the	grading	
system used by Cannavò et al.,26	but	again	additional	symptoms,	such	as	Beau’s	lines,	
were not taken into account and interrater reliability assessment of this scoring 
system	has	not	been	performed	yet.	Additional	studies	assessing	the	reliability	and	
sensitivity	 of	 the	 different	 scoring	 systems	 and	 larger	 observational	 case-control	
studies concerning clinical signs of nail psoriasis to decide which symptoms should be 
part	of	an	optimal	nail	score	are	needed.
	 We	did	not	find	a	correlation	between	mean	NAPSI	scores	and	mean	PASI	scores.	
This	raises	the	question	of	whether	nail	psoriasis	is	a	comorbidity	of	psoriasis	or	an	
isolated disease expression. Rich et al.12	 also	 did	 not	 find	 a	 correlation	 between	
baseline NAPSI and PASI scores. However, improvement of PASI score did correlate 
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CHAPTER 2
Introduction
While	skin	manifestations	are	the	most	characteristic	finding	 in	patients	with	psoriasis,	 
nail	 involvement	 is	 an	 often	 overlooked	 feature	 of	 the	 disease.1 The documented 
prevalence	 of	 nail	 psoriasis	 is	 divergent	 and	 varies	 between	 10.0%	 and	 81.8%	 of	
patients	 with	 psoriasis,	 with	 an	 estimated	 lifetime	 incidence	 of	 80-90%.2-17 Nail 
psoriasis	 in	the	absence	of	cutaneous	disease	 is	present	 in	only	5-10%	of	patients	with	
psoriasis.10,18 
 The nail unit can be subdivided into the nail plate, nail bed and nail matrix. The 
nail matrix, at the proximal end of the nail, synthesizes the nail plate.19 Clinical 
manifestations	associated	with	nail	psoriasis	are	divergent	 in	 their	 representation,	
and	correlate	with	the	anatomical	subunit	of	the	nail	that	is	affected	by	the	disease.18 
Psoriatic	 disease	 of	 the	 nail	 matrix	 causes	 characteristic	 nail	 manifestations	 such	 
as	 red	 spots	 in	 the	 lunula,	 leukonychia,	 pitting	 and	 nail	 plate	 crumbling.3 Clinical 
manifestations	 associated	 with	 nail	 bed	 involvement	 are	 oil-drop	 discoloration,	
splinter hemorrhages, subungual hyperkeratosis and onycholysis.3 This variability of 
clinical	manifestations	and	localization	makes	treatment	of	nail	psoriasis	challenging.	
Both	the	delivery	of	effective	topical	drugs	to	the	nail	unit	and	the	toxicity	associated	
with	many	 conventional	 systemic	 therapies	make	 treatment	 even	more	 difficult.11 
In	addition,	nail	disease	can	be	 refractory	 to	 treatment	and	different	 features	can	
respond	 variably	 to	 different	 treatments.19	 However,	 research	 in	 the	 field	 of	 nail	
psoriasis is sparse but certainly important, as the impact of onychopathy on the 
quality	of	life	is	high,	particularly	if	considered	in	terms	of	poor	cosmetic	appearance,	
pain	and	restrictions	in	activity	of	daily	living.4, 13 
	 To	improve	care	for	patients	with	nail	psoriasis,	it	is	essential	to	acquire	knowledge	
concerning	this	disease.	Therefore,	the	aim	of	this	study	was	to	obtain	quantitative	
information	on	 the	 characteristics	of	patients	with	psoriasis	with	nail	 involvement	
compared	with	psoriasis	patients	without	nail	involvement	in	a	large	cohort,	and	to	
give	insight	into	treatment	experiences	of	patients	with	nail	psoriasis.
Material and methods
Setting and participants
A	structured	questionnaire	was	developed	to	assess	the	clinical	characteristics	of	nail	
psoriasis	 and	 to	 assess	 patients’	 experiences	 of	 treatment	 of	 nail	 psoriasis.	 This	
self-administered	 questionnaire	 was	 distributed	 to	 all	 members	 (n=5400) of the 
Dutch	Psoriasis	Association	together	with	an	invitational	letter	explaining	the	purpose	
of	the	study	and	reply-paid	envelopes.	The	questionnaire	was	completed	anonymously	
and	no	incentives	were	given.	The	investigation	was	conducted	from	the	14	April	2011	
Abstract
Background:	Skin	manifestations	are	the	most	characteristic	finding	of	psoriasis.	However,	
nail	involvement	is	also	a	clinical	feature	of	disease	although	it	is	often	overlooked.	
The	documented	prevalence	of	nail	psoriasis	varies	between	10.0%	and	81.1%.
Objectives:	The	aim	of	this	investigation	was	to	gain	knowledge	about	the	prevalence	
and	clinical	manifestations	of	nail	psoriasis	and	patients’	experiences	of	treatment	of	
nail psoriasis. 
Method:	A	structured,	self-administered	questionnaire	was	distributed	to	all	members	
(n=5400)	of	the	Dutch	Psoriasis	Association.	The	questionnaire	enquired	about		socio	-	
demographic	 patient	 characteristics,	 disease-related	 data	 and	 treatment	 of	 nail	
psoriasis.	Patients	reported	their	nail	manifestations	with	photographs	after	instruction.	
Patients	with	nail	psoriasis	were	compared	with	patients	without	nail	psoriasis.
Results: A	response	rate	of	27.0%	was	achieved. The prevalence of nail psoriasis was 
66.0%.	The	most	frequently	observed	psoriatic	nail	manifestation	was	pitting	(65.4%),	
whereas	 red	 spots	 in	 the	 lunula	were	 infrequently	 seen	 (6.5%).	 Patients	with	 nail	
psoriasis	more	frequently	stated	psoriasis	capitis	(75.8%	vs.	65.7%),	genital	psoriasis	
(32.7%	vs.	20.3%)	and	psoriatic	arthritis	(46.4%	vs.	30.6%)	compared	with	patients	
with	psoriasis	without	nail	 involvement.	Only	16.0%	of	patients	received	treatment	
for	nail	psoriasis.	Systemic	therapies	were	most	frequently	stated	as	being	effective	
for nail lesions.
Conclusion: Nail	manifestations	seem	to	be	more	prevalent	in	patients	with	psoriasis	
than	previously	 thought.	 In	 addition,	nail	 psoriasis	 is	 shown	 to	be	associated	with	
widespread	and	more	severe	forms	of	psoriasis,	and	different	treatment	options	are	
experienced	as	being	effective	for	nail	psoriasis.	Notwithstanding,	nail	psoriasis	is	still	
an	often	overlooked	feature	of	the	disease. 
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25.7	±	15.1	years	with	a	mean	duration	of	disease	of	31.7	±	15.9	years.	The	mean	age	at	
diagnosis of psoriasis was 27.6 ± 15.3 years. 
In	total,	62.9%	(n	=	918)	of	the	respondents	had	a	positive	family	history	of	psoriasis.	
Nail Psoriasis
Of	 the	 1459	 respondents,	 963	 patients	 (66.0%)	 stated	 that	 their	 nails	 had	 been	
affected	by	psoriasis	at	some	time	during	the	course	of	their	disease.	This	corresponds	
and	responses	were	accepted	through	to	1	August	2011.	Prior	to	the	distribution	of	the	
questionnaire	a	pilot	study	was	conducted	on	10	patients	to	improve	the	quality	of	
the	questionnaire.
Questionnaire
The	questionnaire	enquired	about	the	sociodemographic	patient	characteristics	(e.g.,	
age, sex, work), psoriasis medical data (e.g., age of onset, type of psoriasis, family 
history,	treatment	history),	questions	concerning	nail	psoriasis	(e.g.,	presence	of	nail	
psoriasis,	features	of	nail	psoriasis,	 localization,	age	of	onset)	and	questions	concerning	
treatment	history	of	 (nail)	psoriasis	and	potential	unmet	medical	need.	 Instruction	
photographs	 showing	 pitting,	 oil-drop	 discoloration,	 leukonychia,	 onycholysis,	 red	
spots in the lunula, splinter hemorrhages and subungual hyperkeratosis were 
included.	 Based	 on	 these	 photographs,	 patients	 could	 indicate	 which	 of	 the	 nail	
features were present. 
Statistical analysis
Data	 were	 entered	 into	 a	 Statistical	 Package	 for	 Social	 Sciences	 18.0	 (SPSS	 inc.,	
Chicago,	 IL,	 U.S.A.)	 database	 and	 subsequent	 statistical	 analyses	 were	 performed	
using	SPSS.	Descriptive	statistics	were	provided	using	mean	(SD)	and	median	(range)	
for	 normally	 and	 nonparametrically	 distributed	 numeric	 values,	 respectively.	
Frequencies and percentages were used for categorical variables. Missing values 
were	not	included	in	calculation	of	percentages.	Comparisons	of	numeric	variables	
were analysed with the unpaired t-tests or the Mann-Whitney U	test	and	the	χ2 or 
Fisher	exact	 test	was	used	 for	differences	between	categorical	variables.	One-way	
ANOVA was used when more than two means were compared. P-values <0.05 were 
considered	to	be	statistically	significant.
Results
Patients 
In	 total,	5400	questionnaires	were	distributed.	Within	the	study	period	1475	were	
completed	and	returned,	resulting	in	a	response	rate	of	27.3%.	Of	the	1475	patients	
who	 completed	 the	 questionnaire,	 16	were	 excluded	 due	 to	missing	 values.	 After	
exclusion	of	invalid	questionnaires,	1459	datasets	(27.0%)	were	suitable	for	analysis.
Patient characteristics
The	distribution	of	patient	characteristics	is	reported	in	Table	1.	The	mean	age	±	SD	of	
the respondents was 57.5 ± 13.7 years. Among the respondents, 736 were female (51.1 
%)	and	705	were	male	(48.9%).	The	self-reported	mean	age	at	onset	of	psoriasis	was	
Table 1			Sociodemographic	and	clinical	characteristics	of	patients	with	and	
without nail involvement.
Nail 
involvement
(n = 963)
No nail 
involvement
(n = 496)
p- valuea All patients
(n = 1459)
Gender,	n	(%)
    Female 464 (48.2) 272 (54.8) 0.012 736 (50.4)
    Male   489 (50.8) 216 (43.5) 705 (48.3)
    Not reported   10 (1.0)      8 (1.6)   18 (1.2)
Age (years), mean ±SD  56.9 ± 12.8 58.7 ± 15.1 0.026 57.5 ± 13.7
Age start psoriasis (years),  
mean ±SD
24.4 ± 14.0 28.3 ± 16.7 <0.001 25.7 ± 15.1
Duration	of	psoriasis	(years),	
mean ±SD
32.4 ± 15.3 30.3 ± 16.8 0.024 31.7 ± 15.9
Family	history,	n	(%)
				Positive 621 (64.5) 297 (59.9) 0.153 918 (62.9)
				Negative 188 (19.5) 117 (23.6) 305 (20.9)
    Unknown 154 (16.0)   82 (16.5) 236 (16.2)
Type	of	psoriasis,	n	(%)
    Plaque psoriasis 662 (68.7) 293 (59.1) <0.001 955 (65.5)
				Guttate	psoriasis 546 (56.7) 277 (55.8) 0.868 823 (56.4)
    Pustular psoriasis   49 (5.1)   17 (3.4) 0.153   66 (4.5)
				Psoriasis	capitis 729 (75.7) 324 (65.3) <0.001 1053 (72.2)
    Erythrodermic psoriasis 116 (12.0)   38 (7.7) 0.011 154 (10.6)
				Psoriatic	arthritis 446 (46.3) 151 (30.4) <0.001 597 (40.9)
    Inverse psoriasis 255 (26.5) 102 (20.6) 0.015 357 (24.5)
    Genital psoriasis 315 (32.7) 100 (20.2) <0.001 415 (28.4)
a Level	of	significance;	t-test	for	numerical	statistics	and	χ2-test	for	categorical	statistics.
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	 The	mean	age	at	 the	onset	of	 skin	manifestations	of	psoriasis	 in	 the	group	of	
patients	with	nail	involvement	(24.4	±	14.0	years)	was	significantly	lower	than	in	the	
group without nail features (28.3 ± 16.7 years, p=<0.001).	Thirteen	patients	aged	18	
years	or	younger	returned	the	questionnaire,	of	whom	four	(30.8%)	stated	that	they	
had nail psoriasis. When comparing those with onset of psoriasis under the age of 18 
years	with	those	with	onset	above	the	age	of	18	years,	no	statistical	difference	was	
found for the prevalence of nail psoriasis (p=0.163,	χ2-test). 
Type of psoriasis
As	 shown	 in	 Table	 1,	 psoriatic	 arthritis	 (PsA)	was	 present	 in	 446	 patients	 (46.3%)	 
with	 nail	 psoriasis,	 compared	 with	 151	 patients	 (30.4%)	 without	 nail	 involvement	 
( p=	<0.001,	χ2-test).	The	prevalence	of	nail	psoriasis	in	patients	with	PsA	was	74.7%.	
Regarding	 the	possible	 localizations	of	psoriasis,	genital	psoriasis,	 inverse	psoriasis	
and	 psoriasis	 capitis	were	 also	 seen	 significantly	more	 frequently	 in	 patients	with	 
nail involvement. 
Treatment nail psoriasis
Of	the	963	patients	with	nail	psoriasis,	158	(16.4%)	indicated	that	they	had	received	
treatment	specific	for	their	nail	psoriasis	 (Table	2).	Figure	2	shows	which	therapies	
patients	found	to	be	effective	for	their	nail	psoriasis,	whether	or	not	started	initially	
for	 their	 nail	 lesions.	 The	 three	 therapies	 most	 frequently	 mentioned	 as	 being	
effective	 for	 treatment	of	nail	 lesions	were	all	 systemic	 therapies	 (biologics,	n=20;	
to	 17.8%	 of	 the	 entire	 study	 population	 (n=5400).	 The	most	 frequently	 observed	
psoriatic	 nail	 manifestation	 was	 pitting	 (65.4	 %)	 followed	 by	 onycholysis	 (57.7%)	
(Table 2). Splinter hemorrhages and red spots in the lunula were infrequently seen 
(13.5%	and	6.5%,	respectively).	Nail	psoriasis	involved	predominantly	the	nail	matrix	
and	 nail	 bed	 simultaneously	 (59.0%).	 Most	 frequently,	 both	 the	 fingernails	 and	
toenails	were	affected	simultaneously	(62.0%,	n=	597).	The	mean	number	of	affected	
fingernails	was	5.9	±	3.3	and	the	mean	number	of	affected	toenails	was	5.3	±	3.3.
 The mean age at onset of nail psoriasis was 36.4 ± 14.7 years. Figure 1 shows that 
nail	features	started	predominantly	after	the	onset	of	the	cutaneous	lesions,	with	a	
mean	delay	of	11.5	±	13.0	years.	However,	psoriatic	involvement	of	the	nail	may	begin	
at	almost	any	age,	given	the	broad	range	reported	by	the	patients	(age	range	1-90	
years).	 Of	 the	 patients	 with	 nail	 psoriasis,	 3.7%	 had	 nail	 psoriasis	 as	 an	 initial	
presentation	of	 their	 psoriasis,	 and	 16.8%	of	 the	patients	developed	psoriatic	 skin	 
and	nail	lesion	simultaneously.	The	remaining	patients	(79.5%)	developed	nail	lesions	
after	the	start	of	cutaneous	psoriasis	manifestations.	
Figure 1.		Distribution	of	ages	at	onset	of	nail	psoriasis	vs.	onset	of	psoriasis.
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Table 2			Self-reported	characteristics	of	patients	with	nail	psoriasis.
Nail involvement ( n = 963)
Age at onset of nail psoriasis (years), mean ±SD 36.4 ± 14.7
Duration	of	nail	psoriasis	(years),	mean	±SD 20.4 ± 13.5
Localization,	n	(%)
  Fingernails only 244 (25.3)
  Toenails only 108 (11.2)
  Both 597 (62.0)
  Unknown   14 (1.5)   
Nail	features,	n	(%)
		Pitting 630 (65.4)
  Onycholysis 556 (57.7)
		Oil-drop	discoloration 399 (41.4)
  Subungual hyperkeratosis 324 (33.6)
  Leukonychia 309 (32.1)
  Splinter hemorrhages 130 (13.5)
  Red spots   63 (6.5)
Treatment	for	nail	psoriasis,	n	(%)
  Yes 158 (16.4)
  No 781 (81.1)
  Unknown    24 (2.5)
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overestimation	and	likely	must	be	revised	downwards.	Nevertheless,	even	assuming	
that	all	of	the	non-responders	do	not	have	nail	involvement,	still	17.8%	of	the	patients	
with	psoriasis	in	the	Dutch	Psoriasis	Association	stated	that	they	have	nail	involvement.	
The	true	percentage	of	nail	involvement	in	patients	with	psoriasis	will	therefore	lie	
between	17.8%	and	66.0%.	 In	the	 literature,	percentages	of	patients	with	psoriasis	
with	nail	involvement	vary	between	10.0%	and	81.8%.4, 9, 20, 8, 10, 12, 14, 15, 21, 22, 7 Comparison 
of	 the	 different	 prevalence	 numbers	 of	 nail	 psoriasis	 found	 in	 different	 studies	 is	
difficult	as	a	consequence	of	the	different	methodological	designs.	A	design	comparable	
with the present study was used in two studies.4, 15	Both	studies	sent	a	questionnaire	
to	members	of	their	national	psoriasis	association	and	found	higher	prevalence	rates	
of	79.2%	and	72.8%.	Most	prevalence	studies	were	secondary-based	studies	including	
consecutive	patients	with	psoriasis	from	outpatient	clinics.	Diagnosis	was	made	by	
clinical	examination.	These	studies	 found	prevalence	rates	varying	between	47.4%	
and	 78.3%.	 Two	 studies7, 14	 included	 consecutive	patients	with	 psoriasis	 from	 their	
outpatient	clinical	and	excluded	patients	using	systemic	therapies.	The	nail	psoriasis	
prevalence	rates	were	66.7%	and	47.4%,	the	mean	Psoriasis	Area	and	Severity	Index	
(PASI) was 12.8. One study10	 included	consecutive	patients	with	an	exacerbation	of	
their	psoriasis	and	found	a	prevalence	of	78.3%.	Augustin	et	al.13 examined the nails of 
patients	from	both	primary	and	secondary	care	and	found	a	prevalence	of	40.9%.	A	
phase	III	study	of	378	patients	with	psoriasis	with	PASI	>12	found	a	prevalence	of	nail	
psoriasis	of	81.8%.21 More severe psoriasis seems to be related to a higher prevalence 
of nail psoriasis.13, 15, 21 It might be expected that our prevalence number is an 
overestimation,	as	patients	who	are	members	of	a	patients’	association	might	have	
more	 severe	 psoriasis,	 but	 the	 a	 prevalence	 rate	 of	 66.0%	 seems	 in	 line	with	 the	
discussed	cohort	studies.	Only	two	studies	found	prevalence	rates	below	40.0%.12,22 
The	prevalences	found	in	the	remaining	studies	varied	between	40%	and	80%,	and	
are in line with the result of the present study.
	 Few	previous	 studies	 investigated	 the	 prevalence	 of	 nail	 psoriasis	 in	 children.	
These studies showed a lower prevalence of nail psoriasis compared with adults, 
varying	from	7.0%	to	39.4%.23-26 In our study only 13 children aged 18 years or younger 
responded,	 of	 whom	 30.8%	 stated	 that	 they	 had	 nail	 psoriasis.	 Most	 likely,	 few	
children	 are	members	 of	 the	 Dutch	 Psoriasis	 Association.	 Larger	 studies	must	 be	
conducted	to	estimate	the	prevalence	of	nail	psoriasis	among	children.	We	did	not	
find	a	significant	difference	of	the	prevalence	of	nail	psoriasis	between	patients	with	
childhood onset of psoriasis vs. adult onset, but lower prevalence rates of nail 
psoriasis in paediatrics are expected as we found that nail psoriasis seems to express 
several	years	after	the	onset	of	the	cutaneous	psoriasis	lesion.
	 It	is	evident	from	this	study	that	there	are	few	patients	who	received	therapy	for	
their	nail	psoriasis,	as	only	16.0%	stated	that	they	received	some	form	of	treatment.	
A 1996 study by de Jong et al.4	on	the	same	patient	group	revealed	that	35.4%	had	
fumaric acid, n=20; and methotrexate, n=16). In total, 108 respondents reported that 
they	 had	 experienced	 some	 form	 of	 treatment	 that	 was	 effective	 for	 their	 nail	
psoriasis.	Of	all	the	patients	with	nail	psoriasis,	46.7%,	stated	that	they	would	like	to	
receive treatment for their nail disorder.
Discussion
Few	large	studies	on	the	epidemiology	of	nail	psoriasis	and	patients’	experiences	of	
treatment of nail psoriasis have been conducted. The present study illustrates that 
66%	of	the	patients	with	psoriasis	reported	nail	involvement	at	some	time	during	the	
course	of	their	skin	disease,	starting	predominantly	several	years	after	the	onset	of	
cutaneous	psoriasis	lesions.	Furthermore,	very	few	patients	received	treatment	for	
their	nail	psoriasis,	while	nail	lesions	can	have	a	substantial	impact	on	patients’	quality	
of life.4	However,	some	patients	certainly	experienced	the	positive	effect	of	several	
psoriasis	treatment	options.
	 The	large	number	of	patients	responding	to	our	questionnaire	provides	valuable	
insight	 into	 the	epidemiology	of	nail	psoriasis,	which	 is	a	presentation	of	psoriasis	
that	has	received	limited	attention	from	medical	professionals	until	now.	Two-thirds	
of	the	patients	reported	nail	psoriasis,	which	indicates	a	high	prevalence.	It	may	be	
assumed	that	patients	with	nail	psoriasis	preferentially	returned	the	questionnaire,	
which	might	have	caused	a	response	bias.	Therefore,	the	value	of	66.0%	might	be	an	
Figure 2.		Effective	therapies	against	nail	psoraisis	based	on	patients’	experiences.
UV, ultraviolet.
20 20 
16 
8 7 6 
4 3 3 3 3 
15 
0 
5 
10 
15 
20 
25 
Bio
log
ics
 
Fu
ma
ric
 ac
id 
M
et
ho
tre
xa
te
 
To
pic
al 
co
rti
co
ste
ro
ids
 
UV
 th
er
ap
y 
Cic
los
po
rin
e 
Pe
dic
ur
e 
Ac
itr
eti
n 
Lo
ca
l in
jec
tio
n 
Ar
tiﬁ
cia
l n
ail
 
Na
il p
oli
sh
 
Ot
he
r 
N
um
be
r 
of
 p
ati
en
ts
 
Treatment modality 
CHAPTER 2 PREVALENCE AND CLINICAL CHARACTERISTICS OF NAIL PSORIASIS
58 59
2
had	no	relationship	with	punctuate	and	pustulate	psoriasis.	On	the	other	hand	we	did	
find	a	relation	between	the	different	localizations	of	psoriasis	(genital,	joints,	capitis	
and	inverse)	and	nail	involvement.	The	association	between	nail	psoriasis	and	these	
localizations	 of	 psoriasis	 (genital,	 capitis	 and	 inversa)	 has	 not	 been	 described	
previously to our knowledge. The presence of nail psoriasis was already correlated 
with	more	 severe	 clinical	manifestations	 of	 psoriasis	 in	 terms	 of	 higher	 PASI.7, 13, 16 
Moreover,	nail	psoriasis	is	significantly	more	frequently	seen	in	PsA,	even	reaching	a	
prevalence	 of	 70-80%.33	 Our	 data	 confirmed	 that	 PsA	 occurs	 more	 frequently	 in	
patients	 with	 nail	 psoriasis.	 The	 pathophysiology	 of	 nail	 dystrophy	 has	 been	
postulated to be more closely associated with joint symptoms than with skin 
symptoms.1	It	has	been	hypothesized	that	there	is	a	direct	link	between	inflammation	
of	the	distal	interphalangeal	joint	and	psoriatic	nail	changes	via	the	enthesis,	which	
forms	the	connection	between	those	structures.	 1, 34-36	Taken	all	 these	findings	 into	
account,	it	might	be	hypothesized	that	patients	with	nail	psoriasis	are	more	likely	to	
have	more	extensive	and	severe	forms	of	psoriasis	with	widespread	localization	and	
involvement	 of	 joints.	 All	 of	 these	 findings	 should	 be	 taken	 into	 account	 when	
considering	the	therapeutic	options	for	patients	with	psoriasis	with	nail	involvement.
As	our	questionnaire-based	study	asked	retrospectively	for	information,	a	recall	bias	
might	be	present,	which	can	cause	either	an	over-	or	underestimation	of	the	results.	
Also,	 a	 selection	bias	might	be	 created	by	questioning	 the	members	of	 the	Dutch	
Psoriasis	Association,	as	members	of	a	patient-support	association	may	possibly	not	
represent	a	random	sample	of	patients	with	psoriasis.	It	may	be	speculated	that	these	
patients	are	perhaps	more	interested	or	worried	about	their	disease	or	they	might	
suffer	from	more	severe	psoriasis.	On	the	other	hand	the	influence	of	social	desirability	
in	answering	the	questions	was	minimized.	Bearing	in	mind	the	multiple	differential	
diagnosis for nail psoriasis, we deliberately asked if diagnosis was made by a general 
practitioner	or	a	medical	specialist.	The	main	advantage	of	the	study	design	was	that	
a	large	number	of	patients	could	be	included.
Conclusion
In	summary,	nail	manifestations	seem	to	be	more	prevalent	in	patients	with	psoriasis	
than previously thought, and nail psoriasis seems to be associated with more 
extensive	forms	of	psoriasis.	However,	only	a	minority	of	patients	with	nail	psoriasis	
receive	treatment,	but	patients	have	experienced	positive	effects	on	nail	symptoms	
with	different	 types	of	 therapies.	When	considering	 therapy	 for	patients	with	nail	
psoriasis	these	results	might	influence	the	choice	of	therapy.	Nail	psoriasis	still	seems	
to be an overlooked feature of the disease and further research must focus on the 
effect	of	psoriasis	treatment	on	the	nails.
used	treatment	for	psoriatic	nail	lesions.	This	percentage	more	than	halved	in	a	time	
frame	of	16	years,	while	the	therapeutic	options	for	psoriasis	have	increased.	
	 Studies	 concerning	 the	 quality	 of	 life	 in	 patients	 with	 psoriasis	 with	 nail	
involvement	showed	that	the	impairments	and	restrictions	experienced	because	of	
the	nail	disease	are	significant.4, 13, 15, 27 Despite data showing that nail disease can be 
an	important	determinant	of	functional	impairment	in	psoriasis,	management	of	nail	
psoriasis	 is	 still	 often,	 or	 even	more,	 overlooked	 compared	 to	 16	 years	 ago.	 One	
possible	 explanation	 for	 this	 undertreatment	 is	 that	 therapies	 for	 psoriatic	 nail	
disease	are	perceived	to	be	ineffective	by	dermatologists,	and	results	are	seen	only	
after	 a	 long	 period	 of	 treatment,	 as	 nails	 grow	 and	 recover	 slowly.	 The	 principal	
motivation	to	seek	treatment	is	most	often	the	cutaneous	component,	and	the	focus	
of psoriasis treatment therefore goes to the cutaneous component. Langley and 
Dauden18 concluded that the clinical evidence for nail psoriasis treatments are sparse, 
and	the	effect	of	most	treatment	modalities	is	not	proven	in	clinical	trials,	but	recent	
investigations	concerning	systemic	therapies	in	nail	psoriasis	have	shown	promising	
results.18, 28, 29	In	addition,	our	results	on	patients’	experience	support	such	findings.	
Patients	stated	that	they	have	experienced	positive	effects	of	treatments	on	their	nail	
psoriasis,	in	particular	with	systemic	therapies.	Our	data	support	the	findings	that	nail	
psoriasis	can	be	treated	effectively,	but	studies	and	publications	must	focus	more	on	
the	effects	of	therapies	on	nail	psoriasis	because	evidence	is	missing.
	 The	 prevalence	 of	 the	 different	 manifestations	 seen	 in	 nail	 psoriasis	 varies	
considerably	 in	 the	 literature.	 Our	 result,	 showing	 that	 pitting,	 onycholysis	 and	
oil-drop	discoloration	were	the	most	frequently	seen	nail	changes,	is	 in	agreement	
with most previous studies.14, 21, 30, 31 The study design, using photographs in self-ad-
ministered	 questionnaires,	 made	 it	 possible	 to	 collect	 data	 on	 the	 clinical	
manifestations	 of	 nail	 psoriasis	 in	 a	 large	 number	 of	 patients.	 A	 limitation	 of	 this	
design	is	that	patients	self-assessed	the	presence	of	nail	features,	which	might	give	an	
over-	or	underestimation	of	nail	features.	Nevertheless,	the	results	are	in	line	with	
previous	cohort	studies,	so	we	could	confirm	that	onycholysis,	pitting	and	oil-drop	
discoloration	are	frequently	seen	in	nail	psoriasis.14, 21, 30 We found that red spots in 
the	lunula	and	splinter	hemorrhages	were	infrequently	found	in	nail	psoriasis	(6.5%	
and	13.5%,	respectively).	This	is	in	line	with	the	findings	of	Kyriakou	et	al.,14 who found 
a	prevalence	of	red	spots	in	the	lunula	of	1.3%,	and	with	the	results	of	Aktan	et	al.,32 
who	found	a	prevalence	of	0.4%.	Prevalence	numbers	of	splinter	hemorrhages	in	the	
literature	 vary	 between	 1.0%	 and	 42.0%,14, 16, 21, 31, 32 only one study found splinter 
hemorrhages	 in	 the	 top	 three	 most	 frequently	 seen	 nail	 manifestation	 in	 nail	
psoriasis.8
	 Previous	studies	have	already	focused	on	the	correlation	between	nail	psoriasis	
and	 skin	 involvement	 patterns	 (e.g.,	 plaque-type	 psoriasis,	 psoriasis	 punctuate,	
psoriasis pustulosa).12, 14 In accordance with these studies we found that nail psoriasis 
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CHAPTER 3
Introduction
Psoriasis	 vulgaris	 is	 a	 chronic	 inflammatory	 skin	 disorder	 which	 is	 frequently	
accompanied	by	nail	changes	and/or	 joint	disease	(i.e.	psoriatic	arthritis,	PsA).	The	
prevalence	of	nail	disease	among	psoriasis	patients	varies	between	10%	and	81%,	and	
the	reported	lifetime	incidence	in	psoriatic	patients	is	80%	to	90%.1 The characteris-
tics	 of	 nail	 psoriasis	 are	 pitting,	 onycholysis,	 splinter	 hemorrhages,	 subungual	
hyperkeratosis,	red	spots	in	the	lunula,	oil-drop	discoloration,	leukonychia	and	nail	
plate crumbling, which can be divided into nail matrix and nail bed symptoms.2,3 
Psoriatic	nail	lesions	rarely	appear	as	the	only	clinical	manifestation	of	psoriasis,	as	
psoriasis	limited	to	the	nails	occurs	in	only	1%	to	18%	of	patients	with	psoriasis.2,4,5
 It is known that psoriasis on visible areas of the skin, such as the face and hands, 
may	 have	 a	 substantial	 negative	 impact	 on	 physical,	 psychological	 and	 social	
dimensions of quality of life (QoL).6-10 Fingernail psoriasis is also highly visible and 
therefore	 it	 is	 likely	 to	 influence	QoL,	but	 the	 impact	of	 this	disease	on	QoL	 is	 an	
underexplored	area.	As	a	result,	little	information	is	available	concerning	this	topic.	
Besides	the	cosmetic	aspect,	 intact	nails	play	a	critical	role	 in	protecting	the	distal	
phalanges of the digits from mechanical and chemical trauma. The nails contribute to 
the	tactile	discrimination	and	fine	motor	capacities	of	the	fingertips,	and	consequently	
partly	or	total	loss	of	nail	quality	means	that	those	functions	may	be	compromised.11 
De Jong et al.12	 were	 the	 first	 to	 describe	 the	 consequences	 of	 nail	 psoriasis	 on	
patients’	 daily	 life,	 and	 they	 reported	 that	 the	 condition	 can	 be	 associated	 with	
varying degrees of physical impairment and loss of dexterity, including the ability to 
retrieve	small	objects.	The	objective	of	our	study	was	to	 investigate	the	 impact	of	
fingernail	 psoriasis	 on	 patients’	 QoL	 using	 validated	 questionnaires	 concerning	
health-related	quality	of	life	(HRQoL)	and	a	modified	disease-specific	questionnaire.
Material and Methods
Study design and participants
A	cross-sectional	observational	study	was	performed	among	patients	with	clinically	
diagnosed	fingernail	psoriasis	(Nail	Psoriasis	Severity	Index,	NAPSI	>5)	who	visited	the	
outpatient	 clinic	 of	 the	 Department	 of	 Dermatology	 of	 the	 Radboud	 university	
medical	center,	Nijmegen,	The	Netherlands.	After	informed	consent	had	been	given,	
49	 patients	 (≥18	 years)	 were	 included	 between	 December	 2009	 and	 July	 2012.	
Patients	who	had	used	artificial	nails	in	the	past	6	months	or	had	presence	of	a	skin	
disease	(other	than	psoriasis)	associated	with	nail	manifestations	were	excluded.	To	
exclude	patients	with	concomitant	onychomycosis,	clippings	and	subungual	scrapings	
of	 affected	 fingernails	 were	 collected	 for	 direct	 microscopic	 examination	 (10%	
Abstract
Background:	The	impact	of	various	dermatological	conditions	on	quality	of	life	has	
been extensively studied, however the impact of nail psoriasis on quality of life is an 
underexplored area. 
Objective:	To	investigate	the	impact	of	fingernail	psoriasis	on	patients’	quality	of	life.
Methods:	 A	 cross-sectional	 observational	 study	 using	 validated	 questionnaires	
concerning	quality	of	life	(Short	Form-36,	and	a	modified	onychomycosis	questionnaire)	
was	performed	in	49	patients	with	fingernail	psoriasis.
Results:	 The	 mean	 Short	 Form-36	 scores	 for	 fingernail	 psoriasis	 patients	 were	
comparable	to	the	mean	scores	of	the	Dutch	reference	population.	However,	mean	
scores	on	the	modified	onychomycosis	quality	of	 life	questionnaire	for	all	domains	
were	 reduced.	 Localisation,	 gender	 and	 duration	 of	 nail	 psoriasis	 influenced	 the	
impact	of	nail	psoriasis	on	patients’	quality	of	life.	
Conclusion:	 Fingernail	 psoriasis	 can	 interfere	 with	 patient’s	 social,	 mental,	 and	
physical	 well-being.	 Assessing	 patients’	 quality	 of	 life	 in	 daily	 practice	 offers	 the	
opportunity	of	a	patient-centred	approach	to	treatment.
CHAPTER 3 QUALITY OF LIFE IN PATIENTS WITH NAIL PSORIASIS 
68 69
3
instructions	from	Drake	et	al.,11	with	0	representing	the	worst	and	100	representing	
the best QoL. The scale was compared to the Dermatology Life Quality Index (DLQI) 
by	 bivariate	 correlation	 (convergent	 validation).16 We	 found	 a	 good	 correlation	
between both scores (r=-0.712, p<0.01).
Visual Analogue Scales (VAS) for pain and Patients’ Global Assessment (PGA) of disease 
severity. To	measure	 pain,	 two	VAS	of	 100	mm	each	were	 included.	 The	first	 VAS	
assessed	 the	 pain	 sensation	 experienced	 from	 nail	 lesions,	 and	 the	 second	 VAS	
measured	the	pain	sensation	of	the	cutaneous	psoriasis	lesions.	Other	requirements	
included the PGA of disease severity on a scale of 0 to 4 (complete control of nail 
psoriasis to no control).
Statistical analysis
Data	were	entered	in	a	Statistical	Package	for	Social	Sciences	(SPSS	18.0,	SPSS	Inc.,	
Chicago,	 Ill,	 USA)	 database	 and	 subsequently	 statistical	 analyses	were	 performed.	
Descriptive	 statistics	 were	 provided	 using	 mean	 (± standard	 deviation,	 SD)	 and	
median (range) for normally and non-parametric distributed numeric values, 
respectively.	Missing	values	were	not	included	to	calculate	percentages.	We	analysed	
the	influence	of	possible	relevant	variables	(e.g.,	gender,	age,	disease	severity)	on	the	
QoL scores. Comparison of numeric variables were analysed with the unpaired t-tests 
or the Mann-Whitney U test. The χ2	 or	 Fisher	 exact	 test	was	 used	 for	 differences	
between	 categorical	 variables.	 ANOVA	 and	 Gabriel’s	 post	 hoc	 tests	 were	 used	 to	
determine	the	(significant)	differences	between	more	than	two	groups	in	a	univariative	
analysis	 of	 variance	 setting.	 P-values	 <0.05	 were	 considered	 to	 be	 statistically	
significant.	All	tests	were	two-sided.
Results
We	enrolled	23	women	(46.9%)	and	26	men	(53.1%)	with	a	mean	age	of	48	years	(±SD	
13.4).	 Further	 descriptive	 demographic	 patient	 characteristics	 are	 summarized	 in	
Table 1 and	have	been	extensively	analysed	in	a	previous	article	by	van	der	Velden	et	al.3
SF-36
Table 2 shows the mean scores for the 9 dimensions of the SF-36. When compared to 
the mean values of the healthy Dutch reference group,15	 no	 significant	differences	
were found except for the role emotional functioning dimension.	Patients	with	nail	
psoriasis scored a mean value of 94.6 (±SD 20.8) compared to a score of 82.3 (±SD 
32.9) (p<0.001) in the reference group. The mean values in all domains were higher 
for males compared to females, except for the domain of expected health change. 
potassium	hydroxide	preparations)	and	fungal	culture.	Cultures	were	carried	out	on	
two	different	types	of	Sabouraud	dextrose	agar:	one	agar	contained	chloramphenicol	
and cycloheximide, and one agar contained chloramphenicol without cycloheximide. 
None	of	the	patients	tested	positive	for	fungus	on	nail	clippings	or	scrapings.	Patients	
who	were	unable	to	fill	in	the	questionnaire	because	of	illiteracy	or	mental	impairment	
or	 who	 had	 suffered	 a	 recent	 serious	 life	 event	 that	 could	 affect	 their	 present	
experienced QoL were also excluded. We have previously studied the clinical features 
of	fingernail	psoriasis	in	the	above-mentioned	patient	group.3
Survey details
The	survey	consisted	of	a	questionnaire	taken	by	interview	(H.M.J.	van	der	Velden)	
and	 self-administered	 questionnaires.	 The	 interview	 included	 items	 concerning	
demographic	 patient	 characteristics	 and	 psoriasis-related	 data.	 The	 severity	 of	
fingernail	psoriasis	was	measured	by	the	NAPSI	(range	0-80).13 Severity of psoriasis of 
the skin was assessed by the Psoriasis Area and Severity Index (PASI) (range 0-72).14 
The	following	self-administered	questionnaires	were	included:	
SF-36. The	 SF-36	 is	 a	 generic	multidimensional	 instrument	 used	 for	 patients’	 self-	
assessment	of	HRQoL,	consisting	of	the	following	9	dimensions:	(1)	limitations	in	physical	
activities	because	of	health	problems	(physical functioning);	 (2)	 limitations	 in	usual	
activities	 because	 of	 physical	 health	 problems	 (role physical functioning, RP); (3) 
bodily pain; (4) general health perceptions; (5) vitality; energy and fatigue; (6) social 
functioning;	(7)	limitations	in	usual	role	activities	because	of	emotional	health	problems	
(role emotional functioning); (8) mental health; (9) expected health change. The subscale 
scores	were	transformed	to	a	0-100	scale	with	higher	scores	indicating	better	HRQoL	
in the domain being measured. We used the validated Dutch version of the SF-36. 
Normative	data	have	been	estimated	for	the	Dutch	population	by	Aaronson	et	al.15
Modified fingernail onychomycosis QoL questionnaire. At the start of this study an 
adequate	 and	 validated	 questionnaire	 assessing	 the	 disease-specific	 QoL	 of	 nail	
psoriasis had not been developed yet. Drake et al.,11 developed a validated onychomy-
cosis-specific	 questionnaire	 designed	 to	 quantify	 the	 impact	 of	 onychomycosis	 on	
patients’	 QoL.	 Considering	 our	 patient	 population,	we	 used	 the	 fingernail-specific	
questionnaire.	 The	 questionnaire	 consisted	 of	 24	 questions	 concerning	 social	
dimension	 (9	 questions),	 emotional	 dimension	 (10	 questions)	 and	 nail-related	
symptoms	(5	questions).	To	develop	a	Dutch	version	of	the	questionnaire,	the	original	
questionnaire	was	translated	‘back’	and	‘forward’.	The	questionnaire	was	linguistically	
modified	without	any	relevant	change	to	the	original	questionnaire.	We	replaced	the	
question	 ‘others	 are	 afraid	 of	 catching	mycosis	 from	me’	 by	 ‘others	 are	 afraid	 of	
catching	 nail	 psoriasis	 from	 me’.	 Scale	 scores	 were	 calculated	 according	 to	 the	
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nail	manifestations.	Females	recorded	more	impaired	QoL	in	all	three	scales	compared	 
to	men,	however	no	statistical	significance	was	reached.	Increasing	age	seems	to	give	
a	decreased	impact	of	fingernail	psoriasis	on	patients’	QoL,	as	a	trend	of	increasing	
scores	 was	 seen	 with	 increasing	 age.	 Patients	 with	 both	 fingernails	 and	 toenails	
involved	 recorded	 lower	 scores	 in	 all	 three	 scales	 compared	 to	 patients	with	 nail	
psoriasis	limited	to	the	fingernails.	Statistical	significance	was	reached	in	the	symptom	
scale (p=0.023).	We	could	not	show	a	clear	correlation	between	disease	severity,	as	
measured	by	the	NAPSI,	and	the	disease-specific	QoL	score.	The	mean	scores	for	the	
three	dimensions	(social	problems,	emotional	problems,	symptoms)	increased	when	
the	duration	of	fingernail	psoriasis	was	prolonged,	indicating	that	the	negative	impact	
of	 fingernail	 psoriasis	 decreased	 when	 duration	 of	 fingernail	 psoriasis	 increased.	
Patients	diagnosed	with	PsA	and	fingernail	psoriasis	scored	higher	QoL	scores	when	
compared	to	fingernail	psoriasis	patients	without	PsA;	statistical	significance	was	not	
reached.	Fingernail	psoriasis	influenced	emotional	well-being,	social	dimension	and	
symptoms	more	negatively	in	patients	with	a	higher	educational	level.
VAS for pain and PGA of disease severity
Patients	assessed	their	disease	severity	with	a	mean	PGA	of	three,	which	indicates	
limited	control	of	fingernail	psoriasis.	The	majority	of	patients	(69.4%)	stated	limited	
None	of	these	differences	were	significant	(data	not	shown).	A	decrease	in	the	mean	
values in each domain was observed with increasing age, especially for the physical 
functioning, social functioning and expected health change dimensions, where 
statistical	significance	was	reached	(97.9	vs.	75.0	p=0.016, 92.1 vs. 75.0 p=0.017, 67.9 
vs. 53.0 p=0.027,	respectively).	Patients	with	PsA	documented	decreased	HRQoL	in	all	
domains except for expected health change.	Significant	lower	scores	were	found	in	
the domains of physical functioning, role physical functioning and bodily pain (63.1 vs. 
91.7 p=0.002, 56.3 vs. 83.1 p=0.045, 65.3 vs. 81.0 p=0.049,	respectively).
Modified fingernail onychomycosis QoL questionnaire
Table	3	shows	the	results	of	the	modified	fingernail	onychomycosis	QoL	questionnaire,	 
and	Table	4	shows	the	mean	scores	in	relation	to	relevant	variables.	The	calculated	
mean	score	for	the	social	scale	was	75.1	(±SD	22.0),	for	the	emotional	scale	78.8	(±SD	
16.6), and for the symptom scale 74.4 (±SD 21.0). The most important aspects 
influencing	patients’	QoL	were	the	feeling	that	other	people	noticed	their	nail	problem	 
and that their nails look neglected, which are both part of the social dimension. It is 
noteworthy	that	49%	of	patients	experienced	some	degree	of	pain	caused	by	their	
Table 1			Sociodemographic	and	clinical	patient	characteristics.
Feature Patients
(n = 49)
Gender,	n	(%)
    Male
    Female
26 (53.1)
23 (46.9)
Age (years) mean ±SD 48 ± 13.4
Age at psoriasis onset (years), mean ±SD 29 ± 14.1
Duration	of	psoriasis,	(years),	mean	±SD 19 ± 13.6
Age at nail psoriasis onset, (years), mean ±SD 38 ± 12.6
Duration	of	nail	psoriasis,	(years),	mean	±SD 10 ± 8.1
Localization	of	nail	psoriasis,	n	(%)
    Fingernails only
    Toenails only 
				Both,	finger-	and	toenails
10 (20.4)
NA
39 (79.6)
NAPSI, mean ±SD 26.6 ± 14.5
PASI, median (range) 3.7 (0.0 – 29.5)
BSA,	%,	mean	±SD 6.6 ± 11.2
BSA, Body Surface Area; NA, Not applicable; NAPSI, Nail Psoriasis Severity Index; PASI, Psoriasis Area 
and	Severity	Index;		SD,	standard	deviation.
Table 2   Mean SF-36 scores in our study compared to a healthy Dutch reference 
group 15.
Study patients
(n = 49) 
Reference groupa
(n = 1742)a
mean (± SD) mean (± SD)
Physical	functioning	 86.7 (22.5) 83.0 (22.8)
Role	physical	functioning	 78.6 (36.5) 76.4 (36.3)
Role	emotional	functioning	 94.6 (20.8)* 82.3 (32.9)*
Vitality,	energy	and	fatigue	 66.7 (20.2) 68.6 (19.3)
Mental health 75.5 (15.9) 76.8 (17.4)
Social	functioning	 84.5 (19.7) 84.0 (22.4)
Bodily pain 78.1 (20.5) 74.9 (23.4)
General	health	perceptions 68.2 (20.0) 70.7 (20.7)
Expected health change 55.1 (24.5) NA
aAaronson	et	al.	[15].
*Significant	(p=<0.001).
Scores	range	from	0	(worst	quality	of	life)	to	100	(best	quality	of	life).	SD,	standard	deviation,	NA,	not	
available.
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SF-36	 domains;	 vitality,	 energy	 and	 fatigue	 (r=-0.390,	 p<0.01);	 role	 emotional	
functioning	 (r=-0.390,	 p=0.05);	 social	 functioning	 (r=-0.405,	 p<0.01); bodily pain 
(r=-0.546, p<0.01).
Discussion
It	 is	 well	 known	 that	 patients	 with	 chronic	 medical	 conditions,	 such	 as	 psoriasis,	
report diminished QoL.8,9 There is evidence that psoriasis located on visible body 
parts has a greater impact on QoL, compared to lesions located on less visible body 
areas.7,10	Fingernail	disease	is	highly	visible	and	therefore	it	is	likely	to	influence	QoL.	
Previous studies have shown that onychomycosis impairs various aspects of QoL,11,17 
and	only	a	few	studies	investigated	the	effect	of	nail	psoriasis	on	patients’	QoL.12,18,19 
Our	results	indicate	that	fingernail	psoriasis	can	interfere	with	important	aspects	of	
patients’	 QoL	 and	 that	 nail-specific	 questionnaires	 may	 contribute	 to	 more	
individualised	and	problem-specific	treatment	of	these	patients.
	 Our	SF-36	data	confirmed	that	age	and	gender	influences	patients’	well-being.	
The impact on HRQoL was lower for males and gained with increasing age, as generally 
observed.15,20,21	It	is	assumed	that	increasing	impairment	of	physical	functioning	is	the	
result	 of	 an	 increase	 in	 comorbidities	 and	 the	 diminishing	 vitality	 associated	with	
increasing age.
	 Our	 observations	 showed	 comparable	 SF-36	 scores	 in	 both	 patients	 with	
fingernail	psoriasis	and	the	healthy	Dutch	reference	population.15 These data indicate 
that	 fingernail	 psoriasis	 does	not	 determine	patients’	 perceptions	of	 their	 general	
health. Heydendael et al.,6 studied the impact of psoriasis of the skin on HRQoL, also 
using	 the	 SF-36.	 They	 compared	 a	 group	 of	 85	 patients	with	moderate	 to	 severe	
psoriasis (mean PASI 13.7) with a Dutch reference group of 1742 persons without 
chronic	illness,	and	found	impairment	of	HRQoL	in	patients	with	psoriasis	compared	
to healthy controls. This study shows that the outcome of the SF-36 scores can be 
influenced	by	cutaneous	psoriasis	lesions.	In	the	present	study	patients	were	treated	
for	their	cutaneous	lesions,	resulting	in	a	median	PASI	of	only	3.7,	which	indicates	low	
activity	of	skin	disease.	Consequently	 the	 impact	of	additional	cutaneous	psoriasis	
lesions	on	patients’	HRQoL	is	considered	to	be	limited	in	this	study.	An	explanation	for	
the	 small	 impairment	 in	 physical	 and	 mental	 domains	 of	 the	 SF-36	 in	 fingernail	
psoriasis	is	that	the	SF-36	is	not	a	particularly	sensitive	measure	for	nail	disorders;	it	
was	 designed	 to	 estimate	 HRQoL	 and	 does	 not	 specifically	 assess	 the	 burden	 of	
fingernail	 disease	 on	 patients’	 QoL.	 To	 compensate	 for	 this	 limitation,	 we	 used	 a	
modified	onychomycosis	questionnaire	designed	by	Drake	et	al.,11 which focuses on 
QoL	issues	in	patients	with	a	nail	disease,	and	applied	the	questionnaire	to	patients	
with	fingernail	psoriasis.	The	results	indicated	that	fingernail	psoriasis	has	a	relevant	
impact	on	patients’	QoL	on	either	social,	emotional	or	symptom	dimensions.
to no control of nail psoriasis. Mean scores on the VAS were 15.4 mm (±SD 3.0) for 
the	pain	sensation	caused	by	fingernail	psoriasis	and	22.0	mm	(±SD	4.0)	for	the	pain	
sensation	caused	by	the	skin	lesions.	Correlation	between	the	VAS	for	pain	caused	 
by	fingernail	psoriasis	and	the	total	modified	onychomycosis	QoL	score	was	-0.298	
(p=0.05),	 indicating	 that	 pain	 of	 the	 nail	 apparatus	 negatively	 influences	 the	QoL.	
Significant	correlations	were	also	found	between	this	VAS	for	pain	and	the	following	
Table 4			Mean	scale	scores	of	the	modified	onychomycosis	score	in	relation	to	
relevant variables.
Social  
problems
Emotional 
problems
Symptoms
N m mean mean mean
All 49 0 75.1 78.8 74.4 
Gender
Male
Female
26
23
0
76.7
73.2
82.6
74.6
79.2
68.6
Age, years
< 40
40 - 55
>	55
14
18
17
0
74.0 
70.7
80.6
77.0
78.5
80.7
75.8
71.4
76.5
Highest	educational	level
Primary	education
Junior	general	secondary	education
Senior	general	secondary	education/	
pre-university	education
Community college 
University	of	professional	education
University of science
3
16
2
9
15
4
0
91.7
78.0
100.0
80.0
65.2
64.6
84.2
82.0
97.5
80.8
73.7
67.5
78.3
73.1
100.0
80.6
70.0
65.0
Localization	of	nail	psoriasis
Fingernails
Finger- and toenails
10
39
0
81.4
73.4
87.3
76.7
88.3*
70.2*
Duration	of	nail	psoriasis,	years
< 6 
6 - 10 
>	10	
16
13
17
3
61.8*
78.8
81.2*
70.9
79.4
82.8
64.7
82.5
74.1
Psoriatic	arthritis
Yes
No
9
40
0
84.9 
72.8 
85.0 
77.4 
82.2 
72.6 
*Significant	(p<0.05).	0	to	100	scale:	0	is	worst	quality	of	life,	100	is	best	quality	of	life.
N,	number	of	patients;	m,	missing.
CHAPTER 3 QUALITY OF LIFE IN PATIENTS WITH NAIL PSORIASIS 
76 77
3
on	QoL	is	eliminated	in	a	disease-specific	questionnaire.	Patients	seem	to	accept	their	
nail	disease	better	with	increasing	age.	Earlier	studies	also	noted	a	decreased	impact	 
of	disease	with	increasing	age	in	patients	with	psoriasis.9 
	 Patients	with	nail	psoriasis	of	both	finger-	and	toenails	reported	reduced	disease-	
specific	QoL	 in	all	 three	dimensions	compared	to	patients	with	exclusive	fingernail	
psoriasis,	but	this	was	only	significant	for	the	symptom	dimension.	Previous	studies	in	
nail	psoriasis	and	onychomycosis	patients	found	fairly	similar	results.17,18 This leads to 
the conclusion that more extended nail disease causes not only more severe 
symptoms,	but	also	more	psychosocial	impairment,	both	in	patients	with	nail	psoriasis	
and	with	onychomycosis.	Disease-specific	QoL	is	also	influenced	by	the	duration	of	
fingernail	psoriasis;	recent	diagnosis	is	associated	with	greater	impairment.	It	seems	
that	the	impact	of	fingernail	abnormalities	fades	over	time	because	of	acceptance.	
These	results	confirm	those	of	Ortonne	et	al.18	We	could	not	show	a	clear	correlation	
between	disease	severity,	as	measured	by	the	NAPSI,	and	the	disease-specific	QoL	score.	
 Most previous studies concerning QoL in nail psoriasis were conducted with 
self-administered	questionnaires,	the	authors	having	to	rely	on	the	patient’s	judgment	
concerning	diagnosis	and	disease	severity.	In	this	study	all	patients	were	interviewed	
and clinically examined by the same trained medical doctor to reach the highest 
validity.	Furthermore,	patients	with	concomitant	onychomycosis	were	excluded	from	
the	 study.	 The	disadvantage	of	 this	 approach	 is	 that	 a	 limited	number	of	patients	
could be included. Therefore, trends can be seen according to the mean scores of the 
questionnaires,	but	statistical	significance	was	not	always	reached.	A	larger	number	
of	patients	is	needed	to	confirm	these	findings.	Another	limitation	of	this	study	might	
be	a	selection	bias,	because	we	included	patients	who	visited	the	outpatient	clinic	of	
a	 tertiary	 referral	hospital	and	 therefore	 sought	attention	 for	 their	psoriasis.	They	
may	not	represent	a	random	sample	of	fingernail	psoriasis	patients,	because	these	
patients	might	suffer	from	more	severe	(nail)	psoriasis	or	may	experience	a	greater	
disease burden.
In	summary,	fingernail	psoriasis	seems	to	reduce	patient’s	physical,	mental	and	social	
well-being and should not be overlooked by dermatologists. Given the burden of 
disease	in	individual	patients,	an	instrument	which	accurately	and	precisely	measures	
the burden of nail psoriasis would be valuable for both clinical care and research 
purposes.	Assessing	patients’	QoL	offers	the	opportunity	to	address	these	issues	in	a	
patient-centred	approach	to	treatment.
 Drake et al.,11	used	their	questionnaire	for	onychomycosis	patients	and	compared	
the	 results	 from	 four	 different	 countries	 (Germany,	 Italy,	 France	 and	 the	 United	
States).	These	results	are	in	line	with	our	data	concerning	fingernail	psoriasis	patients,	
showing	 comparable	 impact	 of	 both	 nail	 diseases	 on	 patients’	 QoL.	 On	 the	 other	
hand,	the	Polish	onychomycosis	patients	investigated	by	Szepietowski	et	al.17 scored 
much	lower	mean	scores	on	all	dimensions	than	our	fingernail	psoriasis	patients.	This	
could	be	explained	by	significant	cultural	differences	in	notions	of	health	and	illness	
perceptions	between	different	countries.11
	 Using	the	modified	onychomycosis	QoL	questionnaire	showed	that	patients	with	
nail psoriasis seem to experience the greatest burden on the social dimension. 
Patients	are	most	frequently	worried	about	the	judgement	of	others	concerning	their	
nails.	In	addition,	pain	experienced	by	nail	psoriasis	also	seems	to	be	an	important	
aspect	of	the	burden	of	this	disease.	Half	of	the	patients	stated	that	they	experienced	
pain	in	their	fingers	and	nails	as	scored	by	the	modified	questionnaire.	Ortonne	et	al.18 
reported	a	similar	percentage	of	59%.	The	results	we	found	on	the	VAS	scores	on	pain	
caused by nail lesions are in line with these results. The VAS score correlated with the 
total	 modified	 onychomycosis	 QoL	 score	 and	 various	 dimensions	 of	 the	 SF-36,	
indicating	that	increasing	pain	caused	by	nail	psoriasis	negatively	influences	the	QoL.	
As a consequence, we emphasize that clinicians should take the social burden and 
pain	caused	by	nail	psoriasis	into	account	when	treating	patients	with	nail	psoriasis.
	 The	 QoL	 scores	 resulting	 from	 the	 disease-specific	 QoL	 questionnaire	 were	
influenced	by	different	variables.	Interestingly,	we	found	a	trend	in	women	and	patients	
with	higher	educational	levels	to	show	more	impaired	QoL	in	all	three	investigated	
dimensions. Szepietowski et al.17 found similar results according to gender and 
educational	 level	 in	patients	with	onychomycosis.	However,	no	gender	differences	
according to the symptom dimension were found. They registered more severe 
symptoms	 in	 patients	 with	 lower	 educational	 levels.	 Ortonne	 et	 al.18 also found 
statistically	significant	greater	impairment	in	women	with	nail	psoriasis	as	measured	
by	their	disease-specific	questionnaire,	NPQ10,	which	was	published	after	the	start	of	
this	study	and	therefore	could	not	be	used	in	this	study.	Furthermore,	Augustin	et	al.19 
measured	QoL	 in	1430	nail	psoriasis	patients	using	the	DLQI	and	found	also	higher	
scores,	i.e.	greater	impairment,	in	women.	The	gender	differences	were	also	seen	in	
the	 SF-36	 questionnaire	 and	 are	 therefore	 probably	 not	 disease-specific.	 The	
influence	of	 the	educational	 level	may	be	explained	by	 the	 fact	 that	patients	with	
higher	 educational	 levels	 are	 generally	more	 socially	 active.	 Therefore,	 they	 have	
more	opportunities	to	have	their	nail	disease	noticed	by	other	people.17
	 Increasing	age	seems	to	decrease	the	impact	of	fingernail	psoriasis	on	disease-	
specific	 QoL.	 However,	 previously	 we	 stated	 that	 older	 patients	 with	 fingernail	
psoriasis documented more impaired HRQoL on the SF-36. This might be explained by 
the	fact	that	the	factor	‘general	health’	or	in	other	words	the	impact	of	comorbidities	
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CHAPTER 3
Introduction
Psoriasis	is	a	chronic,	inflammatory	skin	disease	characterized	by	notable	lesions	that	
may appear on variable parts of the body.1 It can be experienced as extremely 
distressing,	and	is	known	to	affect	patients’	quality	of	life	(QoL)	comparable	to	that	of	
other chronic diseases.2,3	 Psoriasis	 can	 be	 found	 at	 several	 different	 localizations	
which	may	be	of	various	 impact	on	patients‘	QoL.	 In	particular	psoriasis	on	highly	
visible	areas	of	the	skin,	such	as	the	face	and	hands,	can	have	a	significant	impact.4 
One	of	the	easy	visible,	and	difficult	to	conceal	localizations	are	the	nails.	A	substantial	
number	of	psoriatic	patients	have	nail	involvement,	varying	from	10%	to	80%,	with	an	
estimated	lifetime	incidence	of	80-90%.2, 4-19	This	prevalence	is	even	higher	in	patients	
with	psoriatic	arthritis	(PsA).19 The most prevalent features seen in nail psoriasis are 
pitting	 and	 onycholysis.16, 18, 20-22 Despite the high prevalence of nail psoriasis, the 
specific	impact	of	nail	psoriasis	on	patients’	functioning	and	well	being	has	not	gained	
much	attention	in	the	past.	Nails	enhance	fine	touching,	tactile	sensitivity,	retrieving	
small	objects	and	play	a	role	in	an	individual’s	body	image	perception.	It	 is	already	
known	that	nail	abnormalities	 in	general	are	considered	a	significant	problem,	and	
can	 influence	 a	 person’s	 self-esteem.23, 24	 Previous	 literature	 showed	 that	 patients	
suffering	from	nail	psoriasis	can	also	experience	alterations	in	QoL.7 The burden of 
nail psoriasis can be determined by physical symptoms, psychological burden and 
restrictions	in	profession	and	activities.7 Moreover, nail psoriasis always has been a 
therapeutic	 challenge	 for	 patients	 and	 dermatologists	 because	 the	 nail	 apparatus	
limits	the	absorption	of	most	of	the	topical	treatments.25 Treatment tends to focus on 
clearing	 the	 cutaneous	 component,	 and	 the	 nails	 are	 often	 overlooked	 by	 the	
clinicians, so nail features are frequently a longstanding problem.7
	 The	 aim	 of	 this	 study	 was	 to	 achieve	 more	 insight	 into	 the	 QoL	 of	 psoriatic	
patients	with	nail	psoriasis	by	means	of	validated	questionnaires,	and	to	characterize	
the	patients	with	nail	 involvement	which	are	more	prone	to	the	 impact	of	the	nail	
alterations	caused	by	psoriasis.	
Material and methods
Patients
A	 self-administered	 questionnaire	 was	 distributed	 to	 all	 members	 (n=5400) of the 
Dutch	Psoriasis	Association	together	with	an	invitational	letter	explaining	the	purpose	
of	the	study.	The	same	patients	were	involved	in	a	previous	study	on	the	epidemiology	
of nail psoriasis.18	The	questionnaire	was	completed	anonymously	and	no	 incentives	
were	given.	The	investigation	was	conducted	from	14	April	2011	and	responses	were	
accepted	through	to	1	August	2011.	The	questionnaire	involved	the	following	validated	
questionnaires.
Abstract
Background: Psoriasis	can	be	found	at	several	different	localizations	which	may	be	of	
various	impact	on	patients‘	quality	of	life	(QoL).	One	of	the	easy	visible,	and	difficult	
to	conceal	localizations	are	the	nails.
Objective:	 To	 achieve	 more	 insight	 into	 the	 QoL	 of	 psoriatic	 patients	 with	 nail	
psoriasis,	 and	 to	 characterize	 the	 patients	 with	 nail	 involvement	 which	 are	more	
prone	to	the	impact	of	the	nail	alterations	caused	by	psoriasis.	
Method:	A	self-administered	questionnaire	was	distributed	to	all	members	(n=5400) 
of	the	Dutch	Psoriasis	Association.	The	Dermatology	Life	Quality	Index	(DLQI)	and	the	
Nail Psoriasis Quality of life (NPQ10) score were included as QoL measures. Severity 
of cutaneous lesions was determined using the Self-Administered Psoriasis Area and 
Severity Index (SAPASI). 
Results: Patients	with	nail	psoriasis	scored	significantly	higher	mean	scores	on	the	
DLQI (4.9 vs. 3.7, p=<0.001) and showed more severe psoriasis (SAPASI, 6.6 vs. 5.3, 
p=<0.001).	 Patients	with	 coexistence	 of	 nail	 bed	 and	 nail	matrix	 features	 showed	
higher	 DLQI	 scores	 compared	 with	 patients	 with	 involvement	 of	 one	 of	 the	 two	
localizations	 exclusively	 (5.3	 vs.	 4.2	 vs.	 4.3,	p=0.003).	 Patients	with	 only	 nail	 bed	
alterations	scored	significant	higher	NPQ10	scores	when	compared	with	patients	with	
only	 nail	 matrix	 features.	 Patients	 with	 psoriatic	 arthritis	 (PsA)	 and	 nail	 psoriasis	
experiences	more	 impairments	 compared	with	 nail	 psoriasis	 patients	without	 PsA	
(DLQI 5.5 vs. 4.3, NPQ10 13.3 vs. 7.0). Females scored higher mean scores on all QoL 
scores.
Conclusion:	Greater	attention	should	be	paid	to	the	possible	impact	nail	abnormalities	
have	on	patients	with	nail	psoriasis,	which	can	be	identified	by	nail	psoriasis	specific	
questionnaires	such	as	the	NPQ10.	As	improving	the	severity	of	disease	may	have	a	
positive	influence	on	QoL,	the	outcome	of	QoL	measurements	should	be	taken	into	
account when deciding on treatment strategies. 
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was	used	for	differences	between	categorical	variables.	One	way	ANOVA	was	used	
when more than two means were compared. P-values	of	≤0.05	were	considered	to	
be	statistically	significant.	
Results
Patients 
The	patient	characteristics	and	clinical	details	are	presented,	and	extensively	analysed	
before by Klaassen et al.18	A	total	of	5400	questionnaires	were	sent	out,	and	1459	
questionnaires	 were	 returned	 and	 suitable	 for	 analysis.	 The	 mean	 age	 of	 the	
respondents was 57.5 years (±SD 13.6 years). Among the respondents, 736 were 
female	 (51.1%)	and	703	were	male	 (48.9%).	Of	 the	 total	 group	of	 respondents	963	
patients	(66.0%)	reported	nail	involvement.	
SAPASI 
Table 1 shows the mean rates of the scores (DLQI, SAPASI and NPQ10), subdivided for 
patients	with	and	without	nail	psoriasis.	Psoriasis	severity,	as	measured	by	the	SAPASI,	
was	 for	 respondents	 with	 nail	 psoriasis	 significantly	 higher	 when	 compared	 with	
psoriatic	patients	without	nail	involvement,	6.6	(±SD	4.9)	and	5.3	(±SD	4.3)(p =<0.001) 
respectively.	 When	 distinguishing	 between	 exclusively	 nail	 matrix	 involvement,	
exclusively nail bed involvement or coexistence of both, SAPASI scores were 
significantly	higher	in	patients	with	coexisting	symptoms	from	both	localizations	(5.6	
vs.	 5.8	 vs.	 7.2	 respectively,	p=<0.001).	Mean	 SAPASI	was	 significant	 higher	 in	 nail	
psoriasis	 patients	with	PsA	 compared	with	nail	 psoriasis	 patients	without	 arthritic	
involvement	(7.0	vs.	6.2	respectively,	p=0.010).	The	correlation	between	having	nail	
psoriasis	and	the	SAPASI	was	small,	but	significant	0.133	(p=<0.001).
DLQI
Patients	with	nail	involvement	experienced	significant	more	impaired	QoL	compared	
with	patients	without	nail	psoriasis,	mean	scores	were	4.9	(±SD	5.0)	and	3.7	(±SD	4.4)	
respectively	 (p=<0.001). The presence of nail symptoms is associated with greater 
impairment	 in	 all	 DLQI	 domains	 (see	 Table	 2).	 There	 was	 a	 significant	 correlation	
between DLQI scores and having nail psoriasis of 0.115 (p=< 0.001), even when 
correcting	 for	 SAPASI	 scores.	QoL	was	also	 significantly	more	 impaired	 in	patients	
with	coexistence	of	nail	bed	and	nail	matrix	 features	compared	with	patients	with	
involvement	of	one	of	the	two	localizations	exclusively	(5.3	vs.	4.2	vs.	4.3	respectively,	
p=0.003).	The	mean	DLQI	scores	for	nail	psoriasis	patients	with	PsA	were	significantly	
higher	when	compared	with	nail	psoriasis	patients	without	PsA	(5.5	vs.	4.3,	p=<0.001). 
In	addition,	the	DLQI	scores	for	psoriasis	patients	with	PsA	(without	nail	manifestations)	
was	equal	to	the	score	of	nail	psoriasis	patients	with	involvement	of	both	nail	matrix	
Dermatology Life Quality Index (DLQI)
Patients’	QoL	was	measured	using	the	DLQI.	The	DLQI	consists	of	ten	questions	on	
several	 aspects	 of	 patients’	 life	 that	 may	 be	 affected	 by	 a	 skin	 disease.26 This 
international	validated	questionnaire	comprises	ten	questions	concerning	six	areas;	
symptoms	and	feeling,	daily	activities,	leisure,	work	and	school,	personal	relationship	
and	treatment.	Each	question	is	scored	on	a	four	or	five-point	Likert	scale.	The	scores	
are summed, giving a range from 0 (no impairment of life quality) to 30 (maximum 
impairment).26	The	Dutch	version	of	the	DLQI	is	a	back-	and	forward	translation	of	the	
questionnaire	by	a	native	speaker,	and	has	been	approved	by	the	original	group	of	
Finlay	 et	 al.	 in	 1998.	 No	 substantial	 modifications	 have	 been	 made	 during	 the	
translation	of	the	DLQI,	only	linguistically.
Nail Psoriasis Quality of life (NPQ10)
The	NPQ10	 is	a	 10-item	quality	of	 life	questionnaire	 specific	 for	nail	psoriasis.	The	
questionnaire	was	designed	and	validated	by	Ortonne	et	al.27	Each	question	is	scored	
on a three-point scale; ranging from 0 to 2. Summing the scores gives a range from 0 
(no impairment on QoL) to 20 (maximum impairment).27 No validated Dutch version 
existed.	 Therefore,	 the	 questionnaire	 was	 backward	 and	 forward	 translated.	 One	
item	was	excluded.	This	question	concerning	the	interference	of	nail	psoriasis	with	
the ability to drive a car, was removed because of the wide age range of the target 
population	and	the	chance	on	lots	of	missing	data.	Consequently,	the	score	can	range	
from 0 to 18. Eventually, scores were converted to percentages.
Self-Administered Psoriasis Area and Severity Index (SAPASI) 
This	instrument	allows	patients	to	assess	the	severity	of	their	psoriasis.	Patients	rate	
redness,	 induration	 and	 scaliness	 of	 an	 average	 psoriasis	 lesion	 using	 three	 visual	
analogue	 scales,	 and	 shade	 the	 involved	 area	 of	 their	 skin	 on	 a	 silhouette	 of	 the	
human	body.	Based	on	silhouette	shading,	an	investigator	assigns	a	numeric	value	of	
0 to 6 using the same cut points of the Psoriasis Area and Severity Index (PASI).28 The 
SAPASI weights the involved area as the original PASI score.29 The range of the SAPASI 
is	0-72,	with	increasing	SAPASI	scores	indicating	increasing	severity	of	psoriasis.	
Statistical analysis
Data	were	entered	in	a	database	and	subsequently	statistical	analysis	was	performed	
using	 Statistical	 package	 for	 Social	 Sciences	 (SPSS	 20.0,	 IBM	 Corp,	 Armonk,	 NY).	
Descriptive	statistics	were	provided	using	mean	(±SD)	and	median	(range)	for	normally	
and	 non-parametric	 distributed	 numeric	 values	 respectively.	 Frequencies	 and	
percentages were used for categorical variables. Missing values were not included to 
calculate percentages. Comparison of numeric variables were analysed with the 
unpaired t-tests or the Mann-Whitney U test and the chi square or Fisher exact test 
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3
and	 nail	 bed	 (without	 arthritic	 involvement)	 (	 4.1	 vs.	 5.0	 respectively,	 p=0.078). 
Correlation	between	the	DLQI	and	SAPASI	was	0.487	(p=<0.001). 
NPQ10
The results of the NPQ10 are shown in Table 1 and 3. The mean QoL score for all nail 
psoriasis	 patients	 was	 9.9	 (±SD	 14.0).	 Men	 with	 nail	 psoriasis	 scored	 significantly	
lower	 on	 the	NPQ10	 compared	with	women	 (7.5	 and	 12.6	 respectively,	p=<0.001) 
which indicates less impairment of QoL caused by nail psoriasis in men. Mean NPQ10 
scores	were	significantly	higher	for	PsA	patients	with	nail	 involvement	when	compared	
with	patients	with	nail	involvement	without	PsA,	13.3	and	7.0	respectively	(p=<0.001). 
When	comparing	scores	between	the	different	localizations	of	nail	psoriasis,	QoL	was	
more	affected	 in	patients	with	solely	nail	bed	features	compared	with	patients	with	 
nail	matrix	features	only.	The	correlation	between	NPQ10	scores	and	the	DLQI	scores	
was r=0.389 (p=<0.001).	Correlation	between	NPQ10	and	SAPASI	scores	was	0.209	
(p=<0.001).	When	looking	at	the	questions	separately,	patients	were	most	restricted	
in	putting	on	shoes	or	socks	and	activities	around	the	house	(see	also	Table	3).
Discussion
This	study	shows	that	nail	psoriasis	can	have	detrimental	effects	on	QoL.	Distress	are	
particularly	prominent	in	nail	psoriasis	patients	with	PsA,	female	gender,	and	more	
extensive	 nail	 psoriasis.	 Using	 the	 NPQ10	 gives	 insight	 into	 the	 daily	 restrictions	
patients	with	nail	psoriasis	experience.	Combining	data	concerning	individual	restrictions	
Table 2  Dimensions Dermatology Life Quality Index (DLQI).
Nail involvement
n = 963 
mean (±SD)
No nail 
involvement 
n = 496
mean (±SD)
p - value
Symptoms and feelings 1.7 (1.5) 1.5 (1.4) <0.001
Daily	activities 1.1 (1.4) 0.8 (1.2) <0.001
Leisure 0.8 (1.3) 0.5 (1.1) <0.001
Work or school 0.4 (0.7) 0.2 (0.6) <0.001
Relationships 0.4 (1.0) 0.3 (0.8) 0.017
Treatment 0.5 (0.8) 0.4 (0.7) <0.001
 n,	number;	SD,	standard	deviation.
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(SAPASI)	and	these	results	still	showed	that	patients	with	nail	psoriasis	had	worse	QoL	
independent of the severity of their cutaneous lesions. Our data show that the 
presence of extended nail disease of both nail matrix and nail bed psoriasis 
simultaneously	can	have	a	negative	influence	on	QoL	independent	from	the	influence	
of PsA or psoriasis severity. However, when using the DLQI it stays unclear if the 
differences	 found	 on	 the	 DLQI	might	 be	 explained	 by	 solely	 the	 presence	 of	 nail	
lesions,	higher	prevalence	of	PsA,	more	severe	psoriasis	in	this	group	of	patients	or	 
a	combination	of	factors.
	 So,	when	using	the	DLQI	in	patients	with	both	skin	lesions	and	nail	features,	it	is	
difficult	to	separate	the	influence	of	nail	features	on	QoL	from	the	cutaneous	lesions.24 
To overcome this problem, Ortonne et al.27 developed a QoL scale measuring solely 
the	impact	of	nail	psoriasis	on	patients’	quality	of	life	(NPQ10).	The	NPQ10	showed	
good	 internal	 consistency	 (cronbachs’	 α	 0.88)	 and	 reproducibility	 and	 the	 results	
correlated with the DLQI scoring (R=0.48).27	The	NPQ10	 is	 the	first	and	only	scale,	
until	 now,	 focusing	 on	 nail	 psoriasis	 specifically,	 however,	 few	 studies	 used	 this	
questionnaire.	The	present	study	shows	that	nail	psoriasis	restricted	patients	most	
frequently	in	putting	on	shoes	or	socks	(21.2%	and	25.1%)	and	activities	around	the	
house	(25.3%).	Nail	psoriasis	patients	were	rarely	limited	in	getting	dressed	or	turning	
around	keys	(1.8%	and	8.8%).	Of	all	nail	psoriasis	patients	35.8%	experienced	pain	to	
a	greater	or	lesser	extent.	The	localization	of	psoriasis	in	the	nail	apparatus	seems	to	
be	 associated	 with	 the	 degree	 of	 impairment	 of	 QoL.	 Patients	 with	 nail	 bed	
involvement	solely	stated	significant	higher	mean	scores	on	the	NPQ10	compared	to	
patients	with	 solely	nail	matrix	 involvement.	This	finding	emphasizes	 that	nail	bed	
features,	such	as	subungual	hyperkeratosis	and	onycholysis,	might	restrict	patients	
more	than	matrix	lesions	(e.g.,	pitting).	This	is	in	contrast	with	the	finding	that	patients	
with	 both	 nail	 matrix	 and	 nail	 bed	 involvement	 simultaneously	 scored	 significant	
higher	scores	on	the	DLQI	when	compared	with	patients	with	features	of	one	of	the	
two	localizations	solely.	However,	patients	with	simultaneous	involvement	of	nail	bed	
and	nail	matrix	seem	to	have	significant	more	severe	psoriasis	which	results	in	higher	
DLQI	 scores	 as	 the	 DLQI	 reflects	 the	 impact	 of	 the	 cutaneous	 lesions	 and	 not	
specifically	 the	 nail	 features.	 In	 addition,	 the	 DLQI	 takes	 the	 impact	 of	 cosmetic	
effects	 of	 disease	 into	 account	 as	 the	 focus	 of	 the	NPQ10	 is	 centered	 around	 the	
restrictions	nail	features	entail.	Patients	with	both	nail	bed	and	nail	matrix	features	
might	 score	 higher	 on	 the	 DLQI	 as	 a	 combination	 of	 features	may	 have	 a	 higher	
esthetical	impact.	In	contrast,	nail	bed	features	might	interfere	more	with	functioning	
which	 may	 lead	 to	 higher	 NPQ10	 scores	 compared	 with	 patients	 with	 solely	 nail	
matrix	manifestations.
	 Patients	with	PsA	and	nail	involvement	scored	significantly	higher	mean	NPQ10	
scores	compared	with	nail	psoriasis	patients	without	PsA.	This	could	either	indicate	
that	 patients	 with	 PsA	 have	 more	 severe	 nail	 psoriasis	 and	 consequently	 more	
with	data	concerning	QoL	will	allow	us	to	 individualize	treatment	for	patients	with	
nail psoriasis. 
	 Previous	literature	showed	that	psoriasis	can	have	substantial	effects	on	patients	
QoL, and the impact has been shown to be similar to that of major chronic diseases 
including cardiovascular diseases, diabetes mellitus and depression.3,30,31 However, 
the	specific	impact	of	nail	lesions	on	patients’	QoL	gained	little	attention	in	the	past.4,15 
QoL	 questionnaires	 in	 dermatology	 can	 be	 generic,	 dermatology-specific	 or	 dis-
ease-specific.32 Studies focusing on the impact of nail features on QoL predominantly 
used	 the	 DLQI,	 a	 non-disease-specific	 questionnaire,	 measuring	 the	 impact	 of	
cutaneous disorders in general.33 Our results on the DLQI are in agreement with 
previous	studies.	Radtke	et	al.	(questionnaires-based	survey,	n=	2449)	found	higher	
impairment	of	QoL,	using	the	DLQI,	 in	patients	with	psoriasis	and	nail	 involvement	
when	 compared	 with	 patients	 without	 nail	 involvement	 (mean	 scores	 7.2	 vs.	 5.3	
respectively,	 p=<0.001).15 They also found higher cutaneous psoriasis severity in 
patients	with	nail	involvement.	A	study	by	Augustin	et	al.	(outpatient	clinic,	n=3531)	
also	assessed	QoL	using	the	DLQI	on	patients	with	psoriasis.	Again,	significant	higher	
mean	scores	were	stated	by	patients	with	nail	features	(men	8.6	vs.	6.9,	and	women	
9.5	 vs.	 7.6).	 However,	 patients	 with	 nail	 psoriasis	 generally	 also	 had	more	 severe	
psoriasis	 (PASI	 score),	more	 frequently	 PsA	 and	 longer	 duration	 of	 psoriasis.4 Nail 
involvement	seems	to	decrease	patients	QoL	additionally	to	the	cutaneous	lesions.	
However,	 QoL	 differences	 might	 be	 suggested	 to	 be	 attributed	 to	 the	 fact	 that	
psoriasis	 patients	with	 nail	 involvement	 have	 a	 higher	 prevalence	 of	 PsA	 or	more	
severe	 psoriasis.	 Previous	 literature	 showed	 that	 in	 psoriasis	 patients,	 joint	
involvement	places	an	additional	burden	on	the	already	diminished	QoL	caused	by	
the cutaneous lesions.34, 35	This	could	also	contribute	to	the	differences	of	QoL	scores	
found	between	psoriasis	patients	with	and	without	nail	features,	as	patients	with	nail	
psoriasis	have	significantly	more	frequently	PsA.18 However, our data showed that the 
impact of having nail psoriasis on the QoL is comparable to impact of PsA (in psoriasis 
patients	without	nail	involvement)	provided	that	nail	psoriasis	is	present	in	both	nail	
matrix	and	nail	bed.	In	addition,	a	study	of	Rosen	et	al.	showed	decreased	QoL	scores	
in	patients	with	PsA	compared	with	psoriasis	patients	without	joint	involvement	on	
different	QoL	scores,	except	for	the	DLQI.	This	could	be	explained	by	the	fact	that	the	
DLQI	reflects	the	impact	of	the	cutaneous	lesions,	not	of	the	restrictions	caused	by	
the joint problems.34	Moreover,	QoL	differences	might	be	suggested	to	be	caused	by	
differences	 in	 severity	 of	 cutaneous	 psoriasis	 lesions.	 As	 nail	 manifestations	
predominantly	precede	the	presentation	of	PsA,	it	would	be	interesting	to	determine	
the	impact	of	nail	manifestations	in	the	course	of	their	disease.36	We	found	significant	
higher	SAPASI	scores	in	patients	with	nails	psoriasis	(6.6	vs.	5.3,	p=<0.001). Previous 
studies	also	 confirmed	higher	disease	 severity	 in	patients	with	nail	psoriasis.9,15,16,32 
Therefore we conducted a secondary analyses controlling for severity of psoriasis 
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restrictions	in	daily	live	or	that	having	arthritis	negatively	affects	the	items	questioned	
in	 the	 NPQ10.	 Further	 research,	 correlating	 nail	 psoriasis	 severity	 scores	 of	 these	
groups	with	NPQ10	scores	have	to	confirm	or	renounce	this	hypothesis.	
	 Gender	 seems	 to	 influence	 QoL	 scores	 as	 women	 score	 higher	 on	 both	 QoL	
scores. Zachariae et al. reported comparable results using the DLQI.37 Both found that 
women scored higher on items concerning experiences of embarrassment or self 
consciousness	 and	 influence	 of	 disease	 on	 the	 choice	 of	 clothing.	 This	 might	 be	
explained	by	the	fact	that	women	and	men	respond	different	to	disfiguring	disease.37, 38
Limitations
A	 selection	 bias	 might	 be	 created	 by	 questioning	 the	 members	 of	 a	 psoriasis	
association,	as	members	of	a	patient	support	association	may	possible	not	represent	
a	random	sample	of	patients	with	psoriasis.	It	may	be	speculated	that	these	patients	
are	perhaps	more	worried	about	their	disease	or	they	might	suffer	from	more	severe	
psoriasis	than	psoriasis	patients	who	did	not	join	a	patient	support	group.	Interview	
by a medical doctor might be more accurate, however, the study design made it 
possible	to	include	a	large	number	of	patients.	Modifying	the	NPQ10	is	also	a	limitation	
of	the	study.	However,	as	the	questionnaire	is	sparsely	used,	this	study	gained	insight	
into	the	experienced	restrictions	of	nail	disease	despite	of	using	a	modified	version.
Conclusion
In	clinical	practice,	there	is	a	great	challenge	for	dermatologists	to	 improve	QoL	of	
patients	with	nail	psoriasis.	To	do	so,	greater	attention	should	be	paid	to	the	possible	
limitations	 that	 these	patients	experience	which	can	be	 identified	by	nail	psoriasis	
specific	questionnaires	such	as	the	NPQ10.	As	improving	the	severity	of	disease	may	
have	a	positive	influence	on	QoL,	the	outcome	of	QoL	measurements	should	be	taken	
into	account	when	deciding	on	 treatment	 strategies.	 In	addition,	patients’	gender,	
presence	 of	 PsA	 and	 localization	 of	 nail	 features	 can	 have	 a	 role	 in	 individualized	
treatment of nail psoriasis. 
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CHAPTER 4
Introduction
Nail	 involvement	 is	seen	 in	10%	to	80%	of	psoriatic	patients	and	manifests	as	 features	
resulting	 from	 nail	 matrix	 or	 nail	 plate	 alterations.1,2,3,4 The variability of clinical 
manifestations	makes	treatment	challenging,	and	the	efficacy	of	therapies	in	nail	disease	
seems limited because of the impermeability of the nail plate and inaccessibility of 
the nail matrix.1	 However,	 research	 into	 the	 field	 of	 nail	 psoriasis	 is	 important,	 as	 
the impact of onychopathy on quality of life is high.3,5	Fortunately,	attention	to	nail	
psoriasis	 is	 increasing,	 and	 more	 and	 more	 studies	 are	 attempting	 to	 evaluate	
therapeutic	options	for	nail	psoriasis.	
	 The	 use	 of	 validated	 severity	 scores	 is	 important,	 particularly	 in	 this	 era	 of	
evidence-based medicine. Scoring systems are not only required to evaluate the 
severity of disease and to monitor treatment response, but also to compare results 
from	different	studies.	The	Psoriasis	Area	and	Severity	Index	(PASI)	is	widely	accepted	
as the criterion for assessment of psoriasis severity.6	However,	it	does	not	specifically	
consider	 the	 severity	 of	 nail	 involvement	 and	 is	 therefore	 of	 no	 use	 in	 evaluating	
treatments for nail psoriasis. Several scoring systems have been proposed to assess 
nail psoriasis severity. Despite the importance, there is lack of consensus on the most 
appropriate of these measures.7,8 The Nail Psoriasis Severity Index (NAPSI) is the most 
frequently used scoring system; however, a number of other scoring systems for nail 
psoriasis	can	be	identified	in	the	literature.9-15 Each of these tools scores the absence or 
presence	 of	 nail	 psoriasis	manifestations,	 but	 they	 differ	 in	 the	 selection	 and	 type	 of	
scoring of features included, and all have their advantages and disadvantages. The aim of 
this	study	was	to	compare	the	different	nail	psoriasis	scoring	systems	in	patients	with	
fingernail	psoriasis,	and	to	evaluate	the	competence	of	these	different	assessment	
tools	in	relation	to	the	severity	of	nail	psoriasis	in	terms	of	Physician	Global	Assessment	
(PGA).	 Furthermore,	 the	 authors	 attempted	 to	 formulate	 a	 better	 scoring	 system,	
taking into account the advantages and disadvantages of all evaluated tools. 
Material and Methods
Patients
In	 all,	 36	 patients	 with	 fingernail	 psoriasis	 (nail	 PGA	 ≥1)	 were	 included	 in	 this	
prospective,	observational,	single-point	study	performed	at	the	outpatient	clinic	at	
the Department of Dermatology, Radboud university medical center, Nijmegen, The 
Netherlands.	All	 patients	 in	 the	 study,	 conducted	between	March	2011	 and	December	
2012,	were	older	than	18	years.	Patients	who	used	artificial	nails	during	the	preceding	
six	 months	 or	 exhibited	 a	 (skin)	 disease	 associated	 with	 nail	 manifestations	 (e.g.,	
lichen	 planus,	 alopecia	 areata,	 eczema)	 were	 excluded.	 To	 exclude	 patients	 who	 
Abstract
Background:	Scoring	systems	are	indispensable	in	evaluating	the	severity	of	disease	
and monitoring treatment response. 
Objective: We sought to evaluate the competence of various nail psoriasis severity 
scoring systems and to develop a new scoring system.
Method:	The	authors	conducted	a	prospective,	observational,	single-point	study	of	
36	patients	given	the	diagnosis	of	fingernail	psoriasis.	Seven	scoring	systems	were	
evaluated:	 Nail	 Psoriasis	 Severity	 Index	 (NAPSI),	 modified	 NAPSI,	 target	 NAPSI,	
Psoriasis Nail Severity Score , Nail Area Severity, Baran and Cannavò et al. All tools 
were	 correlated	with	 the	 Physician	Global	 Assessment.	Obtained	 information	was	
integrated	 into	 the	 Nijmegen–Nail	 psoriasis	 Activity	 Index	 tooL	 (N-NAIL),	 and	
interrater and intrarater reliability will be assessed.
Results:	 Physician	 Global	 Assessment	 showed	 an	 acceptable	 correlation	 with	 the	
scoring system designed by Baran (r=0.735, p=< 0.01) and the Psoriasis Nail Severity 
Score (r=0.734, p=<0.01).	Target	NAPSI	showed	low	correlation	(r=0.203,	p=>0.05).	
The	 correlation	 between	 Physician	 Global	 Assessment	 and	 the	 N-NAIL	 was	 0.861	
(p=<0.01). Excellent agreement was found for the intrarater and interrater reliability 
of the N-NAIL. 
Limitations: Sample size was limited.
Conclusion: An adequate nail psoriasis scoring system is needed, as studies of 
treatments for nail psoriasis are on the horizon. Clinical severity of nail psoriasis was 
best	 reflected	by	 the	N-NAIL,	 followed	by	 the	Baran	system	and	 the	Psoriasis	Nail	
Severity Score.   
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model,	average	agreement).	Agreement	can	be	qualified	as	excellent,	substantial,	or	
moderate for ICC values in the 0.81 to 1.00, 0.61 to 0.80, and 0.40 to 0.60 ranges, 
respectively.
Results
Patients
A	 total	 of	 36	psoriatic	patients	with	fingernail	 psoriasis	were	enrolled.	Descriptive	
patient	characteristics	are	summarized	in	Table	2.	The	mean	age	of	the	included	patients	
was	51.5	(±SD	15.0)	years.	Eleven	women	(30.6%)	and	25	men	(69.4%)	were	included.	
had	 (concomitant)	 onychomycosis,	 clippings	 and	 subungual	 scrapings	 of	 affected	
fingernails	were	collected	for	direct	microscopic	examination	(10%	potassium	hydroxide	
preparations)	and	fungal	culture.	All	patients	were	stabile	on	systemic	and/or	topical	
antipsoriatic	therapy	for	at	least	three	months.
Survey details
A	 medical	 history	 was	 taken	 by	 interview.	 Subsequently,	 a	 trained	 investigator	
(KMGK), assessed seven nail psoriasis scoring systems: NAPSI11,	 modified	 NAPSI10, 
target NAPSI14, the Nail Area Severity (NAS)15, the Psoriasis Nail Severity Score (PNSS)13, 
a system developed by Baran,12 and a tool developed by Cannavò et al.9 Scores were 
assigned	to	patients’	fingernails.	Explanatory	notes	and	an	outline	of	the	differences	
among	 the	 seven	 assessment	 tools	 are	 displayed	 in	 Table	 1.	 Patients	 had	 digital	
photographs	taken	of	each	of	their	fingernails.	The	photographs	were	then	rated	by	
four independent clinicians trained in nail psoriasis scoring, who assigned an overall 
fingernail	PGA	to	each	patient.	The	PGA	chosen	for	this	study	was	a	five-point	ordinal	
static	scale	(ranging	from	clear	to	very	severe)	used	to	assess	the	global	severity	of	
disease.	Interrater	agreement	was	assessed	for	the	PGA.	In	addition,	the	severity	of	
psoriasis was assessed by the PASI (PASI, range 0-72).16 
 Based on the results, a new nail psoriasis scoring system-the Nijmegen-Nail 
psoriasis Assessment Index tooL (N-NAIL)-was developed. To assess the interrater 
intrarater reliability of the new system, two dermatologists not involved in the design 
of	the	study	received	brief	instruction.	Subsequently,	a	computer	displayed	a	series	
of	photographs	of	the	fingernails	of	25	patients	randomly	selected	from	the	group	of	
36. To asses intrarater reliability, these photographs were randomly repeated with an 
interval of at least one week.
Questionnaires
Two quality-of-life scores, the Dermatology Life Quality Index (DLQI), and the Nail 
Psoriasis Quality of life 10 (NPQ10), were included in the study.17, 18 
Statistical analysis
Data	were	entered	in	a	Statistical	Package	for	Social	Sciences	(SPSS	20.0,	IBM	Corp.,	
Armonk,	 NY)	 database	 and	 subsequently	 statistical	 analyses	 were	 performed.	
Descriptive	statistics	were	provided	using	mean	(±SD)	and	median	(range)	for	normally	
distributed	 and	 nonparametric	 distributed	 numeric	 values,	 respectively.	 The	
correlations	 between	 the	 measures	 were	 evaluated	 by	 the	 Spearman	 correlation	
coefficients	 or	 Pearson	 correlation	 coefficients	 for	 parametric	 and	 nonparametric	
distributed	 variables,	 respectively.	 Concordance	 of	 the	 PGA	 scores	 by	 the	 four	
clinicians	was	determined	by	 intraclass	 correlation	 coefficient	 (ICC).	 The	 interrater	
and intrarater reliability of the N-NAIL was determined using the ICC (two-way mixed 
Table 1  Outline of the various systems that score nail psoriasis severity.
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Pitting +* +† +‡ + † +‡ +* +§
Leukonychia +* +* +‡ - - - -
Red spots lunula +* +* +‡ - - - -
Crumbling +* +§ +‡ - +‡ +* -
Onycholysis +* +§ +‡ +§ +‡ +* +§
Splinter hemorrhages +* +* +‡ - - - -
Oil drop +* +§ +‡ - +‡ - +§
Subungual hyperkeratosis +* +* +‡ +≠ +‡ +* +≠
Beau’s lines - - - +¶ - - -
Feature is scored (+) or not scored (-) in the tool. 
NAPSI, Nail Psoriasis Scoring Index; NAS, Nail Area and Severity; PNSS, Psoriasis Nail Severity Score.
*Feature	is	scored	for	absence	or	present	as	0	or	1	point,	respectively.
‡Feature	is	scored	qualitatively	for	severity	(1=	mild,	2=moderate,	3=severe).
§Feature	is	scored	quantitatively	for	percent	area	of	involvement	.
†Feature	is	scored	quantitatively	(numeric)	for	number	of	pits	(1=1-10,	2=11-49,	3=>50	in	modified	
NAPSI	and	1=<10,	2=10-20,	3=>20	in	Baran)
≠Feature	is	scored	quantitatively	in	thickness	(mm).
¶Feature	is	scored	quantitatively	for	number	of	Beau’s	lines	(1=1,	2=	2-3,	3=	>	3)
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The N-NAIL
Based	 on	 detailed	 analysis	 of	 the	 correlation	 of	 the	 current	 nail	 psoriasis	 scoring	
systems with the PGA, the N-NAIL was developed (Appendix) and used for the same 
36	patients	as	the	other	scoring	systems.	The	correlation	between	the	PGA	and	the	
N-NAIL was 0.861 (r=0.861, p=<0.01)	indicating	a	higher	correlation	than	any	of	the	
current	 scoring	 systems.	 The	 N-NAIL	 was	 stable	 for	 multiple	 ratings	 of	 the	 same	
patient	by	a	single	observer	(ICC	rater	1:	0.989,	95%	confidence	interval	0.975-0.995;	
rater	 2:	0.967,	 95%	 confidence	 interval	0.919-0.986),	 and	 the	 interrater	 reproducibility	 
was excellent with an ICC of 0.899.
Discussion
Scoring	 systems	 are	 indispensable	 for	 the	 evaluation	 and	 comparison	 of	 medical	
treatments.	Over	the	past	few	years,	promising	treatment	options	for	nail	psoriasis	
have	become	available.	This	has	increased	the	need	for	an	optimal	scoring	system	for	
this	disease.	Several	tools	have	been	suggested	and	used	in	many	publications.	For	
this study, seven nail psoriasis scoring systems were evaluated, compared, and 
Correlation
The	ICC	for	interrater	consistency	of	the	PGA	was	0.920,	indicating	excellent	agreement	
between	raters.	Therefore,	the	principal	investigator’s	PGA	scores	could	be	used	to	
correlate with the nail psoriasis scoring systems. The mean scores of the scorings 
systems	and	the	correlation	coefficients	with	the	PGA	are	shown	in	Table	3. The PGA 
showed	an	acceptable	correlation	with	the	Baran12 assessment tool (r=0.735, p=<0.01) 
and the PNSS (r=0.734, p=<0.01). Of the nail psoriasis scoring systems, only the target 
NAPSI	showed	low	correlation	with	the	PGA	(r=0.203,	p=>0.05).	The	remaining	tools	
showed	moderate	correlation	with	 the	PGA.	Of	 the	quality-of-life	 scores,	only	 the	
target-NAPSI	 and	 the	 NAS	 showed	 a	 significant	 correlation	with	 the	 NPQ10	 (r=0.490,	
p=<0.01 and r=0.387 p=0.05,	respectively).	
Table 2		Patients	characteristics	(n=36).
Feature
Gender,	n	(%)
     Female
     Male
11 (30.6) 
 25 (69.4)
Age (years), mean (±SD)  51.5 (15.0)
Age start psoriasis (years), mean (±SD) 29.2 (15.3)
Age start nail psoriasis (years), mean (±SD) 36.5 (16.6)
Duration	of	psoriasis	(years),	mean	(±SD)				 22.6 (14.5)
Mean delay (years), mean (±SD) 7.22 (11.4)
Family	history,	n	(%)
				Positive
				Negative
    Unknown
18 (50.0)
15 (41.7)
   3 (8.3)
Nail	psoriasis	localization,	n	(%)
    Fingernails
    Fingernails and toenails
    Unknown
10 (27.7)
23 (63.9)
   3 (8.4)
Nail	feature,	n	(%)
				Pitting
    Leukonychia
    Red spots lunula
    Crumbling
    Onycholysis
    Splinter hemorrhages
				Oil-drop	discoloration
    Subungual hyperkeratosis
				Beau’s	lines
29 (80.6)
15 (41.7)
 6 (16.7)
18 (50.0)
35 (97.2)
33 (91.7)
22 (61.1)
18 (50.0)
11 (30.6)
Table 3   Mean scores of the various nail psoriasis scoring systems and their 
correlation	with	the	Physician	Global	Assessment	(PGA).
Score Mean (overall) SD Correlation  
with PGA
PGA 2.03 0.97 1
Baran 20.08 15.54 0.735*
PNSS 12.64 7.39 0.734*
NAPSI 27.25 15.43 0.669*
Modified	NAPSI 23.58 15.05 0.665*
Cannavò et al. 20.06 14.42 0.653*
NAS 27.64 22.41 0.472*
Target NAPSI 10.22 4.60 0.203
NPQ10 3.07 3.63 0.202
DLQI 7.17 6.46 0.160
PASI 4.67 3.10 0.149
*	Correlation	is	significant	at	the	0.01	level.
DLQI, Dermatology Life Quality Index; NAPSI, Nail Psoriasis Severity Index; NAS, Nail Area Severity; 
NPQ10, Nail Psoriasis Quality of life 10; PASI, Psoriasis Area and Severity Index; PGA; Physician Global 
Assessment; PNSS, Psoriasis Nail Severity Score.
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23-25 Based on these surveys, it was decided to exclude red spots in the lunula from the 
scoring	system,	as	they	have	little	influence	on	the	clinical	picture.	Leukonychia	was	
also	omitted	from	the	N-NAIL,	because	it	is	as	least	as	frequently	seen	in	the	healthy	
population.23	Therefore,	leukonychia	seems	to	be	nonspecific	for	nail	psoriasis.	In	addition,	
the	two	scoring	systems	best	correlating	with	the	PGA	both	included	only	four	nail	
psoriasis	 features,	 of	 which	 three	 are	 scored	 by	 both	 (onycholysis,	 pitting,	 and	
subungual hyperkeratosis). The authors chose to include these three nail features in 
the N-NAIL because they are frequently seen in nail psoriasis and, more importantly, 
largely determine the clinical picture of disease.3,26-29	 In	 addition,	 both	 oil-drop	
discolorations	 and	 onycholysis	 are	 the	 results	 of	 the	 same	 pathogenic	 process,	
namely,	parakeratotic	changes	in	the	nail	bed.	Desquamation	of	these	parakeratotic	
cells at the hyponychium leads to onycholysis.30,31 As onycholysis is related to oil-drop 
discoloration,	 the	 authors	 chose	 to	 integrate	 those	 two	 features	 into	 one	 single	
feature. In the N-NAIL, they are scored by percentage of involved area to give an 
impression	of	the	severity.	Finally,	it	was	decided	to	include	Beau’s	lines	in	this	new	
assessment tool. The scoring developed by Baran was the only system to include 
Beau’s	lines.12	Even	though	Beau’s	lines	are	far	from	specific	for	nail	psoriasis,	a	recent	
study has shown that the prevalence in nail psoriasis is much higher than in the 
general	population,23	and	they	define	a	large	extent	of	the	clinical	picture.
	 As	a	result	of	the	evaluation	of	the	existing	scoring	systems,	the	authors	chose	to	
score	all	ten	fingernails	in	the	N-NAIL	as	a	consequence	of	the	low	correlation	between	
the PGA and the target-NAPSI. Scoring one single nail does not seem to illustrates the 
clinical	severity	of	nail	psoriasis;	the	evaluation	of	more	nails	seems	relevant.	Recently	
a	new	nail	psoriasis	scoring	systems,	the	Nail	Assessment	in	Psoriasis	and	Psoriatic	
Arthritis,	was	published,	and	demonstrated	that	at	least	four	fingernails	need	to	be	
scored	by	 the	NAPSI	 for	a	 representative	reflection	of	nail	psoriasis	 severity	when	
compared with the total NAPSI scores.32	Nail	Assessment	 in	Psoriasis	and	Psoriatic	
Arthritis	focuses	on	quality	of	life	and	patient	need.	This	can	be	complementary,	as	
previous	 studies	 have	 shown	 that	 nail	 psoriasis	 can	 have	 a	 substantial	 impact	 on	
patients’	quality	of	 life.3, 33 However, as presented in our results, clinical severity is 
better	 represented	 by	 using	 a	more	 qualitative	 scoring	 system	 like	 the	N-NAIL.	 In	
addition,	as	already	shown	by	Parrish	et	al.,14	the	NAPSI	might	lack	sensitivity	to	reflect	
responsiveness	because	it	scores	only	presence	or	absence	of	manifestations.	
Conclusion 
To	 our	 knowledge,	 this	 study	 is	 the	 first	 to	 compare	 seven	 different	 nail	 psoriasis	
severity	scores	in	correlation	with	clinical	severity.	An	adequate	nail	psoriasis	scoring	
system is needed, as studies on treatments for nail psoriasis are upcoming. Clinical 
severity	of	nail	psoriasis	was	best	reflected	by	the	N-NAIL,	 followed	by	the	Baran12 
system and the PNSS. The N-NAIL showed excellent agreement among raters.
correlated	with	the	clinical	severity	in	terms	of	PGA	to	find	out	in	which	the	clinical	
severity	 is	optimal	mirrored.	The	authors	were	able	to	show	that	the	nail	psoriasis	
score developed by Baran12	and	the	PNSS	showed	an	acceptable	correlation	with	the	
PGA.	However,	integrating	the	obtained	information	from	these	evaluations	resulted	
in	the	development	of	the	N-NAIL,	which	clearly	reflected	clinical	severity	better	than	
existing	scoring	systems,	accompanied	by	excellent	agreement	on	reliability.	
 Because no gold standard for nail psoriasis severity scoring exists, it was decided 
to use clinical severity, expressed as PGA, as the reference in this study. The 
established interobserver consistency between PGA scores of the four independent 
clinicians turned out to be very high (0.920), proving the value of the PGA as a mean 
to	express	disease	severity	in	these	patients.	A	limitation	of	the	study	was	the	use	of	
photographs in the assessment of the agreement of PGA and N-Nail between 
observers.	The	predominant	limitation	experienced	was	the	assessment	of	subungual	
hyperkeratosis based on photographs. However, when analyzing the interobserver 
agreement	for	the	PGA,	the	ICC	was	0.920	and	for	the	N-NAIL	it	was	0.899,	indicating	
excellent	 agreement	 between	 clinical	 observations	 and	 observations	 based	 on	
photographs. A study of Farhi et al.19 also showed that the PGA for psoriasis severity, 
based on photographs, is an accurate and consistent method.19 
 A major drawback of all current nail psoriasis scoring systems is the lack of 
validation.	 Spuls	 et	 al.	 already	 demonstrated	 that	 none	 of	 the	 severity	 scores	 for	
plaque psoriasis are adequately validated.20	The	NAPSI	and	the	modified	NAPSI	are	
the only systems that have been validated to some extent.10, 14, 21, 22 Cassell et al. 
showed	good	interrater	reliability	(0.98	Cronbachs’	alpha)	and	construct	reliability	of	
the	modified	NAPSI.	However,	they	found	significant	interobserver	variability	when	
using the NAPSI score. Aktan et al. assessed the interobserver reliability of the NAPSI 
and found moderate to good interobserver consistency.21 However, it was suggested 
by	Parrish	et	al.	that	the	NAPSI	score,	regularly	used	in	clinical	trials,	lacks	sensitivity	
to	reflect	meaningful	clinical	improvement.14	They	illustrated	that	significant	clinical	
improvement	of	 severity	 of	 nail	 psoriasis	 is	 sometimes	not	 reflected	 in	 the	NAPSI	
score.14 This is in line with our results, as both scores showed only moderate 
correlation	with	clinical	severity	in	terms	of	PGA.	When	looking	at	the	N-NAIL	scoring	
system, intraobserver and interobserver reliability showed excellent agreement.
The N-NAIL
Following	 the	extensive	analyses	of	 the	existing	nail	psoriasis	 scoring	systems,	 the	
authors	found	that	the	newly	constructed	N-NAIL	better	reflects	clinical	severity	than	
all other tested nail psoriasis scoring systems. In the N-NAIL, red spots in the lunula 
and leukonychia were not included. Red spots in the lunula are documented in several 
other disorders (e.g., lichen planus, alopecia areata), and are an infrequently seen 
feature	with	a	prevalence	between	0.4%	and	10.1%	in	patients	with	nail	psoriasis.2, 21, 
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Appendix			The	Nijmegen-Nail	psoriasis	Activity	Index	tooL.
Feature Manner of scoring
Onycholysis/oil-drop	discoloration 0= absent
1=	0-25%
2=	25-50%
3=>	50%
Pitting 0 = absent
1= mild
2= moderate
3= severe
Crumbling 0= absent
1= mild
2= moderate
3= severe
Beau’s	lines 0= absent
1= 1 Beau Line
2= 2 Beau Lines
3=	≥	3	Beau	Lines
Subungual hyperkeratosis 0= absent
1= 1 mm
2= 2mm
3=	≥	3mm
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CHAPTER 5
Introduction
Although	the	most	characteristic	findings	of	psoriasis	are	skin	manifestations,	another	
commonly recognized feature is nail involvement. The documented prevalence of 
nail	involvement	in	psoriasis	patients	varies	between	15%	and	79%,	with	an	estimated	
lifetime	incidence	of	80-90%.1-7
	 Clinical	manifestations	associated	with	nail	psoriasis	are	heterogeneous	in	their	
representation	 and	 many	 psoriatic	 nail	 features	 may	 morphologically	 resemble	
onychomycosis.	 Onychomycosis	 is	 the	most	 common	 nail	 disease	 and	 constitutes	
about	half	of	all	nail	abnormalities.8	Clinical	discrimination	between	nail	psoriasis	and	
onychomycosis	often	is	difficult.	Diagnostic	techniques	including	direct	microscopy,	
fungal	culture	and	polymerase	chain	reactions	may	identify	onychomycosis	and	help	
to	distinguish	it	from	nail	psoriasis.	However,	coexistence	of	onychomycosis	and	nail	
psoriasis	also	occurs,	as	both	are	frequent	disorders	in	the	general	population.9 It is 
hypothesized	 that	 morphological	 abnormalities	 in	 psoriatic	 nails	 are	 predisposing	
factors	for	onychomycosis	and	vice	versa.	In	healthy	nails,	the	compact	orthokeratotic	
nail	plate	acts	as	a	natural	barrier	preventing	the	development	of	fungal	infections,	
which may be disturbed in abnormal nail plates in diseases such as nail psoriasis. 
Therefore,	it	is	hypothesized	that	the	prevalence	of	onychomycosis	in	patients	with	
nail	psoriasis	might	be	higher	than	in	the	general	population.9, 10 However, the immune 
response	 against	 microbial	 skin	 infections	 appears	 to	 be	 remarkably	 strong	 in	
psoriasis,	and	the	fast	 turnover	of	 the	nails	 in	psoriasis	patients	may	constitute	an	
effective	defense	against	dermatophytes.11 Therefore, a decreased prevalence of ony - 
chomycosis might be possible as well. The documented prevalence of onychomycosis 
in	patients	with	nail	psoriasis	 varies	 considerably	 in	 the	 literature	and	conclusions	
concerning	the	prevalence	and	vulnerability	of	psoriatic	nails	for	onychomycosis	are	
ambiguous.	Consequently,	our	primary	goal	was	to	systematically	review	all	available	
literature concerning the prevalence of onychomycosis.
 The secondary aim was to review the literature concerning the pathogens of 
onychomycosis	in	psoriatic	patients.	Onychomycosis	can	be	a	fungal	infection	with	a	
mould	or	a	yeast.	Dermatophytes	are	the	most	frequently	causative	pathogens	found	
in	onychomycosis	and	are	responsible	for	up	to	90%	of	toenail	infections	and	at	least	
50%	 of	 fingernail	 infections.12	 Several	 publications	 suggest	 that	 onychomycosis	 in	
psoriatic	patients	is	more	commonly	caused	by	a	yeast	than	in	non-psoriatic	patients.11, 
13, 14	 Other	 publications	 cannot	 confirm	 these	 data.15, 16 Knowing if there do exist 
differences	in	the	spectrum	of	pathogens	responsible	for	onychomycosis	in	normal	
patients	and	in	psoriatic	patients	is	not	only	important	for	the	individual	patient,	who	
may need other drugs to treat the onychomycosis but also might help to understand 
the	assumed	immunological	differences	between	psoriatic	and	non-psoriatic	individuals.	
Abstract
We	 systematically	 reviewed	 all	 available	 literature	 concerning	 the	 prevalence	 of	
onychomycosis	 in	 patients	 with	 nail	 psoriasis	 and	 the	 distribution	 of	 pathogens	
causing	onychomycosis	 in	this	specific	group	of	patients.	Databases	searched	were	
Pubmed, EMBASE and the Cochrane Controlled Clinical Trial Register. All studies 
reporting	on	the	prevalence	of	onychomycosis	 in	nail	psoriasis	were	obtained,	and	
quality	 assessment	 was	 determined	 by	 the	 STrengthening	 the	 Reporting	 of	
OBservational	 studies	 in	 Epidemiology	 checklist.	 Literature	 search	 revealed	 720	
studies, of which 10	 studies	met	 the	 inclusion	criteria.	The	major	 limitation	of	 the	
review was the heterogeneity of the included studies, which prevented the possibility 
to	 conduct	 a	 meta-analysis.	 However,	 the	 average	 prevalence	 of	 18.0%	 of	 ony-	
chomycosis	in	psoriatic	patients	seems	to	be	increased	when	compared	with	control	
groups	 and	 literature	 on	 healthy	 population,	 even	 though	 the	 ultimate	 evidence	
remains	 lacking.	 An	 in	 the	 literature	 hypothesized	 shift	 in	 causative	 agents	 from	
dermatophytes	 to	 yeasts	 and/or	 moulds	 could	 not	 be	 confirmed.	 The	 clinical	
consequence	of	the	relatively	high	prevalence	of	onychomycosis	in	psoriasis	may	be	
a general advise to rule out onychomycosis or concomitant onychomycosis in these 
patients	 with	 (suspected)	 nail	 psoriasis.	 This	 advise	 is	 stressed	 by	 the	 relative	
simplicity	of	treating	the	contribution	of	onychomycosis	in	the	nail	dystrophy	but	also	
the fact that nail psoriasis mostly is treated by immunosuppressive drugs, like 
steroids,	methotrexate	or	biologics	which	may	aggravate	mycotic	nail	infections.
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or	by	a	histomycological	diagnostic	test	with	periodic	acid	Schiff	staining.	Excluded	
were	review	articles	and	articles	published	only	in	abstract	form.	Also	articles	without	
a control group were excluded. When results from the same study were published 
more	than	once,	data	from	interim	publications	were	excluded.	Articles	without	data	
on	the	prevalence	of	onychomycosis	in	nail	psoriasis	were	excluded	during	the	first	
selection	step.	Differences	in	selection	between	the	reviewers	were	discussed	with	a	
third	investigator	when	necessary.
	 Once	 the	 relevant	 studies	 were	 identified,	 full	 publications	 were	 retrieved	 
and	 reviewed	 for	 final	 inclusion.	 The	 two	 reviewers	 (KMGK	and	MCP)	 determined	
independently	 which	 studies	 indeed	 fulfilled	 the	 inclusion	 criteria.	 The	 bibliographies	 
of	 the	 included	 articles	were	 retraced	 for	 additional	 articles.	 Reviewers	were	 not	
blind	to	the	names	of	authors,	institutions	or	journals.
	 The	 same	 reviewers	 independently	 extracted	 data	 using	 a	 predefined	 data	
extraction	form,	which	included:	study	design,	author,	source	of	data,	number	and	
origin	 of	 the	 psoriatic	 patients,	 number	 and	 origin	 of	 the	 controls,	 method	 for	
selecting	 cases,	 population	 characteristics,	 localization	of	 nail	 clipping,	 prevalence	
number	and	specification	of	species.	Methodological	quality	of	the	reviewed	studies	
was	assessed	independently	by	use	of	the	STrengthening	the	Reporting	of	OBservational	
studies in Epidemiology (STROBE) criteria, which involved an assessment of both 
internal and external validity.17 Disagreements were resolved by consensus, and when 
consensus	could	not	be	reached,	by	a	third	investigator.	Three	categories	for	quality	
assessment	were	established	arbitrary.	When	the	study	fulfilled	more	than	80%	of	
the	criteria	stated	in	STROBE	it	was	categorized	as	A,	B	when	50-80	%	of	the	criteria	
were	met	and	C	when	less	than	50%	of	the	criteria	could	be	achieved.
Results
Study selection
A	 total	 of	 723	eligible	 articles	were	 identified	using	 the	described	 search	 terms	 in	
Pubmed, EMBASE and Cochrane search databases, from which 152 duplicate records 
were	removed.	From	the	remaining,	542	articles	were	excluded	because	abstracts	
showed that the studies were not eligible for inclusion because they did not directly 
deal	with	the	subject.	Finally,	29	articles	seemed	to	be	relevant	for	detailed	evaluation.	
After	 full	 text	 screening,	 10	 articles	 were	 considered	 appropriate	 for	 inclusion	 (see	
Figure 2).11, 13, 15, 16, 18-23	 The	 clinical	 and	 study	 characteristics	 of	 the	 included	 articles	 are	
summarized in Table 1. Of the ten studies included, six were published between 2000 
and 2012, two studies were published in the 1990s 15, 24 and two studies were published 
in the 1980s.16, 22	The	total	number	of	patients	assessed	in	these	studies	was	2176,	with	 
a	range	of	70-561	patients	per	study.	The	studies	were	predominantly	conducted	in	
Methods
We	 performed	 a	 systematic	 review	 of	 all	 studies	 investigating	 the	 prevalence	 of	
onychomycosis	in	psoriatic	patients.	Search	strategies	were	developed	in	consultation	
with	 a	 research	 librarian	 with	 systematic	 review	 expertise.	 Three	 bibliographic	
databases	 were	 searched	 for	 articles	 published	 from	 January	 1980	 to	 April	 2012.	
Involved databases were PubMed, EMBASE and the Cochrane Controlled Trial Register. 
Medical Subject Heading and free text searches embracing the following terms were 
used:	‘psoriasis’,	‘nail’	and	‘onychomycosis’,	including	all	possible	synonyms	and	nail	
features	 (see	also	Figure	 1).	The	 literature	search	was	 limited	 to	articles	written	 in	
English, French, German and Polish language.
	 After	the	 initial	search	was	performed, titles	and	abstracts	 identified	from	the	
searches were reviewed for relevance by two independent reviewers (KMGK and 
MCP), taking into account the inclusion and exclusion criteria. Inclusion criteria were 
full	 text	 papers	 which	 included	 prevalence	 studies	 of	 onychomycosis	 in	 psoriatic	
patients	and	confirmed	diagnosis	of	onychomycosis	by	direct	microscopy	and	culture	
Figure 1.  Search strategy.
#1 Nails (MesH)
#2 Nail*
#3 Toenail*
#4 Fingernail*
#5 Leuconychia
#6 Leukonychia
#7	Pitting
#8 Subungual hyperkeratosis
#9 Onycholysis
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 Psoriasis (MesH)
#12 Psoria*
#13 #11 or #12
#14 Onychomycosis (MesH)
#15 Fungal
#16 Yeast
#17 Dermatophyte
#18 #14 or #15 or #16 or #17
#19 #10 AND #13 AND #18
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various European countries (n= 7), two studies were conducted in Asia, and one 
combined	Canadian/American	study	was	included.
Prevalence
The	prevalence	figures	for	onychomycosis	in	psoriatic	patients	for	each	of	the	studies	
are summarized in Table 2. As shown in this Table, the sources of data were hetero -
geneous	 (e.g.,	 recruitment	 of	 patients,	 localization	 of	 clipping)	 as	 well	 as	 patient	
inclusion and exclusion criteria. This heterogeneity made reliable comparison between 
studies	 impossible.	However,	 the	combined	prevalence	of	18.0%	of	onychomycosis	 
in	 the	studies	 (392	out	of	2176	psoriasis	patients)	compared	to	9.1%	 in	 the	control	
group (159 out of 1748, studies with onychomycosis control group excluded) may give 
some	indication.	
Figure 2.  Flow chart.
PubMed
N = 244
EMBASE
N = 473
Cochrane 
N = 6
N = 723
N = 571
N = 29
N = 10
Duplicate articles excluded 
N = 152 
Excluded after screening 
titles and abstracts 
N = 542 
Excluded after full text 
examination ( N = 20) 
- Unavailable: 2 
- Review article: 1 
- Duplicate study group: 1 
- Subject: 2 
- Language restrictions: 4 
- No control group: 10 
Articles included after 
screening references 
N= 1 
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Table 2   Prevalence numbers of the included studies.
Study Percentage 
onychomycosis 
patients, %
Percentage 
onychomycosis, 
clinically affected 
(patients),%
Percentage 
onychomycosis 
control, %
Percentage 
onychomycosis, 
clinically affected 
(controls),%
Direct 
microscopy
Culture Medium Conclusion
Toenails 
Gupta et al. 15 12.7 27.0 6.9 43.8 +
KOH
+ 1. Sabouraud glucose agar + cycloheximide 
+chloramphenicol + CCG
2. Casamino acids erythriol albumin agar + CCG
3.	 Littman	oxgall	agar	+	streptomycin
Significant	higher	prevalence	in	
psoriasis	patients
Hamnerius et al.18 4.6 U 2.4 U +
KOH	10%
Parkers ink
+ 1. Sabouraud agar + CCG
2. Dermatophyte medium + cycloheximide + 
gentamycine
No	significant	difference.	 
No	altered	susceptibility.
Leibovici et al.19 47.8 U 28.4 U +
KOH
+ Sabouraud glucose agar
1. + Cycloheximide
2. – Cycloheximide
Significant	higher	prevalence	in	
psoriasis	patients
(p=0.0054)
Zawirska et al.23 11.4 U 3.3 U +
KOH	20%
DMSO	40%
+ 1. Sabourauds dextrose agar
2. Sabourauds dextrose agar + cycloheximide + 
chloramphenicol
Higher	prevalence	(significance	
unknown)
Toenails and fingernails
Larsen et al.11 21.5 26.2 12.7 34.0 +
Calcofluor	
white 
+ Sabouraud glucose agar
1. +Chloramphenicol + cycloheximide
2. +Chloramphenicol
No	significant	difference	(p 0.13)
Kacar et al. 20 13.1 28.6 7.9 40.6 +
KOH 
20%
+ 1. Sabourauds dextrose agar on potato agar 
2.	 Lactophenol	cotton	blue	
3.	 Fermentation	test	Wickerham
No	significant	difference	
Pawlaczyck et al.21 6.0 18.8 - 39.5 +
KOH 
20%
+ 1. Sabourauds agar 
2. Sabourauds agar + chloramphenicol + 
cycloheximide
No	significant	difference
Staberg et al.22 26.9 30.8 19.5 U +
KOH
30%
+ Sabourauds dextrose agar
1.  + Chloramphenicol + cycloheximide
Higher prevalence but non-
significant
Stander et al.13 30.4 U 19.6 U + + Malzagar	+	antibiotics	 No	significant	difference
Szepes et al.16 63.1 U - 66.0 + Sabourauds dextrose agar 
1. +penicillin
2.  +streptomycine
No	significant	difference
CCG, gentamicin; KOH, potassium hydroxide; U, unknown, 
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moulds	were	more	frequently	found	in	psoriatic	nails	compared	with	the	pathogens	
found	in	nails	of	non-psoriatic	patients,	although	differences	were	significant	in	only	
the study of Stander et al.11, 13, 16, 19, 22	Three	studies	concluded	that	the	distribution	of	
the	different	 species	was	 comparable	with	 the	control	population,	dermatophytes	
were most frequently found.15, 20 Kacar et al. even found a higher prevalence of 
dermatophytes	 in	 psoriatic	 patients	 than	 in	 controls,	 but	 the	 absolute	 number	 of	
positive	 cultures	 in	 this	 study	was	 remarkably	 low.20 In the two remaining studies no 
pathogen	differentiation	was	available.	Of	the	included	studies	four	studies	focused	
only	on	the	toenails,	the	other	studies	took	nail	samples	from	both	toe-	and	fingernails.	
However	 only	 three	 studies	made	 a	 specification	 between	 finger-	 and	 toenails	 in	 the	
analysis	of	the	pathogen	distribution	(see	Table	4).
 When considering all studies individually, the prevalence of onychomycosis in 
psoriatic	patients	varied	from	4.6%	to	63.1%	compared	to	2.4%	to	66.0%	in	controls.	
Three	 studies	 concluded	 that	 the	 prevalence	 of	 onychomycosis	 was	 significantly	
higher	in	patients	with	psoriasis	compared	with	healthy	controls.	The	remaining	seven	
studies	reported	no	significant	differences	between	the	prevalence	of	onychomycosis	
in	 psoriatic	 patients	 compared	 to	 controls,	 although	 all	 except	 one	 found	 higher	
prevalence	numbers	in	psoriatic	patients.
Pathogens
Various	studies	distinguished	between	the	different	pathogens	and	documented	the	
percentages of dermatophytes, non-dermatophyte moulds, and yeast. Table 3 gives an 
overview	of	these	results.	Five	studies	concluded	that	yeast	and/or	non-dermatophyte	
Table 3			Differentiation	of	pathogens	found	in	psoriatic	patients	with	onychomycosis.
Study Patients Controls Conclusion
Dermatophyte,  
n (%)
Yeast,  
n (%)
Mould,  
n (%)
Dermatophyte,  
n (%)
Yeast,  
n (%)
Mould,  
n (%)
Toenails only
Gupta et al.15 45 (84.9) 3 (5.7) 5 (9.4) 41 (87.2) 3 (6.4) 3 (6.4) No	significant	difference	(p=0.58). 
Dermatophytes most prevalent in both groups
Hamnerius et al.18 No	differentiation No	differentiation No	differentiation No	differentiation No	differentiation No	differentiation No	specification	of	pathogens
Leibovici et al.19 42 (77.8) 6 (11.1) 6 (11.1) 27 (93.1) 2 (6.9) 0 (0) Same	profile	but	moulds	were	more	prevalent	in	psoriatic	
patients
Zawirska et al.23 No	differentiation No	differentiation No	differentiation No	differentiation No	differentiation No	differentiation No	specification	of	pathogens
Toenails and fingernails
Kacar et al. 20 8 (61.5) 3 (23.1) 2 (15.4) 1 (25.0) 0 (0) 3 (75.0) Nail psoriasis risk factor for dermatophyte onychomycosis 
(p=0.02)
Larsen et al.11 8 (36.4) 10 (45.5) 4 (18.2)   12 (50.0) 7 (29.2) 5 (20.8) More	prevalent	yeast	in	psoriasis	patients
Pawlaczyck et al.21 19 (65.5) 8 (27.6) 2 (6.9) 1013 (64.2) 347 (22.0) 148 (9.4) Dermatophytes frequently seen in nail psoriasis
Staberg et al.22 10 (47.6) 10 (47.6) 1 (4.8) 4 (50.0) 4 (50.0) 0 (0.0) Higher	prevalence	yeast	in	psoriasis	patients	with	nail	
involvement
Stander et al.13 22 (28.9) 48 (62.2) 6 (7.9) 11 (55.0) 7 (35.0) 2 (10.0) Higher	probability	of	yeast	in	psoriatic	nails
Szepes et al.16  9 (12.9) 26 (37.1) 35 (50.0) 45 (20.0) 65 (28.9) 115 (51.1) Rate of dermatophytes is lower while the frequency of yeast 
was higher
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Discussion
During the past decades several studies were conducted in order to gain knowledge 
on	the	prevalence	of	onychomycosis	in	psoriatic	patients.	In	some	studies	an	increased	
prevalence	was	shown,	while	this	could	not	be	confirmed	in	others.	The	same	lack	of	
uniformity was found in reports on the involved pathogens in onychomycosis in 
psoriatic	patients.	This	systematic	review	 is	an	attempt	 to	give	an	overview	of	 the	
available literature and acquire more certain knowledge on these clinical relevant 
topics. 
	 We	 systematically	 reviewed	 all	 available	 literature	 on	 the	 prevalence	 of	 ony	-
chomycosis	 in	 psoriatic	 patients.	 After	 thorough	 inspection	 of	 all	 literature,	 ten	
studies	 specific	 focusing	on	 the	prevalence	of	 onychomycosis	 in	 psoriatic	patients	
could be included. However, because of heterogeneity between studies, a meta- 
analysis	could	not	be	made.	These	major	differences	also	indicate	differences	in	their	
methodological	quality.	Tools	of	quality	assessment	are	well	established	in	systematic	
reviews of randomized controlled trials but the use of quality assessment tools to 
appraise	observational	studies	is	less	well	established	and	no	gold	standard	exists.	In	
the absence of these quality assessment tools, we used the STROBE checklist to 
compare the included studies for methodological quality. We have taken into account 
that the STROBE was developed for authors of reports and not for assessing the 
quality of a study, 17, 25 but because no validated tool existed the STROBE was used. 
The absence of accepted quality assessment tools implies that studies included in the 
review were given equal weight in the analyses regardless of methodological quality.26 
Therefore, the results from the STROBE are displayed in Table 1, but were not used to 
strengthen	 or	 weaken	 the	 interpretation	 of	 the	 results	 from	 individual	 studies.	
Overall,	more	than	50%	of	the	included	studies	was	classified	in	the	lowest	category	
(c) which gives some kind of insight into the rather low quality of most studies. Only 
one	study	fulfilled	the	criteria	for	the	highest	STROBE	classification.15 
Prevalence
As	mentioned	above,	a	meta-analysis	could	not	be	made	because	of	the	considerable	
differences	in	the	protocols	of	the	ten	studies.	Factors	limiting	comparability	include	
methods	 of	 case/control	 identification,	 differences	 in	 sample	 size,	 different	 age	
distributions	 of	 the	 study	 populations,	 as	 well	 as	 localization	 of	 nail	 clippings,	
techniques	and	criteria	used	 for	detecting	onychomycosis	and	 the	 focus	on	fingernails	
and/or	 toenails.	 Another	 confounding	 factor	may	 be	 the	 known	 heterogeneity	 in	
prevalence	between	different	ethnic	groups	and	continents.	However,	even	studies	
conducted	 in	the	same	country	can	document	 impressive	differences.21, 23, 27, 28 As a 
consequence	of	these	differences	an	overview	of	the	results	shows	a	wide	variation	
of	the	onychomycosis	prevalence	in	psoriatic	patients,	ranging	from	4.6%	to	63.1%,	
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secondary invasion in an already abnormal nail.33	The	fact	that	psoriasis	patients	may	
use systemic and topical immunosuppressive drugs which may facilitate the 
development	of	fungal	infections	of	the	nail	is	rarely	mentioned	but	certainly	may	be	
of importance.34	 In	 addition,	 it	 is	 mentioned	 that	 abnormal	 capillary	 units	 in	 nail	
psoriasis impairs the defense normally supplied by healthy hyponychium and weakens 
the defense system of the nail against invading microorganisms.19 On the other hand, 
Dorschner et al.35	demonstrated	that	presence	of	antimicrobial	peptides	in	the	nail	
with	activity	against	nail	 pathogens	may	account	 for	 the	ability	of	 the	nail	 unit	 to	
resist	infection	in	the	absence	of	direct	access	to	cellular	immune	system.	Arguments	
contradicting	mentioned	arguments	 favouring	mycotic	 infections	 are	 the	 fact	 that	
the	 immune	 response	 against	 microbial	 skin	 infections	 is	 remarkably	 strong	 in	
psoriasis,	 giving	 a	 possible	 explanation	 why	 the	 prevalence	 of	 onychomycosis	 in	
psoriatic	patient	might	have	been	 lower	than	 in	healthy	controls.36 Furthermore, it 
has	been	shown	that	psoriatic	nails	have	a	higher	turnover	and	desquamation	rate,	
and	thereby	decreasing	the	opportunity	for	fungal	organism	to	invade	the	nail	keratin	
compared to healthy nails.37 
Pathogens
Dermatophytes	are	most	frequently	the	causative	pathogens	found	in	onychomycosis	
in	the	non-psoriatic	population	and	are	responsible	for	up	to	90%	of	toenail	infections	
and	 at	 least	 50%	 of	 fingernail	 infections.	 The	 main	 causative	 dermatophytes	 are	
Trichophyton rubrum and Trichophyton mentagrophytes,	 found	 in	 80-90%.38 Yeast 
and non-dermatophyte moulds are much less frequently cultured as primarily 
pathogens. Of these, Candida species are the most common and account for 
approximately	1.5%	to	6.0%	of	nail	infections,	more	frequently	in	fingernails	than	in	
toenails.8, 10, 39 However, the prevalence of nail disease caused by dermatophytes, 
yeasts	 and	 non-dermatophyte	 moulds	 depends	 on	 localization	 and	 geographic	
region.	 A	 relative	 high	 incidence	 of	Candida	 infections	 is	 generally	 found	 in	more	
tropical climates.40	For	example,	an	incidence	of	38.4%	was	found	in	a	large	number	
of	onychomycosis	patients	 in	Brazil.41 According to a Canadian study, the pathogen 
distribution	in	toenail	onychomycosis	in	the	general	population	showed	predominantly	
dermatophytes	 (92.9%)	 followed	 by	 non-dermatophyte	 moulds	 (4.3%)	 and	 yeast	
(2.8%).42	In	the	above	mentioned	European	ACHILLES	project	the	cultured	pathogens	
in	 fungal	 foot	 infection	 were	 also	 predominantly	 dermatophytes	 (Trichophyton 
species	75.1%),	followed	by	Candida	species	(11.8%)	and	Aspergillus	species	(5.9%).32 In 
the German study by Mügge et al. among	almost	1000	onychomycosis	patients,	yeast	
infections	were	found	the	causative	agent	in	even	higher	percentages,	namely	in	20%	
of	pedal	onychomycosis	and	in	56%	of	finger	nail	onychomycosis.43 
 When looking at the included studies, non-dermatophyte moulds and yeast were 
frequently	cultured,	but	in	majority	of	studies	no	significant	differences	were	found.	
while	the	prevalence	in	the	control	groups	ranged	from	2.4%	to	66.0%.	Combining	all	
ten	studies,	392	of	the	2176	psoriasis	patients	were	diagnosed	with	onychomycosis,	a	
prevalence	 of	 18.0%	 compared	 to	 a	 combined	 prevalence	 of	 9.1%	 in	 the	 control	
groups	 (excluding	 the	 studies	 with	 onychomycosis	 patients	 as	 controls).	 In	 the	
literature	several	studies	investigated	the	prevalence	of	onychomycosis	in	the	general	
population.	 One	 Canadian	 study	 investigated	 the	 prevalence	 of	 onychomycosis	 in	 
15	000	patients	and	found	a	prevalence	of	6.5%	in	the	Canadian	general	population.29 
A	 prevalence	 of	 8.4%	 was	 found	 in	 Finland	 (n=800)	 and	 an	 Indonesian	 study	
documented	a	prevalence	of	4.7%.30, 31 The ACHILLES project, a survey of diseases of 
the	foot	 in	11	European	countries	(19	588	patients)	found	onychomycosis	to	be	the	
most	frequent	fungal	foot	infection	and	estimated	an	extraordinary	high	prevalence,	
based	 on	 mycological	 examination,	 of	 20.9%.32 These studies suggest that the 
prevalence	 of	 onychomycosis	 varies	 considerably	 between	 different	 parts	 of	 the	
world.	 The	 pooled	 prevalence	 of	 18.0%	 among	 psoriatic	 patients	 which	 has	 been	
estimated	 in	 this	 systematic	 review	 seems	 to	 be	 elevated	when	 compared	 to	 the	
prevalence	of	the	control	groups	and	the	percentages	found	in	the	general	population	
except when compared to the results of the ACHILLES project. However, the combined 
prevalence is not fully comparable with these published prevalences in the general 
population	as	the	study	populations	were	not	matched	for	other	predisposing	factors	
such	as	age,	comorbidities	(e.g.,	diabetes)	and	geographical	region.	
	 Looking	in	more	detail	to	the	studies,	three	studies	showed	a	significant	higher	
prevalence	of	onychomycosis	in	psoriasis	patients	than	among	controls.	Furthermore,	
the prevalence of onychomycosis was higher in the psoriasis group compared with 
the	 control	 group	 in	 six	 out	 of	 seven	 remaining	 studies,	 although	 no	 statistical	
differences	 were	 found.	 So,	 in	 only	 one	 out	 of	 ten	 studies	 the	 prevalence	 of	
onychomycosis	in	psoriasis	patients	was	not	higher	than	in	controls.	Therefore,	and	
because	of	the	difference	between	the	prevalence	in	the	general	population,	it	seems	
reasonable to conclude that the prevalence of onychomycosis indeed seems to be 
higher	among	patients	suffering	from	psoriasis,	even	though	the	ultimate	evidence	
remains	lacking.	The	main	reason	of	not	finding	significant	differences	between	the	
prevalence	 of	 onychomycosis	 in	 psoriasis	 patients	 and	 healthy	 controls	 therefore	
may	not	be	the	absence	of	differences	but	rather	the	small	sizes	of	the	groups	that	
were	investigated	and	weaker	methodological	quality	of	some	studies.	Based	on	an	
overview of studies it cannot be proven that the prevalence of onychomycosis in nail 
psoriasis is higher although a tendency towards higher prevalence numbers can be 
seen when all studies are pooled.
	 Various	arguments	 concerning	 the	vulnerability	of	psoriatic	nails	 for	 fungal	micro-	
organisms are discussed. Some authors defend the hypothesis that morphological 
abnormalities	 in	 these	nails	 (e.g.,	hyperkeratosis	and	onycholysis)	are	predisposing	
factors for invasion of the nail by microorganisms,9, 10, 15 as this can be seen as 
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It was hypothesized by Larsen et al. that	the	altered	subungual	tissue	and	onycholysis	
may facilitate the invasion of yeast. Furthermore, the fast turnover of the nails in 
psoriasis	 patients	 theoretically	 may	 constitute	 an	 effective	 defense	 against	
dermatophytes.11	In	addition	it	was	suggested	that	glycoprotein	material,	present	in	
the nail, might be inhibitory to dermatophytes.44	 However,	 localization	 of	
onychomycosis must be taken into account as dermatophytes are the most common 
causative	pathogens	of	onychomycosis	in	toenails,	while	yeasts	are	more	frequently	
isolated	from	fingernails.33 Many of included studies took nail clippings from clinical 
affected	nails	of	both	finger-	and	toenails.	Onychomycosis	in	healthy	controls	is	most	
likely	 localized	 on	 toenails	 while	 psoriasis	 patients	 more	 frequently	 also	 have	
dystrophic	fingernails.7 In the analysis of data (and comparison of healthy controls 
and	psoriasis	patients),	the	pathogen	distribution	has	to	be	specified	for	toenails	and	
fingernails	 separately.	 Unfortunately,	 only	 three	 studies	 made	 a	 specification	
between	finger-	and	toenails	concerning	the	pathogens.	It	seems	that	in	both	patients	
and controls dermatophytes and moulds are predominantly seen in toenails, and 
yeast	in	fingernails.	However,	we	were	not	able	to	draw	conclusion	based	on	these	
three	studies.	All	three	studies	show	different	pathogen	distribution	patterns	when	
controls	were	compared	with	psoriatic	patients.	Because	of	heterogeneity	(e.g.,	nail	
clipping	 localization,	 clinical	 affected	 and	 unaffected	 nails)	 and	 quality	 differences	
between	studies	no	final	conclusion	on	the	microorganisms	found	in	onychomycosis	
in	psoriatic	patients	could	be	made.	
Conclusion
This	systematic	review	gives	an	overview	of	all	available	literature	on	the	coexistence	
of onychomycosis and nail psoriasis. Because of heterogeneity between studies, and 
low	methodological	quality	no	ultimate	conclusion	can	be	drawn	as	no	meta	analysis	
could be conducted. However, when giving an overview of included studies, the 
prevalence	 of	 onychomycosis	 in	 psoriatic	 patients	 seems	 to	 be	 increased	 when	
compared	to	control	groups	and	literature	on	healthy	population,	even	though	the	
ultimate	 evidence	 remains	 lacking.	 A	 hypothesized	 shift	 in	 causative	 agents	 from	
dermatophytes	 to	 yeasts	 and/or	moulds	 could	 not	 be	 confirmed.	 Future	 research	
concerning	 this	 topic	 is	 important.	 The	 clinical	 consequence	 of	 the	 relatively	 high	
prevalence of onychomycosis in psoriasis may be a general advise to rule out 
onychomycosis	 in	 these	 patients	 with	 nail	 abnormalities	 before	 concluding	 the	
patient	 is	 suffering	 from	nail	psoriasis.	 This	advise	 is	 stressed	by	 the	 fact	 that	nail	
psoriasis mostly is treated by immunosuppressive drugs, like steroids, methotrexate 
or	biologics	which	may	aggravate	mycotic	nail	infections.
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CHAPTER 6
Introduction
The	 relationship	 between	 psoriasis	 and	 arthritis	 was	 first	 described	 in	 1818.1 
The	 prevalence	 of	 psoriatic	 arthritis	 (PsA)	 in	 patients	 with	 psoriasis	 varies	 from	
approximately	7%	to	40%	in	literature.2-6 This percentage is even higher in psoriasis 
patients	with	nail	involvement,	reaching	nearly	70%.7
	 Why	psoriasis	patients	with	nail	psoriasis	have	a	notable	higher	prevalence	of	
PsA,	 and	 specifically	 arthritis	 of	 the	 distal	 interphalangeal	 (DIP)	 joint,	 is	 not	 fully	
elucidated.8,9	Originally,	it	was	thought	that	the	link	between	arthritis	and	psoriasis	
could	be	explained	by	an	autoimmune	reaction	to	a	common	autoantigen	in	both	skin	
and synovium.10 However, this hypothesis is challenged by recent studies which 
emphasize	 on	 the	 association	 between	 PsA	 and	 nail	 psoriasis.	 McGonagle	 et	 al.	
proposed a hypothesis concerning the pathogenesis in which entheses play a central 
role.11-13 Entheses are sites at which tendons or ligaments are integrated into bone.14 
They are suggested as the epicenter of both nail psoriasis and PsA, as there might be 
a	direct	anatomical	 link	between	inflammation	of	the	DIP	 joint	and	nail	changes	 in	
psoriasis via the entheses of the extensor tendon.12,13 Imaging studies showed that the 
fibers	of	the	entheses	of	the	extensor	tendon	extent	to,	and	fuse	with	the	area	of	the	
nail matrix.12,15,16 They seem to be integrated into a synovio-entheseal complex 
connecting	nail	and	joint.	This	finding	led	to	the	suggestion	that	nail	manifestations	in	
PsA are an extension of entheseal changes or vice versa.15,17	 Recent	 publications	
explored this hypotheses, and documented that enthesopathy can already be found 
in	the	entheses	of	the	lower	extremities	in	clinically	asymptomatic	patients	with	nail	
psoriasis. As the entheses of the DIP joint are suggested as the anatomical link and 
starting	point	of	a	generalized	disease,	standardized	visualization	and	comparison	of	
these	 structures	 in	 symptomatic	 and	 asymptomatic	 nails	 of	 nail	 psoriasis	 patients	
without	clinical	evidence	of	PsA	would	be	interesting.	Therefore,	the	aim	of	this	study	
was	to	contribute	to	the	elucidation	and	exploration	of	the	hypothesis	concerning	the	
anatomical link between nail psoriasis and PsA with the extensor entheses as the 
epicenter, using three dimensional (3D) ultrasound (US). 
Material and Methods
Patients
A	cross-sectional	cohort	study	was	conducted	at	the	Departments	of	Dermatology	
and Radiology of the Radboud university medical center, Nijmegen, The Netherlands. 
Patients	were	included	from	September	2012	to	March	2013.	A	total	of	56	psoriatic	
patients	 with	 fingernail	 psoriasis	 (NAPSI	 >5),	 32	 psoriasis	 patients	 without	 nail	
involvement	(NAPSI	≤5)	and	32	HCs	were	included.	Referred	patients	diagnosed	with	
psoriasis,	and	psoriasis	patients	 from	the	psoriasis	database	of	 the	Department	of	
Abstract
Background. Patients	with	nail	psoriasis	have	a	higher	prevalence	of	psoriatic	arthritis	
(PsA),	however	the	pathogenetical	 relationship	between	these	 is	unclear.	Entheses	
are suggested as the epicenter of disease, which might explain the pathogenesis in an 
anatomical way.
Objective.	 To	 contribute	 to	 the	 elucidation	 and	 exploration	 of	 the	 hypothesis	
concerning the anatomical link between nail psoriasis and PsA with the extensor 
entheses of the distal interphalangeal joint as the epicenter.
Methods. To explore the pathogenesis of nail psoriasis and PsA, we conducted a 
cross-sectional	cohort	study,	visualizing	 the	entheses	of	 the	distal	 interphalangeal	 joint	 
of	patients	with	fingernail	 psoriasis	 (n=54),	 psoriasis	 patients	without	nail	 involvement	
(n=32) and healthy controls (HC, n=32) using three dimensional ultrasound. 
Results. The	results	showed	that	patients	with	nail	psoriasis	have	significant	thicker	
radial	entheses	compared	to	psoriasis	patients	without	nail	involvement	(1.285	mm	
vs. 1.216 mm, p=0.009) and HCs (1.285 mm vs. 1.223 mm, p=0.008).	No	significant	
differences	in	entheseal	thickness	were	found	between	entheses	of	adjacent	involved,	
and adjacent uninvolved nails (1.297 mm vs. 1.253 mm, p=0.13).	No	differences	were	
found for the ulnar entheses. 
Conclusion. The	present	study	could	not	confirm	an	anatomical	relation	between	nail	
psoriasis and PsA as the underlying, and triggering pathogenic mechanism, as 
entheseal	thickening	is	also	present	in	entheses	of	uninvolved	nails.	An	explanation	
for	the	link	between	nail	psoriasis	and	PsA	might	be	sought	at	the	genetic	level.	
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Wakefield	et	al.	(1=	no	flow,	2=	single	vessel	signal,	3=confluent	vessel	signal	in	less	
than half of the area, 4=vessel signal in more than half of the area).40
Statistics
The	number	of	 included	patients	was	determined	 in	consultation	with	the	statistic	
department of the Radboud university medical center. Data were entered in a 
Statistical	Package	for	Social	Sciences	(SPSS	20.0,	IBM	Corp.,	Armonk,	NY)	database	
and	 subsequently	 statistical	 analyses	 were	 performed.	 Descriptive	 statistics	 were	
provided	using	mean	 (±95%CI)	 or	median	 (range)	 for	 normally	 and	nonparametric	
distributed	numeric	values,	respectively.	To	assess	reliability	of	entheseal	thickness	
assessment,	 the	 images	 of	 220	 randomly	 chosen	 fingernails	 were	 evaluated	
independently	 by	 both	 investigators.	 Intraclass	 correlation	 coefficient	 (ICC)	 values	
were	 calculated	between	 the	 two	 investigators.	ANOVA	was	used	 to	 estimate	 the	
differences	between	the	groups,	and	multiple	linear	regression	was	used	to	determine	
the	 independent	association	between	entheseal	thickness	and	groups	adjusted	for	
age and sex. A p-value	<0.05	was	considered	statistically	significant.	
Dermatology	were	approached,	and	asked	 to	participate	 in	 the	study.	All	psoriatic	
patients	have	been	diagnosed	with	psoriasis	before,	and	participants	were	excluded	
if	they	had	a	current	or	previous	history	of	(psoriatic)	arthritis.	Patients	using	systemic	
antipsoriatic	 therapy	 at	 the	moment	 of	 inclusion	 or	 in	 the	 previous	 three	months	
were	excluded.	Patients	and	controls	with	presence	of	a	disease	other	than	psoriasis	
which	is	associated	with	nail	manifestations	(e.g.,	alopecia	areata,	lichen	planus)	were	
also excluded. 
Clinical data collection
Clinical	data	was	collected	by	a	trained	physician	(KMGK).	Psoriatic	fingernail	features	
and	 nail	 psoriasis	 severity	 were	 assessed	 by	 clinical	 examination,	 using	 the	 Nail	
Psoriasis Severity Index (NAPSI).38 The severity of psoriasis was assessed using the 
Psoriasis Area and Severity Index (range 0-72).39 Clippings and subungual scrapings 
of	 all	 patients	 were	 collected	 for	 direct	microscopic	 examination	 (10%	 potassium	
hydroxide	 preparations)	 in	 order	 to	 rule	 out	 the	 presence	 of	 a	 concomitant	 ony-
chomycosis.	When	present,	the	clipping	was	taken	from	a	clinical	affected	fingernail,	
otherwise	 from	digit	 one	of	 the	 right	hand.	 Patients	with	 concomitant	onychomycosis	
were excluded from the study. 
Ultrasound
The	clinical	examination	(clinical	physician:	KMGK),	ultrasound	imaging	(four	trained	
radiographers)	 and	 ultrasound	 interpretation	 (two	 radiologists:	 WMK	 and	MJMP)	
were	 performed	 separately	 by	 different	 investigators	 who	were	 unaware	 of	 each	
other’s	results.	Both	radiographers	and	radiologist	were	blinded	for	the	diagnosis	of	
the	 patients.	 Patients	 were	 asked	 not	 to	 communicate	 with	 the	 radiographers	
concerning	their	skin	and/or	nail	condition.	The	ultrasound	images	were	performed	
using the SomoVu automated 3D breast volume scanner (ABVS) developed by 
U-systems,	Inc	(Sunnyvale,	CA).	For	all	acquisitions,	a	linear	8-MHz/10-MHz	transducer	
with	a	width	of	 14.5	 cm	was	used.	During	 imaging,	patients	placed	both	pronated	
hands	on	the	bottom	of	a	bin	filled	with	ultrasound	transmission	gel.	The	3D	ultrasound	
was	 conducted	on	all	 ten	fingernails	 in	 two	 stages	 (stage	one	digit	 2	till	 5	of	both	
hands, stage 2 digit 1 of both hands). Axial 3D scans ran from the distal end of the 
fingers	to	the	middle	of	the	most	cranial	midphalanx.	Each	3D	volume	was	generated	
with	an	in-plane	resolution	of	0.285	mm	x	0.285	mm	and	a	slice	thickness	of	0.6	mm.	
Power Doppler of the ABVS was equipped with a two-dimensional handheld linear 
18MHz	 transducer	 for	 all	 ten	 fingernails	 in	 the	 axial	 plane	 of	 the	 nail	 plate.	 The	
radiologist evaluated the images and conducted measurements. Subsequently the 
thickness of the extensor tendon was measured just distal of the DIP joint at the 
division	of	the	tendon	in	an	ulnar	and	a	radial	section,	proximal	to	the	insertion	(see	
Figure 1). Severity of the Doppler signal was graded into four stages according to 
Figure 1.  Axial ultrasonographic appearance (using the automated 3D breast ultra - sound 
system) of the entheses of the extensor tendon of the distal interphalangeal (DIP) joint.
Entheses	are	indicated	by	the	asterisks.	The	image	is	located	just	distal	of	the	DIP	joint	of	digit	4	of	the	left	
hand,	and	shows	the	division	of	the	tendon	in	an	ulnar	and	radial	section.	DP,	distal	phalange,	s,	skin.
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Results
Patients
We	 included	 54	 patients	 (with	 540	 entheses)	 diagnosed	 with	 fingernail	 psoriasis	
without	PsA,	32	(320	entheses)	psoriasis	patients	without	nail	 involvement,	and	32	
(320	 entheses)	 healthy	 controls	 (HC).	 Two	 patients	were	 excluded	 because	 of	 the	
diagnosis	of	PsA.	Descriptive	patient	characteristics	are	reported	in	Table	1.	The	HCs	
were	 significantly	 younger	 when	 compared	 to	 both	 psoriasis	 groups.	 PASI	 and	
duration	of	disease	were	 comparable	 in	both	psoriasis	 groups	 (3.9	 (0-24.1)	 vs.	 3.0	
(0-9.9), p=0.061	and	23.9	95%CI	19.6-28.2	vs.	26.3	95%CI	20.3-32.3,	p=0.757).	After	
studying	 the	 images,	 421/540	 entheseal	 images	 in	 the	 nail	 psoriasis	 group	 were	
available	for	analyses.	 In	the	psoriasis	group	186/320	fingernails	were	available	for	
analysis,	and	278/320	in	the	control	group.	
Ultrasonography entheses
All entheses were separately analyzed, and the results for radial and ulnar entheseal 
thickness	are	 shown	 in	Table	2.	On	ultrasound	examination	mean	 radial	entheseal	
thickness	 in	 the	 nail	 psoriasis	 group	 was	 with	 1.285	 millimeter	 (mm)	 (95%	 CI	
1.261-1.316),	significantly	thicker	when	compared	to	the	psoriasis	group	without	nail	
involvement	(1.216	mm	95%CI	1.181-1.251	,	p=0.009) or compared to the HCs (1.223 
mm	95%CI	1.194-1.252,	p=0.008).	After	correcting	for	age	and	sex,	entheseal	thickness	
was	 still	 higher	 in	patients	with	nail	 psoriasis	 (see Table 3 for regression analysis). 
Mean	 entheseal	 thickness	 did	 not	 differ	 between	 psoriasis	 patients	 without	 nail	
involvement, and HCs (1.216 mm vs. 1.223 mm, p=0.956). When excluding the entheses 
of	 adjacent	 uninvolved	 nails	 (n=148)	 in	 the	 nail	 psoriasis	 group,	 differences	 were	
comparable (see Table 2).	When	analyzing	the	ulnar	entheseal	data,	no	differences	
between the three groups were found. Only when excluding the measures conducted 
on	 the	 entheses	with	 a	 adjacent	NAPSI	 equal	 to	 zero,	 significant	 thicker	 entheses	
were found in the nail psoriasis group when compared to the psoriasis group without 
nail features (see Table 2). When comparing entheseal thickness between involved 
(NAPSI	 >0)	 and	 uninvolved	 (NAPSI	 =0)	 nails	within individuals diagnosed with nail 
psoriasis,	 no	 significant	 differences	 were	 found	 (radial:	 1.297	 mm	 vs.	 1.253	 mm,	
p=0.13, ulnar: 1.234 vs. 1.199 p=0.223).	When	distinguishing	between	 the	different	
localizations	of	nail	psoriasis	(e.g.,	nail	bed,	nail	matrix),	patients	with	both	nail	bed	
and nail matrix features simultaneously showed the thickest radial entheses. This was 
significantly	higher	when	compared	to	nails	with	solely	nail	matrix	lesions.	The	ulnar	
entheses	were	significantly	thicker	in	nails	with	solely	nail	bed	features	compared	to	
solely	nail	matrix	features.	Power	Doppler	of	the	nail	bed	did	not	show	a	difference	in	
blood	flow	between	the	groups.
Table 1			The	patient	characteristics	of	all	three	groups.
Nail  
involvement † 
(n = 54)
No nail 
involvement ‡
(n = 32)
Healthy  
controls
(n = 32)
p-value
Gender, n (percentage)
    Female 27 (50.0)  16 (50.0) 12 (37.5)
    Male   27 (50.0)  16 (50.0) 20 (62.5)
Age	yr,	mean	(95%CI)  52.9 (49.2-56.7) 55.7 (50.3-61.0) 39.9 (34.7-45.1)** <0.001
Age start psoriasis yr,  
mean	(95%CI)
28.7 (24.5-33.0) 29.9 (23.7-36.1) NA 0.801
Duration	of	psoriasis	yr,	
mean	(95%CI)	
23.9 (19.6-28.2) 26.3 (20.3-32.3) NA 0.757
NAPSI,	mean	(95%CI) 23.4 (19.1-27.7)* 1.8 (1.2-2.4) 2.3 (1.7-3.0) <0.001
PASI, median (range) 3.9 (0-24.1) 3.0 (0-9.9) NA 0.061
Nail	features,	n	(%)
			Pitting	
   Leukonychia
   Red spots lunula
   Crumbling
   Onycholysis
   Splinter hemorrhages
			Oil-drop	discoloration
   Subungual hyperkeratosis
Type	of	psoriasis,	n	(%)
   Plaque psoriasis
			Guttate	psoriasis
   Pustular psoriasis
			Psoriasis	capitis
   Inverse psoriasis
   Genital psoriasis
   Erythodermic psoriasis
41 (75.9)*
16 (29.6)
5 (9.3)
13 (24.1)*
44 (81.5)*
37 (68.5)*
30 (55.6)*
12 (22.2)*
31 (60.8)
29 (56.9)
2 (3.9)
39 (76.5)
12 (24.5)
15 (31.3)
0 (0)
8 (25.0)
8 (25.0)
0 (0)
0 (0)
5 (15.6)
11 (34.4)
2 (6.3)
0 (0)
18 (60.0)
10 (33.3)
3 (9.4)
15 (50.0)
3 (10.3)
4 (13.8)
2 (6.7)
4 (12.5)   
20 (62.5)**
0 (0)
0 (0)
3 (9.4)
7 (21.9)
0 (0)
0 (0)
NA
NA
NA
NA
NA
NA
NA
<0.001
0.004
NS
0.001
<0.001
0.003
<0.001
0.001
0.945
0.042
0.275
0.015
0.128
0.087
0.067
†	NAPSI	≤	5.	
‡ NAPSI	>5.
*	 Significances	were	found	between	patients	with	nail	psoriasis	compared	to	healthy	controls	 
and	psoriasis	patients	without	nail	involvement.
**	Significances	were	found	between	healthy	controls	and	both	psoriatic	groups.
N,	number;	NA,	not	applicable;NAPSI,	Nail	Psoriasis	Severity	Index;	NS,	non	significant;	 
PASI, Psoriasis Area and Severity Index; yr, year.
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Inter-observer agreement
When	taken	all	entheseal	measurements	together,	an	ICC	of	0.805	(95%	CI	0.722–0.861)	
was	found	between	observers,	indicating	a	good	agreement.	When	analyzing	entheseal	
thickness	measurements	for	all	ten	fingernails	separately,	the	ICC	varied	from	0.502	
to	0.917	(digit	1	 right	to	digit	5	 left,	0.911,	0.502,	0.874,	0.660,	0.617,	0.764,	0.790,	
0.905,	0.917,	0.795,	respectively).
Discussion
This	study	is	an	important	contribution	to	the	understanding	and	exploration	of	the	
link between nail psoriasis and PsA. Based upon the high prevalence of nail psoriasis 
in	PsA	patients,	and	the	increased	percentage	of	PsA	patients	with	nail	psoriasis,	it	
was	already	concluded	that	there	is	an	association	between	nail	psoriasis	and	PsA.18,19 
McGonagle	et	al.	hypothesized	on	this	association,	and	proposed	that	entheses	might	
play a key role in the link between nail psoriasis and PsA, as they seem to be the 
anatomical	connection	between	the	nail	apparatus	and	the	DIP	joint.12,13,20,21 According 
to	their	hypothesis,	psoriatic	inflammation	at	the	entheses	of	the	extensor	tendon	at	
the	 dorsal	 side	 of	 the	 distal	 phalange	 can	 induce	 arthritis	 through	 the	 release	 of	
pro-inflammatory	 mediators.	 Alternatively,	 microtraumata	 caused	 by	 the	 forces	
exerted	on	the	entheses	might	induce	a	Koebner	response	resulting	in	an	enthesitis,	
and subsequently nail and joint disease.12,11	If	this	hypothesis	is	correct,	the	first	sign	of	
both	psoriatic	nail	disease	and	psoriatic	joint	disease	is	an	inflammatory	reaction	at	
the	entheses.	This	inflammatory	reaction	would	include	swelling	of	the	entheses,	as	
has	been	shown	in	other	studies	concerning	enthesitis,	followed	by	clinical	signs	of	
nail psoriasis and by radiological and clinical signs of PsA of the DIP joint.22 It may be 
expected that swelling of the entheses of the extensor tendon close to the nail matrix 
is	more	pronounced	in	psoriatic	nails	than	in	healthy	nails.	Therefore,	visualization	of	
the	entheses	of	 the	extensor	 tendon	of	 the	DIP	 joint	 in	psoriasis	patients,	with	or	
without	nail	involvement	is	highly	informative.	In	order	to	test	the	above	mentioned	
hypothesis we decided to measure the thickness of the entheses in several groups of 
(psoriasis)	patients,	as	Gandjbakhch	et	al.	showed	in	a	literature	review	that	94%	of	
studies	measured	the	thickness	of	the	entheses	for	defining	presence	of	enthesitis.22 
Accurate measurements of the entheses of this tendon is prerequisite, since this tendon 
is	a	subtle	structure.	It	is	already	documented	that	conventional	musculoskeletal	US	
is	a	reliable	technique	for	the	visualization	of	entheses	in	general.22-24 However, two 
dimensional	 US	 is	 an	 operator-dependent	 technique	 associated	 with	 operational	
variability	predominantly	caused	by	positioning	of	the	probe;	small	deviations	in	the	
angle	in	which	the	probe	is	placed	can	result	in	differences	in	measured	diameters	of	
entheses.	To	compensate	 for	 this	potential	error	we	decided	to	use	3D	US.	Three-	
dimensional US is emerging as an US modality with a number of possible advantages 
Table 2   The radial and ulnar entheseal thickness compared between the three 
groups.
Mean  
entheseal 
thickness  
(mm)*
p-value Mean 
entheseal 
thickness 
(mm)**
p-value
Radial
Nail psoriasis vs. Psoriasis 1.285 vs. 1.216 0.009 1.297 vs. 1.216 0.003
Nail psoriasis vs. Healthy controls 1.285 vs. 1.223 0.008 1.297 vs. 1.223 0.002
Psoriasis vs. Healthy controls 1.216 vs. 1.223 0.956 1.216 vs. 1.223 0.956
Ulnar
Nail psoriasis vs. Psoriasis 1.225 vs. 1.175 0.090 1.234 vs. 1.175 0.032
Nail psoriasis vs. Healthy controls 1.225 vs. 1.207 0.668 1.234 vs. 1.207 0.387
Psoriasis vs. Healthy controls 1.175 vs. 1.207 0.422 1.175 vs. 1.207 0.422
*  All entheses of the nail psoriasis group were taken into account (also entheses adjacent to nails with 
a NAPSI equal to zero).
**		Entheses	of	fingernails	in	the	nail	psoriasis	group	with	a	NAPSI	equal	to	zero	were	excluded	in	the	
measurement.
Table 3			Regression	parameters	for	radial	entheseal	thickness	(mm)	with	95%	
confidence	intervals	(CI),	an	univariate	and	multivariate	linear	regression	
model.
Entheseal thickness
Variable Unadjusted (95% CI) Adjusted (95%CI)
Sex
    Women
    Men
0.144 (0.169-0.212)
0.00 (reference)
0.142 (0.109-0.176) 
0.00 (reference)
Age (years) 0.000 (-0.001-0.001) -0.001 (-0.003-0.000)
Group
    Nail psoriasis
    Psoriasis
    Healthy controls
0.062 (0.023-0.101)
-0.007 (-0.055-0.040)
0.00 (reference)
0.56 (0.016-0.096)
0.011 (-0.039 – 0.061)
0.0 0 (reference)
CI,	confidence	interval.
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biomechanical factors might also play a role in the ulnar and radial entheses of the 
DIP	 joint	which	might	 clarify	 the	differences	 found.	However,	 future	 research	may	
substantiate	and	further	elucidate	this	finding.	
	 The	presented	results,	showing	that	there	is	no	difference	in	entheseal	thickness	
between entheses of adjacent involved or uninvolved nails within the group of 
patients	with	nail	psoriasis,	militates	against	an	anatomical-based	pathophysiological	
mechanism as promoted in earlier hypotheses.12,13,15,31 In favor of the hypotheses, we 
should	have	found	a	difference	between	the	thickness	of	entheses	of	affected	and	
unaffected	 nails.	 Our	 results	 disputing	 against	 the	 anatomical	 link	 hypothesis	 are	
strengthened	by	a	study	of	Scarpa	et	al.	which	found	no	difference	in	the	distribution	
of	DIP-joint	arthritis	(based	on	X-ray	findings)	between	PsA	patients	with	and	without	
nail involvement,32	 and	 a	 study	 of	 Tan	 et	 al.	 showed	 that	 a	 patient	 with	 a	 high	
inflammation	 signal	 at	 the	 extensor	 entheses	 on	MRI	 had	 no	 nail	 abnormalities.15 
These,	 and	 our	 findings	 argue	 against	 an	 anatomical	 link.	 An	 adaptation	 of	 the	
anatomical	link	hypothesis	could	be	that	entheseal	abnormalities	are	the	initial	sign	
of	 early	 PsA,	 and	 inflammation	 evolves	 secondary	 to	 the	 nail	 apparatus.	 Future	
follow-up	studies	might	be	needed	to	reject	or	confirm	this.		
	 Taking	the	anatomical	based	pathogenic	association	between	nail	psoriasis	and	
PsA	as	a	starting	point,	nail	matrix	 features	of	psoriasis	should	be	most	frequently	
occurring	in	enthesitis,	because	previous	imaging	and	cadaver	studies	showed	that	
the vessels of the extensor tendon fuses with the nail matrix.15,16	When	distinguishing	
between	the	different	localizations	of	nail	psoriasis	in	our	population,	radial	entheses	
were	thinnest	in	patients	with	nail	matrix	features	solely,	and	thickest	in	patients	with	
involvement of both nail matrix and nail bed. On the ulnar side, entheses were 
thickest	 in	 nails	 with	 solely	 nail	 bed	 involvement.	 Our	 findings	 are,	 again,	 not	
compatible	with	an	anatomical	pathogenic	link.	Love	et	al.	associated	the	features	of	
nail	psoriasis	with	PsA,	and	concluded	that	 the	strongest	association	with	arthritis	
could be found for onycholysis, which is the prototype of nail bed involvement in 
psoriasis.17,33	Another	study	concluded	that	the	pattern	of	nail	involvement	(i.e.,	nail	
matrix	 vs.	 nail	 bed	 involvement)	 between	 psoriasis	 and	 PsA	 patients	 was	 almost	
similar.	 Only	 pitting,	 a	 nail	 matrix	 feature,	 was	 more	 frequently	 seen	 in	 psoriasis	
patients	without	arthritic	involvement.	Based	on	our	findings	and	the	literature	there	
does	not	seem	to	be	a	clear	pattern	of,	or	a	predilection	for,	certain	nail	features	in	
nail	psoriasis	patients	with	enthesopathy,	making	an	anatomical	pathogenic	link	not	
very likely.
 Taken all together, our results indicate that an anatomical based pathogenic 
association	between	nail	psoriasis	and	PsA	 is	not	plausible.	Entheseal	 thickening	 is	
present	in	localizations	anatomically	related	to	the	nail	apparatus,	but	also	in	more	
remote entheses, and in entheses linked to clinical uninvolved nails of nail psoriasis 
patients	without	PsA.	However,	the	incidence	of	nail	disease	among	PsA	patients	and	
over	conventional	two-dimensional	US.25 A major advantage of 3D US is that it reduces 
dependability	to	sonographers’	expertise	in	positioning	of	the	probe,	as	it	scans	in	a	
standard manner,25 and several entheses can be scanned in one session. This is the 
first	study	using	3D	US	as	imaging	technique	for	the	visualization	of	the	entheses	in	
nail	psoriasis	patients,	and	our	results	confirmed	that	it	is	a	reliable	technique	showing	
a	 good	 interrater	 reliability	 in	 the	 visualization	 of	 entheses.26 Nevertheless, a 
limitation	of	using	 this	 technique	 in	 the	present	 study	was	 the	number	of	missing	
data. This was caused by a certain lack of experience by the radiographers using a 3D 
US	 transducer	 for	 the	 visualization	 of	 musculoskeletal	 structures	 of	 the	 hand.	
Therefore, technique and protocol development for scanning nails and entheses 
needs	optimization.	
 In response to the hypotheses of McGonagle et al., several studies focused on 
the	entheses	of	PsA	and	(nail)	psoriasis	patients,	and	showed	that	enthesopathy	can	
be present in the absence of clinical joint symptoms.2,20,27 Our results concerning the 
radial entheses of the extensor tendon, are in line with previous studies, concluding 
that	subclinical	entheseal	thickening	can	be	found	in	nail	psoriasis	patients.20 Previous 
studies	 concentrated	 on	 the	 entheses	 of	 the	 lower	 extremities	 and	 the	 common	
extensor of the upper extremity, while the present study visualized the entheses of 
the	extensor	tendon	of	the	DIP	joint.	This	different	approach	was	chosen	in	order	to	
be	able	to	draw	conclusions	concerning	the	above	mentioned	hypothesis,	 in	which	
the	anatomical	 interrelationship	between	the	entheses	of	 this	 tendon	and	the	nail	
apparatus play a role in the development of clinical signs of nail psoriasis. Based on 
our results and the literature it might be concluded that subclinical enthesopathy in 
nail	psoriasis	patients	seems	to	be	present	in	localizations	anatomically	linked	to	the	
nail	apparatus,	but	also	in	more	remote	entheses	which	do	not	have	a	direct	relation	
with the nail.12	Since	increased	tendon	thickness	is	a	common	and	early	feature	of	soft	
tissue	inflammation,22, 28 we decided to assess this feature of enthesopathy, and did 
not focus on the whole spectrum of enthesopathy (e.g., enthesophytes, erosions).28 
This approach made it possible to evaluate numerous entheses.
	 Our	 finding,	 that	 the	 measures	 of	 the	 entheses	 on	 the	 ulnar	 side	 were	 not	
comparable with the measures on the radial side is remarkable. However, previous 
studies	also	showed	preference	for	the	radial	site	in	several	rheumatologic	conditions.	
Tan	 et	 al.,	 concluded	 that	 in	 early	 rheumatoid	 arthritis	 patients,	 a	 propensity	 for	
involvement of the radial side of metacarpophalangeal joints two and three was 
found	for	erosions	and	synovitis.29	They	related	radial	and	ulnar	differences	to	local	
biomechanical and anatomical factors in the joint.29	Another	study	in	patients	with	
rheumatoid	arthritis	also	showed	that	pannus	formation	and	vascularization	appeared	
to	be	localized	preferentially	on	the	radial	side	of	the	proximal	interphalangeal	joints	
and metacarpophalangeal joints.30	Considering	the	marked	differences	between	the	
radial	and	ulnar	sides	in	the	peripheral	small	joints	of	rheumatoid	arthritis	patients,	
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joint	disease	among	nail	psoriasis	patients	is	remarkably	high.	An	explanation	for	this	
could	be	sought	at	the	genetic	level.34, 35 It is already suggested that psoriasis and PsA 
might	not	share	a	common	etiology,	but	have	underlying	genetic	heterogeneity,	as	
PsA	 is	a	clinical	heterogeneous	disease	with	various	extra-articulair	manifestations	
(e.g.,	nail	features,	skin	involvement,	uveitis).36 Several authors have shown that both 
psoriasis	and	PsA	have	genetic	associations	but	also	have	distinct	susceptibility	genes.	
Psoriasis	(without	joint	involvement)	has	a	high	association	with	HLA-C*06,	while	PsA	
patients	 are	 significantly	 more	 frequent	 HLA-C*06	 negative.	 Three	 haplotypes,	
containing B*27 and B*39:01, were associated with PsA but were not increased in a 
psoriasis cohort.35,36	Like	PsA	patients,	nail	psoriasis	patients	are	also	more	frequently	
HLA-C*06	negative.34	This	might	be	an	 indication	that	nail	psoriasis	and	PsA	might	
share	genetic	susceptibility	loci,	explaining	the	coincidence	of	them,	rather	than	an	
anatomical	basis	for	this.	In	the	search	for	genetic	explanations,	it	might	be	taken	into	
account that both nail psoriasis and PsA are associated with more widespread 
disease.3,37
Conclusion
Early	diagnosis	and	treatment	of	PsA	is	important	to	prevent	destruction	of	the	joints,	
and	to	avoid	disease	related	disabilities.	 If	 the	presence	of	nail	disease	 in	psoriatic	
patients	is	a	risk	factor	for	arthritic	disease,	then	the	presence	of	nail	manifestations	
might	 influence	 the	 choice	 and	 timing	 of	 therapy	 in	 these	 patients,	 and	 this	may	
prevent irreversible damage of the joints. Subclinical entheseal thickening of the 
extensor	 tendon	of	 the	DIP	 joint	 is	 present	 in	nail	 psoriasis	 patients.	However,	 an	
anatomical	association	between	nail	psoriasis	and	PsA	as	the	underlying	and	triggering	
pathogenic mechanism is unlikely. Future studies have to be conducted to elucidate 
the	link,	which	might	be	found	in	the	field	of	genetics.	
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Introduction
The purpose of the studies presented in this thesis was to obtain insight into various 
aspects	of	the	spectrum	of	nail	psoriasis.	In	this	concluding	chapter	the	main	findings	
of the current thesis will be outlined and discussed according to the aims of each 
chapter	 as	 formulated	 in	 chapter	 1.	 Subsequently,	 directions	 for	 future	 research	
arising from these conclusions will be outlined.
Aim 1.1:  To obtain more insight into the prevalence and clinical characteristics 
of nail psoriasis.
Although various studies focused on the prevalence of nail psoriasis, the prevalence 
remained	unclear,	with	the	reported	prevalence	ranging	from	10%	to	80%.	Therefore,	
the	prevalence	 in	a	 large	group	of	psoriasis	patients	was	studied	and	described	 in	
chapter 2.2.	Our	data	showed	a	nail	psoriasis	prevalence	of	66%	in	a	group	of	1459	
psoriasis	patients.	Based	on	 the	 study	design	 (self-reported	questionnaires	among	
members	 of	 a	 patient	 association),	 it	might	 be	 possible	 that	 our	 prevalence	 is	 an	
overestimation.	 However,	 when	 comparing	 with	 the	 literature,	 studies	 of	 various	
methodology	predominantly	stated	a	prevalence	between	47%	and	81%,1-6 and only 
two	studies	found	a	prevalence	below	40%,7, 8	indicating	that	the	prevalence	found	in	
this	chapter	might	be	a	good	reflection	of	the	reality.	The	overall	conclusion	is	that	
the	 prevalence	 rate	 of	 nail	 involvement	 in	 psoriasis	 patients	 is	 higher	 than	 often	
estimated,	and	recognition	of	typical	characteristics	of	nail	psoriasis	is	important	as	it	
is	 a	 frequent,	 and	 sometimes	 early,	 manifestation	 of	 the	 disease.	 Therefore,	
knowledge	of	the	prevalence	of	the	different	manifestations	seen	in	nail	psoriasis	is	
essential	for	doctors	treating	patients	with	skin	and	nail	diseases.	In	order	to	focus	on	
the features of nail psoriasis we conducted two studies which are displayed in chapter 
2.1 and 2.2. In chapter 2.1	 onycholysis	 (93.9%),	 splinter	 hemorrhages	 (93.9%),	 and	
pitting	(73.5%)	were	most	frequently	seen,	scored	by	a	trained	clinician.	In	chapter 
2.2	pitting	(65.4%),	onycholysis	(57.7%)	and	oil-drop	discolorations	(41.4%)	were	most	
frequently	 documented	 by	 the	 patients	 themselves.	 Pitting	 and	 onycholysis	 were	
found	frequently	in	both	studies,	despite	the	different	study	designs,	which	is	in	line	
with previous studies.4, 6, 9, 10	 Both	 studies	 showed	 that	 the	 red	 spotted	 lunula	 is	 a	
phenomenon	sparsely	seen	in	nail	psoriasis	(2.0%	and	6.5%,	respectively).	In	contrast,	
Beau’s	lines	were	frequently	seen	in	nail	psoriasis	patients	in	study 2.1. Unfortunately, 
the	presence	of	Beau’s	lines	was	not	asked	in	the	questionnaire	which	was	filled	in	by	
the	patients.	In	literature	Beau’s	lines	in	nail	psoriasis	are	sparsely	taken	into	account,	
only	a	study	of	Garzitto	et	al.11 measured this phenomenon and found a prevalence of 
29.4%.	It	used	to	be	generally	accepted	that	leukonychia	is	a	typical	nail	feature	of	
psoriasis. However, the control group included in chapter 2.1	had	significantly	more	
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quality of studies was generally poor.13 Our data and this review indicate that high 
quality	 research	 on	 the	 effects	 of	 treatments	 on	 nail	 psoriasis	 is	 highly	 needed.	
However, all trials should use one and the same methodology to guarantee that 
comparison of the results will be possible. In conclusion, we hope that with these 
data	 a	 signal	 is	 emitted	 for	 the	 need	 of	 high	 quality	 evidence	 on	 the	 efficacy	 of	
therapies	on	nail	features	as	nail	psoriasis	is	still	undertreated,	and	the	conditions	for	
further	research	need	optimization	as	the	methodologies	differ	and	quality	is	lacking.	
However,	 treatment	 of	 nail	 psoriasis	 needs	 a	 patient-centered	 approach	 as	 the	
systemic	 anti-psoriasis	 therapies	 are	 potential	 toxic,	 so	 the	 advantages	 and	
disadvantages	of	each	therapeutic	option	should	be	taken	into	account.	Furthermore,	
indications	for	prescribing	systemic	treatment	in	nail	psoriasis,	like	severe	cutaneous	
psoriasis,	coexistence	of	psoriatic	arthritis	(PsA),	or	when	nail	psoriasis	is	interfering	
with	patients’	quality	of	life,	should	be	formulated	so	guidelines	can	be	developed.	
Aim 2:  To achieve more insight into the quality of life of  
nail psoriasis patients. 
In response to the low percentage of respondents who received treatment for their 
nail	manifestations	found	in	chapter 2,	it	was	decided	to	investigate	the	impact	of	nail	
features	on	patients’	quality	of	life	in	chapter 3. In chapters 3.1 and 3.2 we presented 
data	of	various	generic,	dermatology-specific	and	nail	psoriasis-specific	quality	of	life	
scores	in	nail	psoriasis	patients.	
 In chapter 3.1	no	validated	specific	nail	psoriasis	quality	of	life	score	was	available	
so it was chosen to use a generic quality of life score, and to modify an onychomycosis 
quality	of	life	questionnaire	developed	by	Drake	et	al.23 By using a generic score (Short 
Form-36)	we	were	able	to	show	that	nail	psoriasis	(with	minimal	cutaneous	activity)	
has	no	influence	on	patients’	perception	of	their	general	health	as	expressed	by	this	
score.	Although	the	modified	onychomycosis	questionnaire	of	Drake	et	al.23 was only 
partly	validated,	the	results	of	this	questionnaire	showed	that	patients	do	experience	
limitations	because	of	their	nails	comparable	to	the	impact	of	onychomycosis.23 The 
results	of	the	modified	onychomycosis	questionnaire	showed	that	patients	with	nail	
psoriasis	 experienced	 the	 greatest	 burden	 on	 the	 social	 dimension.	 Patients	 are	
worried	about	the	judgment	of	others	concerning	their	nails,	but	also	half	of	patients	
experience pain because of the nail features. These results indicate that clinicians 
should	take	the	social	burden	and	pain	caused	by	the	nails	into	account	when	treating	
psoriasis	patients.
 In chapter 3.2, the most frequently used quality of life score in dermatology was 
used,	the	Dermatology	Life	Quality	Index	(DLQI).	Patients	with	nail	psoriasis	scored	
significant	 higher	 mean	 scores	 compared	 to	 psoriasis	 patients	 without	 nail	
involvement (mean DLQI 4.9 and 3.7, p=<0.001	respectively)	indicating	more	impaired	
frequently	 leukonychia	 of	 the	 nails	 when	 compared	 to	 the	 nail	 psoriasis	 patients	
(65.3%	vs.	40.8%,	p=0.015). Based on our result and a similar result found in response 
to	our	article	by	Garzitto	et	al.11,	we	can	conclude	that	leukonychia	is	not	a	specific	
feature for nail psoriasis. The most commonly used nail psoriasis severity scoring 
systems, the Nail Psoriasis Severity Index (NAPSI), uses leukonychia and red spots in 
the lunula as two of the eight classical features seen in nail psoriasis, and does not 
take	 Beau’s	 lines	 into	 account.	 Based	 on	 the	 results	 of	 chapter 2.1 and 2.2, the 
construction	of	the	NAPSI	should	be	reconsidered,	based	on	the	prevalences	of	the	
characteristic	features	found	in	the	nail	psoriasis	and	control	groups.	The	obtained	
data	 on	 clinical	 characteristics	 and	 prevalence	 is	 valuable	 for	 the	 evaluation	 of	
diagnostic	 criteria	 for	 nail	 psoriasis	 and	 education	 of	 dermatologist	 and	 general	
practitioners	in	recognition	of	nail	psoriasis.
Aim 1.2:  To obtain insight into self-reported treatment experiences of patients 
with nail psoriasis.
 
Study 2.2	showed	that	16%	of	nail	psoriasis	patients	received	treatment	for	their	nail	
lesions,	while	47%	of	patients	stated	that	they	would	 like	to	receive	treatment	 for	
their nail features. These data demonstrate that there is a discrepancy between the 
need	for	treatment	in	nail	psoriasis	patients	and	the	actual	number	of	patients	treated	
for	 their	 nail	 psoriasis.	 The	 number	 of	 patients	 treated	 for	 nail	 psoriasis	 is	 even	
considerably	 lower	when	 compared	 to	 data	 on	 a	 similar	 patient	 group	 in	 1996.1 A 
possible	explanation	for	the	low	percentage	of	patients	receiving	treatment	for	their	
nails might be that the cutaneous component dominated the clinical picture, so the 
focus of psoriasis treatment therefore goes to the cutaneous component. Another 
possible	explanation	 for	 this	undertreatment	might	be	 that	 therapies	 for	psoriatic	
nail	disease	are	perceived	to	be	ineffective	by	dermatologists,	and	results	are	seen	
only	after	a	long	period	of	treatment	as	nails	grow	and	recover	slowly.	Finally,	patients	
might consider their treatment as a treatment focusing on the cutaneous psoriasis 
features but be ignorant that the same treatment might combat nail psoriasis as well. 
However	 the	 low	 percentage	 is	 remarkable	 knowing	 that	 treatment	 options	 are	
increasing,	assertiveness	of	patients	is	growing,	and	cosmetic	aspects	are	increasingly	
important. In chapter 2.2 patients	did	report	that	they	experienced	positive	effects	
on their nails of varies predominantly systemic treatments (e.g., biologics, fumaric 
acid,	methotrexate).	In	line	with	the	experiences	of	nail	psoriasis	patients	described	
in study 2.2,	 several	 studies	 documented	 positive	 effects	 of	 various	 treatment	
modalities	 on	 nail	 psoriasis,	 and	 research	 on	 this	 topic	 is	 increasing.12-22 A recent 
Cochrane review showed that there is high quality evidence available for treatment 
of	nail	psoriasis	with	two	anti-	tumor	necrosis	factor	(TNF)	biologics	(infliximab	and	
golimumab) and radiotherapy.13 However, only 18 studies could be included as the 
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Scoring system for quality of life in nail psoriasis might need further development 
and	application.
Aim 3:  To give insight into the various existing nail psoriasis  
severity scoring systems and to develop a scoring system  
better reflecting clinical severity. 
In consequence of the results of study 2.1 and 2.2, experiences gained and the literature, 
it became evident that scoring nail psoriasis severity using the NAPSI had major 
limitations.	Therefore,	the	aim	of	chapter 4	was	to	compare	the	existing	scoring	systems	
including the NAPSI with a standard score for clinical severity to give insight into the 
existing	scoring	systems,	and	to	develop	a	system	which	is	able	to	reflect	clinical	severity	
more accurate. In literature seven nail psoriasis scoring systems were described and 
included in this study. A scoring system developed by Baran et al.26 and the Psoriasis 
Nail Severity Score (PNSS)27	showed	an	acceptable	correlation	with	clinical	severity	in	
terms	 of	 Physician	 Global	 Assessment	 (PGA)	 of	 0.735	 and	 0.734	 respectively.	 The	
frequently	 used	 NAPSI	 showed	 moderate	 correlation	 with	 the	 PGA	 (r=0.669).	 In	
addition,	literature	showed	that	the	NAPSI	is	not	always	responsive	in	the	reflection	of	
clinical improvement.28, 29 This might be caused by the fact that the NAPSI only scores 
presence or absence of clinical nail features instead of severity of these features. 
Consequently, in chapter 4	a	scoring	system	reflecting	clinical	severity	more	accurate	
was developed. In response to the results of chapter 2	and	based	on	the	evaluation	of	
the	existing	nail	psoriasis	 severity	 scores,	we	developed	 the	Nijmegen-Nail	psoriasis	
Activity	 Index	 tooL	 (N-NAIL).	 The	 results	 showed	 that	 the	 N-NAIL	 reflected	 clinical	
severity	much	better	than	the	seven	existing	scoring	systems	(r=0.861).	In	the	N-NAIL	
certain	nail	features	were	added	(Beau’s	lines)	or	removed	(e.g.,	leukonychia,	red	dots	
in the lunula) when compared with the classical nail psoriasis scoring system. Also the 
manner of scoring was adapted, not only absence or presence of nail features were 
scored	but	a	gradation	of	severity	was	given	in	combination	with	numeric	scoring	of	
some	 features	 (e.g.,	 Beau’s	 lines).	 The	N-NAIL	was	 validated	 to	 some	 extent	 as	 the	
interrater and intrarater reliability were established. The results showed an interrater 
reliability	varying	from	0.967	to	0.989	and	an	intrarater	reliability	of	0.899	indicating	
excellent	reproducibility	of	the	N-NAIL.	However	for	further	validation	more	clinimetric	
properties	 should	 be	 investigated.	 Estimating	 the	 responsiveness	 (the	 ability	 of	 a	
scoring	 system	 to	detect	 changes	over	time)	of	 the	N-NAIL	 in	 the	 treatment	of	 nail	
psoriasis	patients	would	be	of	great	value.	In	addition,	the	response	distribution	should	
be	estimated,	examining	whether	the	entire	range	of	the	score	is	used.	But	also	the	 
interpretability,	the	degree	to	which	one	can	assign	qualitative	meaning	to	a	quantitative	
score,	 should	 be	 estimated.	 Eventually	 this	 should	 result	 into	 categorization	 of	 the	
outcomes related to the clinical picture. As reported by the Cochrane report in 2013,13 
quality of life when nail features are present. However, when looking at the 
interpretation	of	the	DLQI	scores	of	the	nail	psoriasis	and	psoriasis	group,	both	fall	
into	the	same	effect	category	(category	two,	DLQI	score	2-5),	indicating	a	small	effect	
on	 patients’	 life.24	 Despite	 the	 significant	 difference,	 the	 clinical	 meaning	 of	 the	
difference	between	the	two	groups	is	questionable,	but	the	difference	is	significant	
and	cannot	be	 ignored.	 In	 the	 interpretation	of	 the	 results	 it	 should	be	 taken	 into	
account	that	the	DLQI	measures	the	impact	of	a	dermatological	condition,	and	not	
specifically	nail	features.	The	difference	between	the	groups	might	be	explained	by	
the higher cutaneous psoriasis severity in the nail psoriasis group as seen in the 
SAPASI (6.6 versus 5.3, p=<0.001	respectively)	or	the	higher	prevalence	of	PsA	in	the	
group	of	nail	psoriasis	patients	as	discussed	in	the	article.	When	using	the	DLQI	the	
specific	impact	of	nail	disease	in	psoriasis	patients	on	quality	of	life	remains	unclear.	
These	results	indicate	that	the	DLQI	is	not	specific	enough	for	estimating	the	burden	
nail	features	may	have	on	patients’	life,	possibly	caused	by	the	nature	of	the	questions	
which	do	not	include	specific	questions	on	the	nails.	
	 In	2010	a	nail	 psoriasis	 specific	quality	of	 life	questionnaire,	 the	Nail	 Psoriasis	
Quality of life (NPQ10) was developed by Ortonne et al., and could be applied in 
chapter 3.2.25	 This	 questionnaire	 showed	 that	 patients	 were	 restricted	 in	 various	
daily	activities	(e.g.,	putting	on	shoes	or/and	socks),	and	36%	of	psoriasis	patients	with	
nail	 involvement	 experienced	 pain.	 Localization	 of	 nail	 psoriasis	 turned	 out	 to	 be	
important as nail bed features lead to more impairments than nail matrix features do. 
In contrast to the DLQI and Short Form-36, the focus of the NPQ10 is centered around 
the	 restrictions	 nail	 features	 entail.	 These	 data	 and	 the	 data	 of	 the	 modified	
onychomycosis	questionnaire	 indicate	that	 it	 is	valuable	to	use	an	 instrument	that	
measures the burden of nail psoriasis for both clinical care and research purposes, as 
it	offers	the	opportunity	for	a	patient-centered	approach.	It	would	be	interesting	to	
apply the quality of life score into the follow-up of treatment to determine the 
changes	 in	 quality	 of	 life	 during	 treatment	 options.	 However,	 in	 our	 opinion	 the	
quality of life score for nail psoriasis needs further improvement and development as 
the	mean	score	of	the	NPQ10	was	9.9%	(on	a	maximum	score	of	100%)	indicating	that	
the	score	is	not	used	in	its	full	range,	and	this	might	reflect	that	most	patients	do	not	
experience	most	 of	 the	 limitations	mentioned,	while	 other	 relevant	 questions	 are	
missing.	Certain	questions	(e.g.,	‘because	of	my	nail	psoriasis,	someone	helps	me	to	
get	dressed’)	might	be	replaced	by	questions	concerning	restrictions	more	specific	
for	nail	psoriasis	patients	as	used	in	the	onychomycosis	score.	However,	the	NPQ10	is	
sparsely	 used	 in	 research	 so	 future	 studies	 are	 needed	 to	 confirm	 or	 reject	 our	
findings,	or	further	modification	and	validation	of	the	onychomycosis	questionnaire	
is needed. The value of the results found in these two studies is that it shows that 
nail	psoriasis	can	have	a	significant	 impact	on	specific	 items	of	patients’	quality	of	 
life,	 and	 clinicians	 should	 pay	 attention	 to	 the	 nails	 in	 the	 treatment	 of	 psoriasis.	 
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healthy	controls	and	nail	psoriasis	patients	treated	with	adalimumab	and	etanercept.	
These results indicate that immunosuppressive therapy increases the risk of 
developing onychomycosis in (nail) psoriasis. In conclusion, the overview indicates a 
higher	vulnerability	of	nail	psoriasis	patients	for	the	development	of	onychomycosis,	
and clinicians should be aware of this vulnerability. For the future it would be 
interesting	to	differentiate	between	nail	psoriasis	patients	which	are	more	prone	to	
develop	a	coexisting	mycotic	 infection	according	 to	 treatment	 type	or	 type	of	nail	
feature	seen	(nail	bed	or	nail	matrix	features).	Hypothetically,	pathogens	most	likely	
invade	 the	nails	of	patients	having	onycholysis	and	hyperkeratosis	preferably	 then	
patients	with	for	example	only	pitting	(matrix	features).	
	 When	looking	at	the	specific	pathogens	causing	onychomycosis	in	nail	psoriasis,	
no	 shift	 in	 causative	agents	 from	dermatophytes	 to	yeast	and/or	moulds	could	be	
seen based on the overview. Also here, the variability in methodology of the included 
studies	made	comparison	troublesome.	Most	studies	did	not	differentiate	between	
pathogens	found	in	the	fingernails	or	toenails,	while	it	is	known	that	localization	of	
onychomycosis must be taken into account as dermatophytes are the most common 
causative	pathogens	of	onychomycosis	in	toenails,	while	yeast	are	more	frequently	
isolated	from	fingernails.36
	 The	major	limitation	of	chapter 5 was the heterogeneity of available studies. We used 
the	STROBE	(STrengthening	the	Reporting	of	OBservational	studies	in	Epidemiology)	
checklist	as	a	quality	assessment	 tool	 for	 the	evaluation	of	 the	quality	of	 included	
studies. However, the primary goal of the STROBE is to serve as a guideline for authors of 
reports	of	observational	studies,	not	for	grading	the	quality	of	studies	in	a	systematic	
review.	For	 reviews	of	observational	 studies	numerous	 tools	have	been	proposed,	
however no tool has been adopted for widespread use. Sanderson et al.37 even 
showed that a candidate tool is missing. In contrast, for randomized controlled trials 
quality tools are well established. In the future a consensus must be reached in the 
development	of	quality	criteria	for	observational	studies	to	promote	higher	quality	
research	and	making	quality	assessment	possible,	also	for	observational	studies.
Aim 5:  To contribute to the elucidation of the link between nail psoriasis an 
psoriatic arthritis.
In	recent	years	several	publications	speculated	on	the	anatomical	link	between	nail	
psoriasis and PsA. In chapter 6	we	 aimed	 to	 contribute	 to	 the	 elucidation	 of	 this	
assumed	link.	Based	on	the	hypothesis	of	McGonagle	et	al.,	suggesting	that	entheses	
might	play	a	key	role	in	the	link	between	nail	psoriasis	and	PsA,	we	investigated	this	
anatomical-based link using three-dimensional ultrasound imaging of the extensor 
tendon	of	 the	distal	 interphalangeal	 joint	 in	nail	psoriasis	patients.	The	 results	 showed	 
that	 patients	with	 nail	 psoriasis	 had	 significant	 thicker	 radial	 entheses	 compared	 to	
it	was	not	possible	to	pool	and	compare	the	results	of	the	different	studies	on	treatment	
of	nail	psoriasis.	The	development	and	the	optimization	of	the	N-NAIL	is	a	first	step	into	
promoting	the	use	of	one	and	the	same	scoring	system	which	reflects	clinical	severity	
accurately,	making	the	comparison	of	treatment	options	in	nail	psoriasis	possible,	and	
eventually	 give	 insight	 into	 the	 treatment	 possibilities	 for	 nail	 psoriasis	 patients.	
However,	the	introduction	of	an	adequate	clinical	scoring	system	alone	will	not	cover	
the	full	load	of	nail	psoriasis.	For	the	future,	an	ultimate	nail	psoriasis	scoring	system	is	
a	system	reflecting	clinical	severity	accurately,	but	also	takes	the	burden	of	disease	and	
patient-reported	outcome	into	account	as	shown	in	chapter 3. In this era of personalized 
medicine	patients’	experience	on	the	effects	of	treatment	should	be	taken	into	account	
and maybe incorporated into the N-NAIL together with a measurement for quality 
of life.
Aim 4:  to systematically review all literature available concerning the 
prevalence of onychomycosis in (nail) psoriasis patients.
The aim of chapter 5	was	to	provide	insight	into	the	susceptibility	of	psoriasis	patients	
for the development of onychomycosis. Because of the heterogeneity of studies it 
was	not	possible	to	perform	a	meta-analysis	 in	this	systematic	review.	Ten	articles	
could be included, and therefore conclusions are based on an overview of these 
systematically	 included	articles.	A	wide	range	 in	prevalence	of	onychomycosis	was	
found;	4.6%	to	63.1%	in	the	psoriasis	group	and	2.4%	to	66.0%	in	control	groups,	with	
a	combined	prevalence	of	18.0%	and	9.1%	respectively.	Prevalences	of	onychomycosis	
in	 the	 general	 population	 documented	 in	 the	 literature	 are	 6.5%,	 8.4%,	 4.7%,and	
20.9%,	so	close	to	the	combined	prevalence	of	the	control	group	of	the	articles	in	this	
review.30-33	However,	the	prevalence	of	onychomycosis	in	psoriasis	patients	seems	to	
be	elevated	compared	to	the	prevalence	in	the	general	population	as	stated	in	the	
literature, and the prevalence found in the control groups of the included studies, but 
the	 ultimate	 evidence	 is	 lacking.	 In	 literature	 various	 arguments	 concerning	 the	
assumed	 vulnerability	 of	 psoriatic	 nails	 for	 fungal	 microorganisms	 are	 discussed.	
Arguments	contradicting	a	favoring	mycotic	infection	are	the	fact	that	the	immune	
response	against	microbial	skin	infections	is	remarkably	strong	in	psoriasis,	and	the	
fast turnover of the nails in psoriasis would protect the nail against invasion of 
microorganisms.34	 The	 morphological	 changes	 of	 the	 nails	 in	 psoriasis	 patients	
(hyperkeratosis, onycholysis), and the use of immunosuppressive therapies for 
psoriasis are arguments for an increased vulnerability of psoriasis nails. In accordance 
to	 the	 latter	 argument	 a	 recent	 article	 was	 published	 on	 the	 development	 of	
onychomycosis	in	nail	psoriasis	patients	after	starting	anti-TNF	therapy.35 The results 
showed	 that	 nail	 psoriasis	 patients	 treated	with	 infliximab	 developed	 significantly	
more	frequently	onychomycosis	 (33.0%)	after	24	weeks	of	treatment	compared	to	
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both	control	groups	(healthy	controls	and	psoriasis	patients	without	nail	involvement).	
However,	 no	 significant	 differences	 in	 entheseal	 thickness	 were	 found	 between	
entheses	of	adjacent	involved	and	adjacent	uninvolved	nails,	and	no	association	was	
found between entheseal thickening and nail matrix features. The results presented in 
chapter 6 make an anatomical based co-pathogenesis of nail psoriasis and PsA less 
likely.	 As	 discussed	 and	 hypothesized	 in	 this	 chapter	 a	 possible	 explanation	 for	 the	
coincidence	of	nail	psoriasis	and	PsA	might	rather	be	sought	at	the	genetic	 level.	As	
previously	described,	the	major	genetic	determinant	for	development	of	psoriasis	is	the	
allele	HLA-cW6	located	on	PSORS1.	However,	patients	with	PsA	and/or	nail	psoriasis	are	
more	 frequently	 HLA-cW6	 negative	 which	 might	 point	 towards	 genetic-based	 but	
immunological	driven	similarities	of	nail	psoriasis	and	PsA	patients.38 As PsA can lead to 
deformity	and	invalidation,	prevention	and	early	recognition	is	important	as	it	seems	
that	 early	 diagnosis	 and	 treatment	 will	 reduce	 irreversible	 joint	 damage.	 It	 is	 still	
questionable	 whether	 early	 intervention	 will	 prevent	 or	 delay	 the	 onset	 of	 PsA	 in	
psoriasis	patients	without	joint	 involvement.	Presence	of	nail	psoriasis	might	help	to	
identify	patients	with	increased	risk	of	development	of	PsA,	however	not	all	patients	
with	 nail	 psoriasis	will	 develop	PsA.	 Therefore	 it	would	 be	 interesting	 to	 search	 for	
similarities	in	the	genetic	profile	of	both	nail	psoriasis	and	PsA	patients	or	to	identify	a	
marker which might be a predictor for the development of PsA. Understanding the 
genetic	 and	 resulting	 immunological	 differences	 between	 the	 different	 psoriasis	
phenotypes may allow the development of targeted therapies that treats nail psoriasis 
patients	before	PsA	is	destructive	and	hereby	may	prevent	disabling	joint	disease.	The	
predominant	 limitation	 in	 the	 search	 for	 an	 explanation	 for	 the	 link	 between	 nail	
psoriasis	and	PsA	is	the	time	span.	Most	patients	develop	arthritic	involvement	years	
after	the	first	signs	of	psoriasis.	This	calls	for	a	registry	or	a	large	longitudinal	cohort	
study	with	an	follow-up	of	certain	decades,	identifying	the	patients	who	develop	nail	
psoriasis	and	eventually	PsA,	and	taken	into	account	that	not	all	patients	with	PsA	have	
nail psoriasis. 
Conclusion
In recent years progress has been made to increase the knowledge on nail psoriasis. 
We	have	shown	that	nail	psoriasis	 is	a	prevalent	 feature	seen	 in	psoriasis	patients	
with	 onycholysis	 and	 pitting	 as	 characteristic	 features.	 Based	 on	 these	 results	 an	
improved nail psoriasis severity scoring system was developed, the N-NAIL. We have 
also	shown	that	patients	with	nail	psoriasis	experience	impaired	quality	of	life,	and	
seem	to	be	more	prone	to	a	mycotic	infection	of	the	nail.	Finally,	we	tried	to	elucidate	
the link between nail psoriasis and PsA, and we showed that most likely this link is not 
anatomically-based.	As	mentioned	above,	there	are	still	many	aspects	to	explore	for	
patients	with	nail	 psoriasis,	 and	 the	presented	 results	will	 hopefully	 contribute	 to	
further unraveling of the spectrum of nail psoriasis.
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Introductie
Het	 doel	 van	 de	 onderzoeken	 gepresenteerd	 in	 dit	 proefschrift	was	 om	 inzicht	 te	
krijgen in de verschillende aspecten van nagelpsoriasis. In dit afsluitende hoofdstuk 
zullen	de	conclusies	van	het	proefschrift	samengevat	en	bediscussieerd	worden	aan	
de hand van de doelstellingen geformuleerd in hoofdstuk 1. Vervolgens zullen 
richtingen	 voor	 toekomstig	 onderzoek	 beschreven	 worden,	 gebaseerd	 op	 de	
geformuleerde conclusies.
Doel 1.1:  Inzicht verkrijgen in de prevalentie en klinische karakteristieken van 
nagelpsoriasis.
Hoewel	in	het	verleden	verschillende	studies	zich	gericht	hebben	op	de	prevalentie	
van	 nagelafwijkingen	 in	 psoriasis	 patiënten	 blijft	 de	 prevalentie	 onduidelijk;	 de	
gerapporteerde	prevalentie	varieert	tussen	de	10%	en	80%	in	de	literatuur.	Daarom	
werd in hoofdstuk 2.2 de	 prevalentie	 in	 een	 grote	 groep	 psoriasis	 patiënten	
bestudeerd	en	gerapporteerd.	De	resultaten	toonden	een	nagelpsoriasis	prevalentie	
van	66%	in	een	groep	van	1459	psoriasis	patiënten.	Gezien	de	onderzoeksopzet	(zelf-
gerapporteerde	vragenlijsten	onder	de	leden	van	een	patiëntenvereniging)	kan	het	
zijn	dat	de	gevonden	prevalentie	een	overschatting	van	de	werkelijkheid	is.	Echter,	
wanneer we dit percentage vergelijken met de percentages beschreven in de 
literatuur,	zien	we	dat	de	prevalentie	varieert	van	47%	tot	81%1-6; slechts twee studies 
vonden	 een	 prevalentie beneden	 de	 40%.	 Dit	 geeft	 aan	 dat	 het	 percentage	
gepresenteerd	in	dit	hoofdstuk	mogelijk	een	reële	afspiegeling	van	de	werkelijkheid	
is. Op basis van de gevonden resultaten en de literatuur kunnen we concluderen dat 
de	prevalentie	van	nagelpsoriasis	onder	psoriasis	patiënten	vaak	onderschat	wordt	
en	 dat	 herkenning	 van	 karakteristieke	 nagelpsoriasis	 manifestaties	 belangrijk	 is	
omdat	het	een	frequent	voorkomend,	en	soms	vroege	manifestatie	van	de	ziekte	is.	
Kennis	 over	 de	 prevalentie	 van	 de	 verschillende	 kenmerken	 die	 in	 nagelpsoriasis	
gezien	worden	is	derhalve	essentieel	voor	artsen	die	patiënten	met	huid	en	nagelaf-
wijkingen behandelen. In hoofdstuk 2.1 en 2.2 worden de resultaten gepresenteerd 
van twee studies waarin de focus op de kenmerken van nagelpsoriasis ligt. In 
hoofdstuk 2.1	 werden	 onycholyse	 (93.9%),	 splinterbloedingen	 (93.9%)	 en	 pitting	
(73.5%)	 het	 meest	 frequent	 gezien.	 In	 hoofdstuk 2.2	 werden	 pitting	 (65.4%),	
onycholyse	(57.7%)	en	het	olievlekfenomeen	(41.4%)	het	frequentst	gedocumenteerd.	
Pitting	en	onycholyse	werden	frequent	gerapporteerd	in	beide	studies,	ondanks	de	
verschillen in studieopzet. Deze bevindingen komen overeen met de literatuur.4,6,9,10 
Beide studies toonden aan dat red spots in de lunula een fenomeen is dat zelden 
gezien	wordt	 in	 nagelpsoriasis	 (2.0%	 en	 6.5%,	 respectievelijk).	 Daarentegen	 toont	
hoofdstuk 2.1	dat	Beau’s	lines	frequent	gezien	worden	nagelpsoriasis.	Helaas	werd	er	
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behandelen.	Het	lage	percentage	is	echter	opmerkelijk	wetende	dat	de	behandelopties	
toenemen,	de	assertiviteit	van	de	patiënten	groeit	en	cosmetische	aspecten	steeds	
belangrijker worden. In hoofdstuk 2.2	verklaarde	patiënten	dat	zij	positieve	effecten	
hebben ervaren op hun nagelafwijkingen van verschillende, voornamelijk systemische 
medicamenten (bv. Biologics, fumaarzuur, methotrexaat). In overeenstemming met 
de	 ervaringen	 van	 de	 patiënten	 beschreven	 in	 hoofdstuk 2.2 laten verschillende 
andere	 studies	 positieve	 effecten	 zien	 van	 verschillende	 behandelopties.12-22 Een 
recent	Cochrane	review	laat	zien	dat	er	gekwalificeerd	bewijs	is	voor	de	effectiviteit	
van	 infliximab	 en	 golimumab	 (anti-tumor	 necrosis	 factor)	 en	 radiotherapie	 op	
nagelpsoriasis.13 Er konden echter maar 18 studies geïncludeerd worden in dit review 
omdat de kwaliteit van de studies over het algemeen laag was.13 Onze resultaten, 
samen met de resultaten gepresenteerd in het review, tonen aan dat hoogwaardig 
onderzoek	 naar	 de	 effecten	 van	 behandelingen	 op	 nagelpsoriasis	 noodzakelijk	 is.	
Trials	naar	de	effectiviteit	van	behandelingen	op	nagelpsoriasis	zouden	echter	allen	
dezelfde methodologie moeten gebruiken om te garanderen dat vergelijking van de 
resultaten mogelijk is en de kwaliteit van de onderzoeken goed is. De behandeling 
van	 patiënten	 met	 nagelpsoriasis	 vraagt	 echter	 om	 een	 patiëntgecentreerde	
benadering	gezien	de	potentiële	toxiciteit	van	de	systemische	antipsoriasismedica-
menten.	Daarom	moeten	de	voor-	en	nadelen	van	ieder	therapeuticum	meegenomen	
worden	 in	 de	behandeloverweging.	 Bovendien	moeten	 er	 indicaties	 geformuleerd	
worden	voor	het	voorschrijven	van	systemische	medicatie	in	nagelpsoriasis	patiënten	
zodat	 richtlijnen	 ontwikkeld	 kunnen	 worden.	 Voorbeelden	 van	 indicaties	 voor	
systemische	 behandeling	 zouden	 kunnen	 zijn	 de	 aanwezigheid	 van	 tevens	 artritis	
psoriatica,	ernstige	cutane	psoriasis,	of	wanneer	de	nagelmanifestaties	de	kwaliteit	
van leven in groter mate beïnvloed. Wij hopen dat met de gepresenteerde resultaten 
een signaal afgegeven wordt voor de noodzaak voor het genereren van onderzoek 
van	hoge	kwaliteit	naar	de	effectiviteit	van	behandelingen	op	nagelpsoriasis.
Doel 2:  Meer inzicht krijgen in de kwaliteit van leven van nagelpsoriasis 
patiënten.
Naar	 aanleiding	 van	 het	 lage	 percentage	 nagelpsoriasis	 patiënten	 dat	 behandeld	
wordt	voor	zijn	nagelmanifestaties	zoals	beschreven	in	hoofdstuk 2, werd er besloten 
om	de	 impact	 van	 nagelpsoriasis	 op	 de	 kwaliteit	 van	 leven	 van	 deze	 patiënten	 te	
onderzoeken in hoofdstuk 3. In hoofdstuk 3.1 en 3.2 presenteren we de resultaten 
van	verschillende	generieke,	dermatologiespecifieke	en	nagelpsoriasisspecifieke	kwaliteit	
van	leven	vragenlijsten	toegepast	op	nagelpsoriasis	patiënten.	Ten	tijde	van	het	opzetten	
van studie 3.1	was	er	geen	gevalideerde	nagelpsoriasis-specifieke	kwaliteit	van	leven	
score beschikbaar en werd ervoor gekozen om een generieke kwaliteit van leven 
score	te	gebruiken	te	samen	met	een	gemodificeerde	onychomycose	kwaliteit	van	
niet	 naar	 de	 aanwezigheid	 van	 Beau’s	 lines	 gevraagd	 in	 de	 vragenlijst	 die	 werd	
ingevuld	door	de	patiënten	geïncludeerd	in	hoofdstuk 2.2. Uit de literatuur blijk dat 
Beau’s	lines	zelden	geëvalueerd	worden	in	nagelpsoriasis	studies.	Alleen	in	een	studie	
van	Garzitto	et	al.11	werd	dit	fenomeen	gerapporteerd	en	zij	vonden	een	prevalentie	
van	29.4%	in	nagelpsoriasis	patiënten.	Het	is	algemeen	aanvaard	dat	leukonychia	een	
karakteristieke	nagelmanifestatie	 is	 in	psoriasispatiënten.	Echter,	de	nagels	van	de	
controlegroep in hoofdstuk 2.1	toonden	significant	vaker	leukonychia	in	vergelijking	
met	de	nagelpsoriasis	patiënten	(65.3%	vs.	40.8%,	p=0.015). Op basis van de gevonden 
resultaten	en	een	vergelijkbaar	resultaat	gevonden	in	een	studie	van	Garzitto	et	al.,	
uitgevoerd naar aanleiding van het onderzoek gepresenteerd in hoofdstuk 2.1, 
kunnen	we	concluderen	dat	leukonychia	een	niet-specifieke	uiting	van	nagelpsoriasis	
is. In het meest frequent gebruikte nagelpsoriasis scoringssysteem, de Nail Psoriasis 
Severity Index (NAPSI), zijn leukonychia en red spots in de lunula geïncludeerd als 
twee	van	de	acht	klassieke	nagelmanifestaties	gezien	in	psoriasis.	Beau’s	lines	worden	
niet gescoord in de NAPSI. Gezien de resultaten beschreven in hoofdstuk 2.1 en 2.2, 
dient	 de	 constructie	 van	 de	 NAPSI	 heroverwogen	 te	 worden.	 De	 gepresenteerde	
gegevens	 met	 betrekking	 tot	 de	 klinische	 karakteristieken	 en	 prevalentie	 van	
nagelpsoriasis	 zijn	 tevens	 waardevol	 voor	 de	 diagnostiek	 en	 evaluatie	 van	
nagelpsoriasis, maar ook voor het onderwijzen van dermatologen en huisartsen in 
het herkennen van nagelpsoriasis. 
Doel 1.2:  Inzicht verkrijgen in de behandelervaringen van patiënten met 
nagelpsoriasis. 
Studie 2.2	 toonde	 aan	 dat	 16%	 van	 de	 nagelpsoriasis	 patiënten	 een	 behandeling	
kreeg	voor	zijn	nagelafwijkingen,	terwijl	47%	van	de	patiënten	verklaarde	dat	zij	graag	
behandeling zouden willen krijgen voor hun nagelpsoriasis. Deze gegevens tonen aan 
dat	 er	 een	 discrepantie	 bestaat	 tussen	 de	 behandelbehoefte	 van	 nagelpsoriasis	
patiënten	en	het	werkelijke	aantal	patiënten	dat	behandeld	wordt	specifiek	voor	hun	
nagelpsoriasis.	Het	aantal	patiënten	dat	voor	nagelpsoriasis	behandeld	wordt	is	zelfs	
aanzienlijk	 lager	 in	vergelijking	met	een	vergelijkbare	groep	patiënten	 in	1996.1 Een 
mogelijke	 verklaring	 voor	 het	 lage	 percentage	 patiënten	 dat	 behandeling	 voor	
nagelpsoriasis	krijgt	zou	kunnen	zijn	dat	de	cutane	psoriasis	manifestaties	het	klinisch	
beeld domineren waardoor de focus van de psoriasis behandeling op de cutane 
component ligt. Een andere mogelijke verklaring zou kunnen zijn dat dermatologen 
behandeling	 van	 nagelafwijkingen	 behorende	 bij	 psoriasis	 als	 ineffectief	 ervaren	
mede omdat resultaten vaak pas gezien worden na een lange behandelperiode 
omdat	de	nagels	 langzaam	groeien	en	herstellen.	Ten	slotte	zouden	patiënten	hun	
psoriasis behandeling kunnen beschouwen als een behandeling gericht op de cutane 
psoriasis laesies onwetende dat dezelfde behandeling ook hun nagelafwijking kan 
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dagelijkse	activiteiten	(bv.	aantrekken	van	schoenen	en/of	sokken)	alsmede	dat	36%	
van	de	psoriasispatiënten	met	nagelafwijkingen	pijn	ervaart.	De	 lokalisatie	van	de	
nagelafwijkingen bleek van belang; nagelbed afwijkingen blijken tot meer beperkingen 
te leiden dan wanneer er alleen nagelmatrix afwijkingen aanwezig zijn. In tegenstelling 
tot	de	DLQI	en	de	SF-36	ligt	de	focus	van	de	NPQ10	op	specifieke	restricties	die	nagel-
afwijkingen met zich mee zouden kunnen brengen. De resultaten van de NPQ10 en de 
gemodificeerde	onychomycose	vragenlijst	 geven	aan	dat	het	waardevol	 is	om	een	
instrument	 te	gebruiken	dat	specifiek	de	ziektelast	meet	die	nagelafwijkingen	met	
zich	meebrengen	omdat	dit	mogelijkheden	biedt	voor	een	patiëntgerichte	aanpak.	
Voor	 de	 toekomst	 zou	 het	 interessant	 kunnen	 zijn	 om	 een	 specifieke	 score	 te	
gebruiken in de follow-up van behandelingen voor nagelpsoriasis om zo veranderingen 
in kwaliteit van leven gedurende behandelingen inzichtbaar te maken. Naar onze 
mening	moeten	de	kwaliteit	van	 leven	scores	voor	nagelpsoriasis	patiënten	echter	
wel verder ontwikkeld en verbeterd worden. De gemiddelde score op de NPQ10 was 
9.9%	(met	een	maximum	van	100%).	Dit	geeft	aan	dat	de	score	niet	in	zijn	volledige	
bereik wordt gebruikt. Een mogelijke verklaring hiervoor zou kunnen zijn dat de 
meeste	patiënten	de	restricties	opgenomen	in	deze	vragenlijst	niet	ervaren	en	andere	
relevante	vragen	missen.	Bepaalde	vragen	(bv.,	‘vanwege	mijn	nagelpsoriasis,	heb	ik	
hulp	 nodig	 bij	 het	 aankleden’)	 zouden	 mogelijk	 vervangen	 moeten	 worden	 door	
vragen	die	betrekking	hebben	op	restricties	meer	specifiek	voor	nagelpsoriasis	zoals	
de vragen die in de onychomycose vragenlijst toegepast worden. De NPQ10 is echter 
nog	nauwelijks	toegepast	 in	onderzoeksverband	en	toekomstig	onderzoek	 is	nodig	
om	onze	bevindingen	te	bevestigen	dan	wel	te	weerleggen.	Verdere	modificatie	en	
validatie	 van	 de	 onychomycose	 vragenlijst	 zou	 ook	 een	 mogelijke	 optie	 voor	 de	
toekomst kunnen zijn. De waarde van de resultaten gevonden in de bovengenoemde 
twee	studies	is	dat	ze	laten	zien	dat	nagelpsoriasis	weldegelijk	een	significante	impact	
kan	hebben	op	specifieke	aspecten	binnen	de	kwaliteit	van	leven	van	patiënten	en	
clinici zouden meer aandacht moeten hebben voor de nagels wanneer zij psoriasis 
gaan	behandelen.	Specifieke	scoringssystemen	voor	de	kwaliteit	van	leven	in	nagel-
psoriasis moeten verder ontwikkeld en toegepast worden. 
Doel 3:  Inzicht geven in de verschillende bestaande nagelpsoriasis 
scoringssystemen voor het bepalen van de ernst van nagelpsoriasis en 
het ontwikkelen van een scoringssysteem dat de klinische  
ernst beter weergeeft.
Naar aanleiding van de resultaten van studie 2.1 en 2.2, onze ervaringen en de 
literatuur, werd het duidelijk dat het scoren van de ernst van nagelpsoriasis middels 
de	NAPSI	limitaties	met	zich	meebrengt.	Het	doel	van	hoofdstuk 4 was daarom om 
de verschillende bestaande nagelpsoriasis scoringssystemen voor de ernst van 
leven vragenlijst primair ontwikkeld door Drake et al.23 Door gebruik te maken van 
een generieke score (Short Form-36, SF-36) was het mogelijk om aan te tonen dat 
nagelpsoriasis	 (met	minimale	 cutane	 psoriasis	 activiteit)	 geen	 invloed	 heeft	op	 de	
perceptie	van	de	algemene	gezondheid	door	deze	patiënten.	De	resultaten	van	de	
gemodificeerde	vragenlijst	van	Drake	et	al.	 lieten	zien	dat	nagelpsoriasis	patiënten	
weldegelijk	restricties	ervaren	vanwege	hun	nagelafwijkingen.	De	resultaten	op	deze	
vragenlijst lieten ook zien dat de voornaamste ziektelast ervaren wordt in de sociale 
dimensie.	Patiënten	maken	zich	zorgen	over	het	oordeel	van	anderen	vanwege	nagel-
afwijkingen.	Daarnaast	ervaart	de	helft	van	de	patiënten	pijnklachten	veroorzaakt	
door de nagelafwijkingen. De gepresenteerde resultaten geven aan dat clinici 
rekening moeten houden met de (sociale) impact en pijnklachten veroorzaakt door 
de	nagelafwijkingen	wanneer	zij	een	nagelpsoriasis	patiënt	behandelen.
 In hoofdstuk 3.2 werd de meest gebruikte kwaliteit van leven score in de 
Dermatologie	 toegepast	 op	 nagelpsoriasis	 patiënten;	 de	 Dermatology	 Life	 Quality	
Index	(DLQI).	Patiënten	met	nagelpsoriasis	scoorden	een	significant	hoger	gemiddelde	
score	 in	 vergelijking	 met	 psoriasispatiënten	 zonder	 nagelafwijkingen	 (gemiddelde	
DLQI 4.9 versus 3.7, p=<0.001,	respectievelijk).	Deze	resultaten	laten	zien	dat	psoriasis	
patiënten	 een	 lagere	 kwaliteit	 van	 leven	 ervaren	 wanneer	 er	 nagelafwijkingen	
aanwezig	zijn.	Wanneer	we	echter	kijken	naar	de	interpretatie	van	de	DLQI	score,	zien	
we	dat	beide	groepen	in	dezelfde	effect	categorie	vallen	(categorie	twee,	DLQI	score	
2-5).	Deze	categorie	geeft	aan	dat	de	invloed	van	de	dermatologische	afwijking	op	de	
kwaliteit van leven laag is.24 De klinische betekenis van het verschil tussen de twee 
groepen	is	twijfelachtig	ondanks	de	significantie,	maar	het	verschil	is	aanwezig	en	kan	
niet genegeerd worden. Bij het interpreteren van de resultaten van de DLQI moet wel 
rekening gehouden worden met het feit dat de DLQI de impact van cutane afwijkingen 
in	het	algemeen	meet	en	niet	 specifiek	de	 impact	 van	nagelpsoriasis.	Het	 verschil	
tussen de beide groepen zou dus mogelijk verklaard kunnen worden doordat de 
psoriasis	in	de	nagelpsoriasisgroep	ernstiger	is	dan	in	groep	patiënten	zonder	nagel-
afwijkingen	zoals	aangetoond	met	de	SAPASI	score	(6.6	vs.	5.3,	p=<0.001,	respectievelijk).	
Een	andere	mogelijke	verklaring	zou	de	hogere	prevalentie	van	artritis	psoriatica	in	
nagelpsoriasispatiënten	kunnen	zijn	zoals	bediscussieerd	 in	het	artikel.	Wanneer	 je	
de	DLQI	gebruikt	blijft	de	specifieke	 impact	van	nagelpsoriasis	op	de	kwaliteit	 van	
leven	dus	onduidelijk.	De	resultaten	tonen	aan	dat	de	DLQI	niet	specifiek	genoeg	is	
om de impact van nagelpsoriasis op de kwaliteit leven te bepalen, wat mogelijk te 
verklaren	is	door	de	aard	van	de	vragen	gezien	deze	niet	specifiek	betrekking	hebben	
op de nagels.
	 In	 2010	 werd	 er	 een	 nagelpsoriasis	 specifieke	 kwaliteit	 van	 leven	 vragenlijst	
ontwikkeld en gepubliceerd door Ortonne et al., de Nail Psoriasis Quality of life 10 
(NPQ10), welke vervolgens toegepast kon worden in hoofdstuk 3.2.25 De resultaten 
van	deze	vragenlijst	lieten	zien	dat	patiënten	voornamelijk	beperkingen	ervaren	in	de	
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maakt.	Uiteindelijk	moet	dit	inzicht	geven	in	de	behandelopties	voor	patiënten	met	
nagelpsoriasis.	De	introductie	van	een	adequaat	klinisch	scoringssysteem	alleen	dekt	
echter	 niet	 de	 gehele	 lading.	 Het	 ultieme	 nagelpsoriasis	 scoringssysteem	 zou	 een	
systeem	moeten	zijn	dat	de	klinische	ernst	accuraat	weergeeft,	maar	ook	de	kwaliteit	
van	leven	en	mening	van	de	patiënt	mee	laat	wegen	zoals	weergegeven	in	hoofdstuk 3. 
In	dit	tijdperk	van	personalized	medicine	zou	naast	de	N-NAIL	ook	de	ervaring	van	
patiënt	en	de	kwaliteit	van	leven	meegenomen	moeten.	
Doel 4:  Systematisch review van alle beschikbare literatuur met betrekking tot 
de prevalentie van onychomycose in (nagel) psoriasis patiënten. 
Het doel van hoofdstuk 5	was	om	inzicht	te	geven	in	de	prevalentie	van	onychomycose	
in	psoriasispatiënten	middels	een	systematisch	review	van	de	literatuur.	Vanwege	de	
heterogeniteit van de studies was het niet mogelijk om een meta-analyse te 
verrichten.	 Er	 konden	 tien	 studies	 geïncludeerd	 worden	 en	 de	 conclusies	 in	 dit	
hoofdstuk	zijn	gebaseerd	op	een	overzicht	van	deze	systematisch	verworven	studies.	
Een	breed	spectrum	van	prevalenties	van	onychomycose	in	psoriasis	patiënten	werd	
gevonden;	 van	 4.6%	 tot	 63.1%	 in	 de	 psoriasis	 groep	 en	 van	 2.4%	 tot	 66.0%	 in	 de	
controle	groep.	Dit	resulteerde	in	een	gecombineerde	prevalentie	van	respectievelijk	
18.0%	en	9.1%.	In	de	literatuur	worden	onychomycose	prevalenties	beschreven	van	
6.5%,	8.4%,	4.7%	en	20.9%	in	de	algemene	populatie.	Deze	waardes	lijken	merendeels	
overeen	 te	 komen	 met	 de	 gecombineerde	 prevalentie	 van	 de	 controle	 groep	
gevonden in dit review.30-33 De	prevalentie	van	onychomycose	in	psoriasispatiënten	
lijkt	verhoogd	te	zijn	in	vergelijking	met	de	prevalentie	in	de	algemene	populatie	en	
de	geïncludeerde	controlegroepen,	maar	het	ultieme	bewijs	hiervoor	ontbreekt	nog.	
In de literatuur worden verschillende argumenten met betrekking tot de 
veronderstelde verhoogde kwetsbaarheid van psoriasisnagels voor mycosen 
geopperd. Argumenten die een verhoogde kwetsbaarheid voor mycosen tegenspreken 
zijn	het	feit	dat	de	immuunrespons	tegen	microbiële	huidinfecties	opvallend	sterk	is	
in	 psoriasispatiënten.	 Tevens	 zou	 de	 verhoogde	 groeisnelheid	 van	 de	 nagels	 van	
psoriasis	patiënten	de	nagel	theoretisch	kunnen	beschermen	tegen	invasie	van	mi-
croorganismen.34	De	morfologische	veranderingen	van	de	nagels	van	psoriasispatiën-
ten	(hyperkeratose,	onycholyse)	en	het	gebruik	van	immunosuppressieve	therapieën	
zijn argumenten voor een verhoogde vatbaarheid voor het ontwikkelen van een 
onychomcyose	in	deze	patiënten	groep.	Een	recent	gepubliceerd	artikel	gaat	in	op	dit	
laatste argument en laat resultaten zien met betrekking tot de ontwikkeling van 
onychomcycose	in	nagelpsoriasispatiënten	na	het	starten	van	anti-TNF	therapie.	De	
resultaten	toonden	dat	nagelpsoriasispatiënten	die	behandeld	werden	met	infliximab	
significant	 frequenter	 een	 onychomycose	 ontwikkelden	 (33.0%)	 na	 24	 weken	
behandeling	 in	 vergelijking	met	 gezonde	 controles	 en	nagelpsoriasis	 patiënten	die	
nagelpsoriasis, inclusief de NAPSI, te vergelijken met een standaard score voor de 
klinische ernst, de Physician Global Assessment (PGA), om op deze manier inzicht te 
krijgen in de kwaliteit van de bestaande systemen en om een scoringssysteem te 
ontwikkelen	die	de	klinische	ernst	beter	weergeeft.	In	de	literatuur	worden	zeven	scorings-
systemen beschreven en deze werden allen gebruikt in hoofdstuk 4. Een scorings-
systeem ontwikkeld door Baran26 en de Psoriasis Nail Severity Score (PNSS)27 lieten 
een	acceptabele	correlatie	met	de	PGA	van	respectievelijk	r=0.735	en	r=0.734	zien.	
De	frequent	gebruikte	NAPSI	score	liet	een	matige	correlatie	ten	aanzien	van	de	PGA	
zien (r=0.669). Daar komt bij dat eerdere studies hebben laten zien dat de NAPSI niet 
altijd	sensitief	genoeg	is	voor	het	weergeven	van	klinische	verbetering	over	tijd.28,29 
Dit wordt mogelijk veroorzaakt doordat de NAPSI alleen de aanwezigheid of 
afwezigheid van de verschillende klinische afwijkingen scoort in plaats van de mate 
van ernst. Naar aanleiding van deze resultaten werd er in hoofdstuk 4 een scorings-
systeem	ontwikkeld	die	de	klinische	ernst	meer	accuraat	weergeeft.	In	de	ontwikke-
lingsfase werden de resultaten van hoofdstuk 2 meegenomen en uiteindelijke werd 
de	Nijmegen-Nail	psoriasis	Activity	tooL	(N-NAIL)	ontwikkeld.	De	resultaten	toonden	
dat	de	N-NAIL	 een	 veel	 betere	 reflectie	 van	de	mate	 van	ernst	 van	nagelpsoriasis	
weergeeft	 in	 vergelijking	 met	 de	 zeven	 bestaande	 scoringssystemen	 (r=0.861).	
Verschillende	nagelafwijkingen	gezien	in	nagelpsoriasis	werden	toegevoegd	(Beau’s	
lines) of verwijderd (bv. leukonychia, red spots in de lunula) in vergelijking met de 
klassieke nagelpsoriasis scoringssystemen. Daarnaast werd de N-NAIL tot op zekere 
hoogte gevalideerd. De resultaten lieten een interobserver betrouwbaarheid 
variërend	van	0.967	tot	0.989	zien	en	een	intraobserver	betrouwbaarheid	van	0.899	
wat	 aangeeft	 dat	 de	 N-NAIL	 een	 excellente	 reproduceerbaarheid	 heeft.	 Voor	 de	
toekomst moeten er echter nog verschillende clinimetrische aspecten van de N-NAIL 
bepaald worden om de score volledig te valideren. Het bepalen van de responsiviteit 
(het	vermogen	van	een	scoringssysteem	om	veranderingen	in	de	tijd	weer	te	geven)	
van de N-NAIL met betrekking tot behandeling van nagelpsoriasis zou van grote 
waarde	 zijn.	 Daarnaast	 zou	 de	 responsdistributie	 bepaald	moeten	worden	waarin	
duidelijk wordt of de score over zijn volledige reikwijdte gebruikt wordt. Maar ook de 
interpretatie,	de	mate	waarin	 je	een	kwalitatieve	betekenis	aan	een	kwantitatieve	
score	geeft,	zou	bepaald	moeten	worden.	Uiteindelijk	zou	dit	moeten	resulteren	in	de	
categorisatie	 van	 de	 uitkomstmaat	 gerelateerd	 aan	 het	 klinische	 beeld.	 Zoals	
gepresenteerd in het Cochrane onderzoek uit 2013, is het niet mogelijk om de 
resultaten van de verschillende studies met betrekking tot de behandeling van 
nagelpsoriasis samen te voegen en te vergelijken omdat de methodologie en de 
manier van scoren van de ernst van nagelpsoriasis verschilt. De ontwikkeling en 
optimalisatie	van	de	N-NAIL	is	een	eerste	stap	richting	de	promotie	van	het	gebruik	
van	een	en	hetzelfde	scoringssysteem	dat	de	klinische	ernst	betrouwbaar	weergeeft	
en	 op	 deze	 manier	 de	 vergelijking	 van	 uitkomsten	 van	 behandelopties	 mogelijk	
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Doel 5:  Om bij te dragen aan het ophelderen van de link tussen nagelpsoriasis 
en artritis psoriatica.     
In	 de	 afgelopen	 jaren	 is	 er	 in	 verschillende	 publicaties	 gespeculeerd	 over	 de	
anatomische	 link	 tussen	 nagelpsoriasis	 en	 artritis	 psoriatica	 (PsA).	 Het	 doel	 van	
hoofdstuk 6 was om bij te dragen aan de opheldering van de gesuggereerde link. 
Gebaseerd op een hypothese van McGonagle et al., die suggereert dat entheses 
mogelijk een sleutelrol spelen in de link tussen nagelpsoriasis en PsA, hebben wij 
deze	op	anatomie	gebaseerde	link	onderzocht	middels	drie	dimensionale	echografie	
van de extensor pees van het distale interphalangeale gewricht in nagelpsoriasis 
patiënten.	De	resultaten	toonden	dat	patiënten	met	nagelpsoriasis	significant	dikkere	
radiale entheses hadden in vergelijking met beide controle groepen (gezonde 
controles	 en	 psoriasis	 patiënten	 zonder	 nagelafwijkingen).	 Er	werden	 echter	 geen	
significante	 verschillen	 gevonden	 tussen	 de	 dikte	 van	 entheses	 aangrenzend	 aan	
aangedane nagels en entheses aangrenzend aan nagels zonder afwijkingen binnen de 
groep	 nagelpsoriasis	 patiënten.	 Ook	werd	 er	 geen	 associatie	 gevonden	 tussen	 de	
dikte van de entheses en aanwezigheid van matrixafwijkingen. De resultaten 
gepresenteerd in hoofdstuk 6 maken een op anatomie gebaseerde co-pathogenese 
van nagelpsoriasis en PsA minder waarschijnlijk. Een mogelijke verklaring voor de 
coïncidentie	van	nagelpsoriasis	en	PsA	zou	misschien	eerder	gezocht	moeten	worden	
op	 het	 niveau	 van	 de	 genetica	 zoals	 bediscussieerd	 en	 gehypothetiseerd	 in	 dit	
hoofdstuk.	De	voornaamste	genetische	determinant	voor	ontwikkeling	van	psoriasis	
is	 het	 allel	 HLA-cW6	 gelokaliseerd	 op	 het	 gen	 PSORS1.	 Patiënten	 met	 PsA	 en/of	
nagelpsoriasis	zijn	frequenter	HLA-cW6	negatief	wat	mogelijk	kan	wijzen	op	een	op	
genetica	 gebaseerde,	 maar	 immunologisch	 gedreven	 overeenkomst	 tussen	 nagel-
psoriasis en PsA.38 Omdat PsA kan leiden tot deformiteit van een gewricht en de 
daarop	 volgende	 invalidatie,	 is	 preventie	 en	 vroege	 herkenning	 belangrijk,	 vooral	
omdat het vroeg stellen van de diagnose en instellen van behandeling mogelijk tot 
minder irreversibele gewrichtsschade leidt. Het is nog de vraag of dat een vroege 
interventie	het	ontstaan	van	PsA	in	psoriasis	patiënten	zonder	gewrichtsklachten	kan	
verkomen	 of	 vertragen.	 Inzicht	 in	 de	 genetische	 (en	 immunologische)	 verschillen	
tussen	de	verschillende	fenotypes	van	psoriasis	kan	mogelijk	in	de	toekomst	richting	
gevend	 zijn	 voor	welke	 groep	psoriasispatiënten	behandeld	moet	worden	om	PsA	
gerelateerde	destructies	en	de	daaruit	voortkomende	invaliderende	gewrichtsziekte	
te	voorkomen.	De	voornaamste	limitatie	in	de	zoektocht	naar	een	verklaring	voor	de	
link	 tussen	nagelpsoriasis	en	PsA	 is	de	tijdspanne.	Het	merendeel	van	de	psoriasis	
patiënten	ontwikkeld	pas	gewrichtsklachten	verscheidene	jaren	na	het	ontstaan	van	
de	eerste	cutane	manifestaties.	Dit	vraagt	om	een	registry	of	een	grote	longitudinale	
cohort studie met een follow-up van een aantal decennia waarbij ook rekening moet 
worden	gehouden	dat	niet	alle	patiënten	met	PsA	nagelafwijkingen	hebben.
behandeld werden met adalimumab of etanercept. Deze resultaten laten zien dat 
bepaalde immunosuppressieve therapieën het risico op het ontwikkelen van een 
onychomycose	in	nagelpsoriasis	patiënten	verhoogt.	
	 Op	basis	van	het	review	kan	geconcludeerd	worden	dat	nagelpsoriasispatiënten	
een verhoogd risico hebben op het ontwikkelen van een onychomycose en clinici zich 
bewust moeten zijn van dit verhoogde risico. Voor de toekomst zou het interessant 
zijn	om	te	differentiëren	tussen	nagelpsoriasispatiënten	die	meer	vatbaar	zijn	voor	het	
ontwikkelen van een coeexistente onychomycose gebaseerd op het type behandeling en 
type	 nagelafwijkingen	 (nagelbed	 of	 nagelmatrix	 afwijkingen).	 Hypothetisch	 gezien	
zouden pathogenen een voorkeur kunnen hebben voor nagels met voornamelijk 
 nagelbedafwijkingen in vergelijking met nagels met bijvoorbeeld alleen nagelmatrix 
afwijkingen 
 In het review werd geen verschuiving gezien in de soort verwekker in psoriasis-
patiënten	ten	opzichte	van	gezonde	controles.	In	de	literatuur	wordt	gesuggereerd	
dat	de	verwekker	van	een	onychomycose	vaker	een	gist	en/of	non-dermatophyt	zou	
zijn wanneer er nagelpsoriasis aanwezig is. Maar ook hier werd de vergelijking van de 
verschillende onderzoeksresultaten bemoeilijkt door de heterogeniteit van de 
geïncludeerde studies. Het merendeel van de studies maakt geen verschil tussen de 
soort pathogenen gevonden in teennagels of vingernagels. Het is echter bekend dat je 
rekening	moet	houden	met	de	lokalisatie	van	de	onychomycose	gezien	dermatophyten	de	
meeste voorkomende verwekker zijn van een onychomycose van de teennagels en 
gisten meer frequent voorkomen aan vingernagels.36 
 De voornaamste beperking van hoofdstuk 5 was de heterogeniteit van de 
beschikbare	 studies.	 Wij	 hebben	 de	 STROBE	 (STrengthening	 the	 Reporting	 of	
OBservational	studies	in	Epidemiologie)	checklist	gebruikt	als	meetinstrument	om	de	
kwaliteit van de geïncludeerde studies te evalueren. Het primaire doel van de STROBE 
is	echter	om	te	dienen	als	leidraad	voor	auteurs	van	observationele	studies	en	niet	
voor	 het	 graderen	 van	 de	 kwaliteit	 van	 studies	 in	 een	 systematisch	 review.	 In	 de	
literatuur	worden	er	verschillende	potentiële	meetinstrumenten	voor	observationele	
studies genoemd, echter geen van allen is geaccepteerd voor algemeen gebruik. 
Sanderson et al.37 toonde zelfs aan dat een kandidaatsinstrument mist. Kwaliteitsin-
strumenten voor gerandomiseerde gecontroleerde trials daarentegen zijn goed 
ontwikkeld. In de toekomst moet consensus over de ontwikkeling van kwaliteitscrite-
ria	 voor	observationele	bereikt	worden	om	kwaliteitsonderzoek	 te	bevorderen	en	
een	kwaliteitsbeoordeling	mogelijk	te	maken,	ook	voor	observationele	studies.	
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